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INTRODUCTION
INTRODUCTION
Cardiac arrhythmia
Sequential contraction of the heart provides adequate blood supply in all parts of the
human body. This contraction is regulated by synchronized electric activation
generated by the specific architecture and composition of the cardiac conduction
system, and by the properties of the cardiac myocytes which are constructed to
generate and transmit force. Uncoordinated contraction of the heart, due to abnormal
heart rhythms (arrhythmia / dysrhythmia) or due to conduction defects, may lead to
clinical symptoms as seizures, syncope or sudden cardiac death. Cardiac arrhythmias
account for more than 10% of all natural death [ l ] . They can be divided in two major
groups: tachycardia (too fast heart rate) and bradycardia (too slow heart rate).
Arrhythmias can originate in the sinoatrial (SA) node, atria, atrioventricular (AV) node,
His-Purkinje system, and ventricles. Except for the last two, they are grouped as
supraventricular arrhythmias, because they originate above the ventricles.
Arrhythmias which originate in the His-Purkinje system or ventricles are described as
ventricular arrhythmias. Depending on their origin in the heart, cardiac rhythm
disturbances or fibrillation can be divided in atrial and ventricular fibrillation. While
atrial fibrillation is not dangerous though difficult to treat, ventricular fibrillation is
most serious and can be the cause of sudden death and has to be treated by electrical
shock therapy. During the last decade many researcher have focussed on uncovering
the mechanism and etiology of the various forms of familial ventricular fibrillation.
The arrhythmias described in this thesis are inherited forms of ventricular fibrillation
(VF) and ventricular tachycardia (VT), caused by electrical disturbances or electric
instability in the heart.
In 2002 it was exactly 100 years ago that the Dutch professor Einthoven, a physiologist
at the University of Leiden reported the recordings of the human electrocardiogram
with the string galvanometer in a festschrift to Professor S. Rosenstein entitled
"Galvanometrische registratie van het menschelijk electrocardiogram" [2]. Hundred
years later we are beginning to understand which proteins and genes are involved in
(ab)normal human electrocardiographic (ECG) recordings. These ECG recordings are a
valuable tool for physicians and have become a hallmark for clinical diagnosis and
treatment of cardiac diseases like congenital Long QT syndrome (LQTS) and familial
hypertrophic cardiomyopathy (FHC). Although the etiology of the inherited cardiac
disorders LOTS and HCM is different, both present with similar clinical features like
cardiac arrhythmia and sudden cardiac death at a young age.
In 1992, the Department of Genetics and Cellbiology of the University of Maastricht
and the Department of Cardiology of the Academic Hospital in Maastricht, initiated a
program to identify the genetic basis of LOTS and other unexplained arrhythmogenic
disorders, in particular hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy
(DCM) and arrhythmogenic right ventricular dysplasia (ARVD or ARVC). At that time
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only one gene, the cardiac beta-myosin heavy chain gene, located on chromosome
14q24, had been shown to be involved in the autosomal dominant form of HCM [3]
and no genes were identified yet for LOTS, DCM or ARVD. Since then, numerous genes
have been identified while 10 sarcomeric genes have been associated with HCM
thereby classifying this disorder as "sarcomeropathy".
The initial breakthrough for genetic analysis of LOTS came in 1995, when within 9
months (between March 1995 and January 1996), mutations in three genes encoding
potassium- and sodium ion channels were reported as disease causing defects in
families with LQTS [4, 5]. Initially, two genes, encoding a cardiac potassium channel on
chromosome 7q35 and a cardiac sodium channel on chromosome 3p21, were
identified by using a candidate gene approach while the third ion channel gene finally
could be identified on chromosome l lpl5-5 by positional cloning [6]. Based on the
similar function of the LQTS gene products, the disorder has been classified as a
"channelopathy".
Today, the DNA laboratory of the Department of Clinical Genetics of the Academic
Hospital Maastricht is one of the two leading centers in the Netherlands that are
specialized in diagnostic genetic analysis in families with LOTS, HCM and other
inherited cardiac diseases. Genetic testing allows confirmation of the diagnosis of a
'rarrifiia'i 'neaft disease, in these families individuals at risk can be genotyped and
carriership can be unequivocally identified. Subsequent follow-up studies of carriers
enables the determination of genotype-phenotype relations which can be used for
predicting possible clinical manifestations of asymptomatic carriers. Today, genetic
analysis has become extremely useful for clinicians to select individuals, being at risk
of sudden cardiac death, for aggressive treatment. In these individuals, who may be
asymptomatic at the time of investigation, the prophylactic use of anti-arrhythmic
agents should be considered. This thesis covers the molecular genetic background of
two distinct familial cardiac diseases LQTS and HCM, the genetic and phenotypic
complexity and the development of a protocol for diagnostic DNA testing. The
arrhythmias caused by defective ion channels, within a morphological and histological
normal heart, are described in the section on "the Long QT Syndrome (LOTS)", whereas
arrhythmias as part of a disease complex, dominated by morphological changes in the
heart, are described in the section on "Familial Hypertrophie Cardiomyopathy (FHC)".
The aims of this thesis were
A) To resolve the genetic basis for two cardiac diseases LQTS and FHC, associated with
arrhythmia and sudden death in young individuals. The genetic basis will be
outlined in Chapter 2 for LQTS and in Chapter 7 for FHC.
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B) To investigate the prevalence of the genetic defects in families diagnosed with
LQTS or FHC. The results are integrated with the results of the chapters referred
under section A.
C) To correlate the genetic defect with a gene-specific phenotype (Chapters 3 and 5)
and pharmacological treatment (Chapter 6). These data were compared with data
from literature. This has been predominantly done for LQTS and has led to a gene
directed screening protocol.
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CHAPTER 2
THE LONG QT SYNDROME
The Long QT syndrome (LOTS) has been referred to as Romano-Ward syndrome, as it
has been described independently in 1963 and 1964 by the cardiologists Romano and
Ward [ l , 2]. They both reported a specific congenital arrhythmia with a history of
sudden death in young and apparently healthy children. LQTS associated with bilateral
deafness, is referred to as Jervell and Lange-Nielsen syndrome, after an initial
description of the disease by Jervell and Lange-Nielsen in 1957 [3]- Actually the JLNS
was already described by Meissner et al in 1856, who reported the collaps and sudden
death of a deaf girl, while two of her brothers died after a terrible fright and violent
rage [4]. The first electrographic registration of LOTS has been reported by Herrlin and
Möller in 1953 [5].
2-1 Clinical features of Long QT Syndrome
Syncope and seizures are the main clinical features of LQTS, which result directly from
cardiac arrhythmia and circulatory arrest. These arrhythmias can be triggered by
adrenergic stimuli such as physical exercise, intense emotion (fright, anger or pain) or
by a loud noise.
Table 1. Characteristics of the common forms of LQTS
Gene mutated
Current affected
Estimated prevalence (%)
Mean QTc
% of events occurring with exercise or emotional stress
Exercise-related trigger
Other triggers
% with events before age 10*
% with events before age 40*
Median age at 1st event
QT shortening with exercise
Efficacy of ß-blockade to prevent events
Efficacy of mexiletine to shorten QT
LQTl
KCNQl
IKs
42
490 ± 43
97
+++
Swimming
40
63
9
< Normal
+++
-
LQT2
KCNH2
IKr
45
495 ±43
51
+
Loud noise
16
46
12
Normal
++
+
LQT3
SCN5A
iNa
8-10
510 ±48
39
-
Sleep/rest
2
18
16
> Normal
+ (?)
+++
Clinical data are based on 112 LQTl subjects, 72 LQT2 subjects, and 62 LQT3 subjects in the international
Long QT registry, as reported by Zareba et al [6],. * P<0.05 among genotypes; ||P<0.05 male versus
female. Adapted from Wilde AAM et al [7]
Already at young age individuals can exhibit syncope (fainting) or seizures due to
cardiac arrhythmia, which is precipitated by an abnormal ventricular repolarization
which is represented by the prolonged QTc time interval (Table l). In 1979, the
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International Long QT Syndrome Registry had been initiated to investigate the
epidemiological and genetic characteristics of the symptomatic probands with LQTS.
From these data it has been estimated that 50% of the symptomatic probands of the
LQTl population had at least one episode of blacking out (fainting) by the age of 10. By
the age of 40 the number of symptomatic patients who had experienced the first
cardiac event had increased to almost 90%. The majority of the individuals in the LQTS
registry had one or more family members with a prolonged QT-interval [8-12],
Qs
toettforniulaQTc»QT-t»n« tin* in mm
\ZRJT
Figure 1. Schematic representation of the standard ECG. Symbol definitions: P
wave » depolarization of the atria; QRS complex - depolarization of the
ventricles; T-wave = repolarization of the ventricles; RR • rate rhythm; QT
interval = time interval of the depolarization and the repolarization of the
ventricular myocardium in milliseconds.
LOTS is characterized by a prolonged QT interval in lead II by standard 12 lead surface
electrocardiogram ECC (Figure 1). The specific ECG pattern in LQTS is caused by
abnormal lengthening of the repolarization phase of the ventricular myocardium
which results in a prolongation of the QT interval. Index patients with a cardiac event
are diagnosed at first on the basis of a prolonged QT interval (QTc) of ± 440
milliseconds corrected for heart rate using the Bazett correction formula [13, 14].
However, recent studies of genotype-phenotype correlations indicated a value of ± 460
milliseconds as more appropriate [8]. The value of the QT interval is also influenced by
age and gender and QT interval duration in adult females is longer than in males [15-
17]. By introducing a set of diagnostic criteria for LQTS according to Schwartz,
presented in Table 2, gender specific criteria were recommended to correct for the
predominance of QTc prolongation in females (13]. The mechanism(s) behind this
gender difference is still unclear but may be related to hormonal effects [16-19]. In
LOTS patients a (sudden) change in heart rate, due to physical exercise or emotional
stress may lead to malignant tachyarrhythmia or polymorphic ventricular arrhythmias
'torsade de pointes' meaning 'turning of the points' due to the alternating positive and
negative major QRS complex named after a typically twisted French bread [20].
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Table 2. Criteria for diagnosis of LQTS syndrome
CHARACTERISTICS POINTS
Electrocardiograph^ findings "
a. QTc "
> 480 msec ' " 3
460-470 msec " ' 2
450 msec (in males) " ' 1
b. Torsade de pointes " 2
c. T-wave alternans l
d. Notched T wave in the three leads 1
e. Low heart rate for age " 0.5
Clinical history
a Syncope
With stress 2
Without stress 1
b. Congenital deafness 0.5
Family history '
a. Family members with LQTS 1
b. Unexplained sudden death at age <30y among immediate 0.5
1. In the absence of medications or disorders known to affect these ECC features.
2. The QT value is corrected for heart rate by using the Bazett formula QTc = QT/VRR, where RR
indicates hart rate [14]
3. Mutually exclusive
4. Resting heart rate below the second percentile for age [26]
5. The same family cannot be counted in a and b.
Adapted from Schwartz PJ et al [13]
In most cases the torsade de pointes is self terminating although, under certain
circumstances, this arrhythmia may deteriorate in live threatening ventricular
fibrillation and sudden cardiac death (SCD) caused by circulatory arrest [21-24]. This
phenomenon classifies the LQTS as a malignant life threatening cardiac disorder.
Therefore, abnormal ECC findings, a positive family history of unexplained syncope or
sudden death of a young family member are very suspect for LQTS. A set of selection
criteria, as proposed by Schwartz et al [13], is used to diagnose LQTS (Table 2). By
allocating numeric points to the clinical features the possibility of LQT may be divided
into low probability (score < 1 point), intermediate probability (score 2-3 points) or
high probability (score > 4 points). In 1999 these criteria were modified by Priori et al
[25], They concluded that in some families, LQTS may appear with very low penetrance
of 25%, which has important clinical implications. The asymptomatic family members
are considered to be normal but in fact, are silent gene carriers and are at risk of
18
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developing TdP if exposed to either drugs that block potassium channels. They are also
unexpectedly at risk of generating affected offspring. Therefore it was no longer
possible to exclude carrier-ship of LQTS in family members of affected patients on
purely clinical grounds and molecular diagnosis should be performed to include or
exclude individuals at risk [25] Specialized laboratories nowadays offer molecular
diagnostic tests to confirm the clinical diagnosis, and to genotype individuals at risk for
carrier-ship (see also Chapter 4 of this thesis).
2-2 The ventricular action potential
The ventricular cardiac action potential is a reflection of subtle interactions of various
cardiac ion channel proteins. In this section, only the channels that are involved in
LQTS will be discussed. Cardiac ion channel proteins are located within the cellular
membrane, creating a barrier between the intracellular and the extra-cellular
compartment of the representation time and voltage dependant openings and
closings [27].
V(mV)
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Figure 2. Overview of the ventricular action potential duration. Involvement of
ion channels in cardiac action potential (phase 0-4) See text for further
details. Modified from Towbin JA et al [28].
In a schematic overview (Figure 2), the four main phases of the ventricular action
potential cell are indicated. By precise orchestrating, a number of voltage-gated ion
channels selectively passes ions across the cell membrane. At rest, the cardiac cells
have a negatively charged membrane potential with a Nernst potential equation of
-85mV. The electric signal, is initiated by pacemaker cells, starting within the
sinoatrial node (SA node) and is transmitted throughout the atria, atrioventricular
node (AV node), the His-Purkinje system and the ventricles. In the initial phase of the
action potential duration (phase 0), the voltage-gated sodium (Na*) channels are
rapidly activated and the cell membrane depolarizes. By briefly opening the ion
channel, sodium ions are allowed to pass through the ion selective pores into the cell.
During the inward sodium current (I^J, the membrane potential becomes less
negatively charged and the sodium ion channels are closed by voltage dependent fast
19
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inactivation [29]. Early repolarization is initiated, immediately after inactivation of the
sodium channels by the potassium transient outward current (I*,,,) in phase l , followed
by a characteristic plateau phase. During this phase, the action potential is maintained
by various small in- and outward currents such as calcium currents, ion exchangers
and other voltage-gated ion channels. During the early plateau phase 2, the action
potential is maintained by distinct calcium currents followed by the repolarization of
the cell membrane in the late phase 2 and early phase 3. The repolarization process
begins when net outward current exceeds inward current. This phase is controlled by
opening, inactivating and closing of three important delayed rectifying potassium
channel currents (I*). Two potassium currents have been associated with LOTS, the
rapidly activating delayed rectifier current (I,J and the slowly activating delayed
rectifier current (I,J. Finally, the membrane potential is brought back to the resting
potential (phase 4). One should note that if the sodium channels are open, the
potassium channels are closed.
ECG
Action-
potential
Figure 3. Schematic representation of action potential duration (APD) of
two inward rectifying potassium ion channel currents I*, and I»,. At the
left side the normal situation is represented, the right side represents
the prolonged APD situation in LQTS. Note that the amplitude of the
current I*, is delayed while the current I,, is decreased [30].
Mutations in genes, encoding these voltage gated ion channels, may lead to lower
current amplitudes or influence the kinetics of these channels and cause improper
gating behavior or altered openings or closings. As a result of this gating defect the
membrane potential may be disturbed and the repolarization process can be delayed
(Figure 3). The increase in action potential duration is reflected by a prolonged QT
interval on the surface ECC. The delayed repolarization process predisposes individuals
with LQTS to develop early after depolarizations (EAD) and promote reentrant
excitation which is a common trigger for cardiac arrhythmias [31].
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2-3 Genetics of Long QT syndrome
Congenital long QT syndrome (LQTS) is estimated to occur in 1 of 10.000-15.000 live
births in the Caucasian population and is inherited as an autosomal dominant trait in
the Romano Ward syndrome (RWS) or as a recessive trait in Jervell and Lange-Nielsen
syndrome (JLNS) [32]. The JLNS is, in addition to a prolonged QT interval, associated
with bilateral sensorineural hearing loss and the International Registry for LQTS has
reported that congenital deafness is present in approximately 7% of the LQTS patients
[12]. At present seven loci and genes (Table 3) including KCNQl, KCNH2. SCN5A,
KCNEl and KCNE2 have been identified in LQTS [33-38]. The genetic defect on locus
LQT4 finally has been identified as the AnkB gene which encodes an ankyrin-B isoform,
a member of a family of versatile membrane adapters [39,40].
Table 3- Chromosomal loci of LQTS, the corresponding genes, proteins and currents
Locus
LQT1
LQT2
LQT3
LQT4
LQT5
LQT6
LQT7
JLNSl
JLNS2
Chromosome
Ilpl55
7q35-36
3P21-23
4q25-27
2lq22.1-22.2
2lq21.1-22.2
17q23-24
Ilpl55
21q22.1-22.2
Gene
KCNQl
KCNH2
SCN5A
AnkB
KCNEl
KCNE2
KCNJ2
KCNQl
KCNEl
Current
1,, subunit
I,, subunit
U, subunit
beta-subunit
beta-subunit
IK,subunit
1,, subunit
beta-subunit
MIM*
192500
152427
603830
600919
176261
603796
170390
220400
-
* MIM: Mendelian Inheritance in Man (http:www.ncbi.nlm.nih.gov/omim)
Recently, the KCNJ2 gene was added to the list as LQT7. Mutations in this gene are
related to Andersen syndrome (AS) which is, besides a prolonged QT interval in a
significant number of cases, associated with periodic paralysis, polymorphic
ventricular tachcardia and dysmorphic features [41-43]- The two genes, KCNQl and
KCNEl have been identified to be involved in both JLNS (JLNSl-2) and RWS [44-46]. In a
mouse model it has been demonstrated that both genes are abundantly expressed in
cardiac tissue and in the stria vascularis of the cochlea [47, 48]. At present, it is
thought that mutations in the potassium channels impair the production of
endolymph (impaired K+ homeostasis) in the stria vascularis. The lack of endolymph
supply accounts for deafness in JLNS patients [47]. In LQTS the majority of the
mutations have been identified in two genes, KCNQl and KCNH2. The results of the
genotyping effort in a group of Dutch LOTS families are in line with the results of an
international large cohort reported by Splawski et al [38]. The KCNQl gene (LQTl)
accounts for approximately 42-45% of the LOTS families, while the KCNH2 gene (LQT2)
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accounts for 40-45% and the SCN5A gene (LQT3) for 8-10% of the reported cases [7, 38,
49]- Mutations in the two regulatory potassium a-subunits MinK (LQT5; KCNEl) and
MiRPl (LQT6; KCNE2) represent a very low percentage (2%-3%) of remainder LOTS
families [38]. Besides the most frequently observed "loss-of-function" missense
mutations, nonsense mutations, insertions and deletions have been reported as well
[38, 50, 51]. Recently, in the KCNQl gene, also a "gain-of-function" mutation has been
reported in a family with atrial fibrillation [52]. A list of the mutations ordered
according to the nature of DNA substitution is presented in Table 4. Several
investigators have also reported 'de novo' mutations in the KCNQl and KCNH2 genes.
In this study we were able to identify 5 families with a 'de novo' mutation in one of the
potassium channels. This was confirmed by haplotyping and mutation detection
analysis (Chapter 3, this thesis).
Table 4. Overview of the mutations identified in LQTS genes
Locus
LQTl
LQT2
LQT3
LQT4
LQT5
LQT6
LQT7
Gene
KCNQl
KCNH2
SCN5A
ANK2
KCNEl
KCNE2
KCNJ2
Total
Missense
72
77
25
1
14
5
10
203
Nonsense
3
7
-
-
-
-
-
10
Insertion
3
11
1
-
1
-
-
16
Deletion
13
IS
3
-
2
-
2
35
Splicing
7
3
-
-
-
-
10
Total
98
113
29
17
S
7
262
%
37%
43%
1 1 %
6%
2%
The mutations were derived from the LQT database www.http7/pc4.fsm.it:8l/cardmoc
2-4 Cardiac ion channels involved in LQTS
In this section only the cardiac ion channel known to be related to the LQTS will be
presented. These ion channels are expressed by genes encoding the pore forming a-
subunits and function-modifying accessory ß-subunits [31J.
The cardiac potassium channels (LQTl and LQT2)
The molecular architecture and the pore forming structure of cardiac voltage-gated K*
channels is formed by tetramerization of four individual a-subunits [53]. Each a-
subunit consists of six trans-membrane spanning regions (S1-S6). A putative voltage
sensor is found in the S4 segment (Figure 4) while the pore forming loop is between
the S5 and S6 segments [27, 54]. One of the cardiac potassium channel proteins is
encoded by the KCNQl gene (LQTl) which is the a-subunit component of the slowly
22
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activating delayed rectifier current (I,J. The o-subunit component of the rapidly
activating delayed rectifier current (IJ is encoded by the KCNH2 gene (LQT2) [34]. The
KCNQl (KvLQTl) gene expresses alternatively spliced variants, the main isoform 1 and
isoform 2. The N-terminal splice variant (isoform 2) is expressed in the heart and is
highest in the midmyocardium [55]- However, if expressed alone, no current is
generated by isoform 2, but coexpression of both isoforms results in a dominant
negative suppression of the 1^ current generated by KCNQl. In KCNH2 (HERG), two N-
terminal splice variants (HERG-A, HERG-B) and one C-terminal splice variant (HERGuso)
have been identified. The HERG-A isoform is not cardiac specific and is also expressed
in the brain while the HERG-B isoform is cardiac specific. HERG-B is, despite a high RNA
Figure 4. Structure of a voltage gated potassium channel. (Kv) n-
subunits are integral membrane proteins with six transmembrane
domains (S1-S6), intracellular N- and C-termini and a the voltage sensor
indicated by a positively charged S4 region (4A) Kv-potassium ion
channels are constructed by assembly of four u-subunits (4B). Adapted
from Pond AL et al [54].
level in the heart, only in low amounts present as a protein. In heterologous expression
the HERG-B isoform displays deactivation kinetics that resembles the I,, current [56,
57]. The C-terminal variant HERGuso is present at =2-fold higher levels in the human
heart than the HERG-A isoform and does not itself generate l„, current [58]. However, it
has a dominant negative effect on l„, when coexpressed in Ltk cells as it modifies the
IK, current by decreasing its amplitude, accelerating its activation and shifts the voltage
dependent activation. Up to now it is still unknown whether the functional potassium
ion channel KCNH2 is composed of alternatively spliced gene products (isoforms) or
consists of homotetrameric a-subunits.
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Auxiliary subunits (LQT5 and LQT6)
Voltage gated ion channels often include one or more ancillary proteins called
auxiliary subunits or ß-subunits that play a modulatory, structural, or stabilizing role
[59]. A family of K' channel regulatory subunits are encoded by KCNE genes [60]. Two
genes, KCNEl and KCNE2, encoding the minimal potassium ion channel or minK
(KCNEl) and the minK-related peptide 1 or MiRPl (KCNE2), have been associated with
LQT5 and LQT6 respectively [36, 37]. Both proteins consist of a single transmembrane
spanning region. The native currents 1^ and I*, are generated by co-expression of the
KCNQl and KCNH2 protein with their corresponding auxiliary ß-subunit, encoded by
KCNEl (LQT5) and KCNE2 (LQT6) which shows the heterogeneous composition of the
functional ion channel [37, 61, 62]. To investigate the underlying mechanism for action
potential prolongation and LOTS in KCNE2 associated mutations, it has been
demonstrated that the kinetic changes, associated with coexpression of KCNE2 to
KCNH2, have little effect whereas changes in channel conduction have large effects on
action potential repolarization The large change in current density makes the affected
patients susceptible to arrhythmias [63].
The cardiac sodium channel (LQT3)
The cardiac voltage-gated Na' ion channel is encoded by the SCN5A gene and is highly
expressed in human myocardium. The protein consists of four internally homologous
domains (Dl-DIV), each of which contains six membrane-spanning segments (S1-S6),
similar to the structure of the potassium channel alpha-subunits. Segment S4
functions as the voltage sensor, important for voltage dependent activation (Figure 5).
The four domains of the channel fold around a central ion-conducting pore, which is
lined by the S5-S6 linker (referred to as the P-segment or P-loop) from each domain
[28]. In addition to LQTS, mutations in the SCN5A gene have been associated with the
Brugada syndrome (BS) which also may present as a familial form of cardiac electric
instability and which is correlated with a high mortality rate [64]. The BS is
characterized by unique ECG features of ST-segment elevations in leads VI and V3 and
is associated with or without right bundle branch block (RBBB) and ventricular
fibrillation [65]. The distinct clinical presentation of LQT3 patients and BS patients was
explained by expressing mutant sodium channels in a heterologous expression system.
Mutations involved in BS resulted in decreased Na* channel function by either
decreased expression levels or various functional defects in activation and fast
deactivation which promote reduced Na' current density (loss-of-function) [28, 66]. In
Europe the incidence of SCN5A mutations in BS has been reported to be 15% in single
cases which indicates genetic heterogeneity [67].
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Since then, mutations in the SCN5A gene have been associated with idiopathic
ventricle fibrillation (IVF) as well as in Lenegre Lev disease, a progressive form of
cardiac conduction disease (PCCD) and with sudden infant death syndrome (SIDS) (68-71).
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Figure S. Structure of a voltage gated (Kv) n-tubunit sodium channel. The u-subunlt of the SCNSA gene
consists of four homologous domains DlDIV. Each domain consists of six transmembrane segments
(S1-S6) and a pore forming region. The voltage sensor is indicated by a positively charged S4 region. On
the outer left and right side two single transmembrane spanning auxiliary subunits are represented as
well. The N- and C- terminal ends of the protein are located in the cytoplasm. Adapted from Felix R et al [72].
2-5 Mutations in ion channel genes are causative for cardiac events in LQTS
The dominant negative effect of mutated ion channel proteins has been demonstrated
by measuring the current in Xenopus /aew's oocytes or mammalian cells by
heterologeous expression of mutated and wild type alleles [73, 74], These functional
tests demonstrated that mutations identified in the SCN5A gene (phase l) caused
delayed inactivation (improper, late closing), and a persistent opening of the channel
which increases the time of repolarization (prolongation of the QT interval) hence
explaining the long QT syndrome phenotype LQT3. In contrary mutations identified in
the rapid- and slow activating rectifying potassium ion channels demonstrated
premature inactivation (closing) which caused delayed repolarization and prolonged
action potential duration explaining the long QT phenotypes involved in LQTl and
LQT2. According to these observations two mechanism have been proposed. The
mechanism 'loss or gain of function' has been proposed to indicate the dominant
effect of missense mutations in most cases. A second mechanism is haploinsufficiency
and has been suggested in case of trafficking defects of the misfolded protein, or
severely disrupted subunits unable to associate with normal subunits. These
mutations will lead to a reduced number of functional ion channels. In either case, the
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currents are expected to be reduced by 50% (haploinsufficiency) or more (dominant
negative effect) [27].
In mutated potassium ion channels, the loss of function may result in reduced gating
properties by modification of the ion channel kinetics due to incorporation of a
mutated u- or ß-subunit [27, 75]- As potassium channels are assembled into tetramers,
mutated proteins may be incorporated by chance. If the mutant freely and at random
associates with wild type subunits into a tetramer and if the mutant is completely
dominant, the current would be reduced to 1/16 (fraction of wild type = 0.5; tetramer
= 4; the contribution is 0.5' = 1/16) and finally result in an overall reduced K' current
(loss of function) indicating that the defective protein is capable of blocking the entire
current by interaction with the wild type protein [50, 76]. Reduced K' currents prolong
action potential duration, a phenomenon which has been observed in individuals with
a KCNQl (LQTl) or a KCNH2 (LQT2) mutation. An identical mechanism has been
proposed in SCN5A mutations which resulted in a sustained opening (gain of function)
of the Na" ion channel in case of LQT3 mutations. The protein defect will be present in
at least 50% of the expressed sodium ion channels.
Insufficient or loss of functional ion channels (haploinsufficiency) may be the result of
inefficient co-assembly of subunits (i.e. potassium channels) or trafficking deficiency
from the endoplasmic reticulum to the plasma membrane as a result of (post-
translational) modification or misfolding of the ion channel protein. In KCNOl and also
in KCNH2 C-terminal mutations (missense, nonsense or frame shift inducing
mutations) have been reported that caused a forme fruste of LOTS by misprocessing or
trafficking defects due to post-translational processes [77-83].
In families with JLNS the disease is transmitted in an autosomal recessive pattern.
Patients with JLNS have severe prolonged QTc values and cardiac events appears
earlier in life than in RWS patients [47]. Up to now two loci for JLNS have been
identified. Homozygous and compound heterozygous mutations in both the KCNOl
gene and KCNEl gene represent JLNSl and JLNS2 respectively [46, 84, 85]. In JLNS
homozygous mutations (the human knock-out) or compound heterozygous mutations
lead to complete loss of the functional cardiac potassium current 1^ explaining the
severe cardio-auditory syndrome [45, 46, 86]. Parents of these patients carry a single
mutation in either the KCNQl or KCNEl gene, which may lead to a mild cardiac
phenotype without hearing loss. Heterozygotes of a specific KCNEl mutation showed
prolonged QTc values however, QTc prolongation was not always present in case of a
KCNQl mutation and gene carriers were phenotypically normal [45. 85. 86].
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2-6 Gene specific triggers in LQTS
By the initiation of the International LQTS Registry it has become possible to study
retrospectively a large genotyped population expressing various clinical characteristics
like the QTc-value, the trigger of the events, the frequency of the events and the age of
onset of symptoms. In the LQTS registry about 1/3 of the individuals had recurrent
syncope. 1/3 had problems during adolescence and 1/3 had no symptoms. Reports
have indicated that these episodes of syncope and seizures are related to gene specific
triggers [87. 88](Chapter 5 this thesis). Additional studies in a larger population
indicated that the number of incidents was highest in LQTl patients and lowest in
LQT3 patients (LQTi>LQT2>LQT3). The majority of LQTl patients experienced events
during exercise and exercise related stress (in particular swimming or diving). LQT2
patients showed cardiac events after a loud noise (by arousal) or an emotional trigger,
while LQT3 patients mainly presented cardiac events during sleep. According to
Schwartz [8] the median age at onset for the first major cardiac event is before the age
of 10 years in 50% of the LQTl patients. In contrary, mostpart of the LQT2 and LQT3
patients were still asymptomatic at age 16. Although the events in the LQT3 patients
were less frequent, the risk for sudden death was higher in LQT3 than LQT2 and LQTl
(8, 89. 90]. In addition to a gene-specific correlation, the clinical phenotype has also
been correlated with the position of the genetic defect within the ion channel
structure. Missense mutations in the C-terminal domain in the LQTl locus have been
associated with a forme fruste phenotype and low penetrance [25, 77]. In contrary,
missense mutations which reside in the transmembrane spanning domains have been
reported to be associated with a more severe clinical phenotype [91].
2-7 Acquired long QT syndrome •
The acquired or drug induced form of LOTS (aLOTS) exhibits a similar form of
ventricular arrhythmia or Torsade de Pointes, often occurring after administration of
specific drugs. The potassium channel KCNH2 (HERG) which is responsible for the LQT2
subtype, is a medication (also cocaine and alcohol) sensitive ion channel, in particular
for QT-prolonging medication like anti-arrhythmic and antidepressant drugs. In
addition, the I*, current is sensitive to electrolyte imbalances such as low extra-cellular
potassium level (hypokalemia), hypomagnesia and hypocalcemia, in particular in
combination with medications mentioned above [92].
Another plausible explanation for the acquired form of LQT is the architecture of the
ion selective pore domain and the amino acid composition of the S6-region [93].
However, despite extensive research only few mutations (Table 5) in ion channels have
been reported in patients with drug-induced LOT (Paulussen ADC, thesis). Some
mutations in KCNH2 have been correlated with hypokalemia-induced LOT syndrome
and, under normal conditions, they present a mild clinical phenotype suggesting an
aLOTS [99, 100]. One single amino acid polymorphism (Thr8Ala, freq.1.6% in the
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general population) in the auxiliary a-subunit KCNE2 (LQT5) has been associated with
antibiotic-induced cardiac arrhythmia [98]. The genetic predisposition for aLOTS may
not only depend on ion channel dysfunction but may also derive from genetic
variations in drug metabolizing enzymes [101, 102]. Finally, sinus bradycardia, left
ventricular cardiomyopathy and female sex predispose individuals to the acquired
form of LQT [24, 30]. The female predisposition for aLOTS is probably correlated with
the longer QT intervals among females as the acquired LOT syndrome occurs more
often in this group [18, 103, 104]. A list of QT-interval prolonging drugs is available at
www.qtdrugs.org.
Table 5. DNA variants in drug-induced long QT
Channel
KCNQ1/I,,
KCNQl/l,,
KCNH2/I,,
KCNH2/I,,
SCN5A/I^
SCN5A/I*,
SCN5A/U
SCN5A/I„„
MiRPl
MiRPl
MiRPl
MiRPl
MiRPl
Variant
R583C
Y315C
R328C
R784W
G615E
L618F
F125OL
U825P
Q9E
A116V
T8A
M54T
I57T
Drug
Dofetilide
Cisapride
Meta-iodobenzyl-
guanidine, a
norepinephrine and
guanethidine analogue
Amiodarone
Quinidine
Quinidine
Sotalol
Cisapride
Chlarithromycine
Quinidine
Sulfametoxazole
Procainamide
Oxatomide
Usage
Anti-arrhythmic
Cholinergic
antagonist
Vasconstrictor,
Inotrope
Anti-arrhythmic
Anti-arrhythmic
Anti-arrhythmic
Anti-arrhythmic
Prokinetic
Antibiotic
Anti-arrhythmic
Antibiotic
Anti-arrhythmic
Antihistamine
Reference
Yang et al [94]
Napolitanoetal[9S]
Chevalier et al [96]
Yang et al [94]
Yang et al [94]
Yang et al [94]
Yang et al [94]
Makita et al [97]
Abbott et al [37]
Sesti et al [98]
Sesti et al [98]
Sesti et al [98]
Sesti et al [98]
These drugs have been reported to provoke ventricular tachycardia in the presence of a specific
mutation in one of the LQTS genes
2-8 Gene-based medical therapy in LQTS patients
Syncope and sudden death in the congenital as well as in the acquired form of Long QT
syndrome, is caused by specific arrhythmia known as polymorphous ventricular
tachycardia, or Torsade de Pointes. The goal of the medical treatment is, to protect
these individuals against this dangerous arrhythmic event. Untreated symptomatic
individuals have a 10-year mortality of 50% and a mortality rate from 1% to 2% per
year [24. 105]. In the past 10 years we have gained better insight in the pathogenetic
en pathophysiologic aspects of the LQTS. Different genes are involved in the
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repolarization defect and treatment will thus depend on the type of the ion channel
involved. Therefore identification of the genetic defect is essential. Currently, the
standard therapeutic approach in LQTS is the initiation of ß-blockers at the time of
diagnosis. In LQTl and LQT2 patients medical treatment mainly includes drug
administration by using antiarrhythmics i.e. propranolol [106].
In case of a LQT3 mutation, patients may benefit from treatment with a sodium
channel blocking agent (Class IB antiarrhythmics i.e. mexilitin). The group of LQT3
patients that suffer from severe sinus bradycardy, may benefit from pacemaker
therapy or in combination with an implantable defibrillator [107]. In the group of LQT2
patients medical treatment was improved by a supplement treatment of exogenous
potassium therapy [108]. The effect of beta-blocker therapy in the LQTS population has
been reported in a retrospective study by Itoh et al [109]. In this study, physicians
reported that patients who carry a mutation in the KCNQl gene responded better to
beta-adrenergic blocking agents than those with a mutation in the KCNH2 gene.
Besides a gene specific response to medical therapy a gender effect on beta-
adrenoceptor blockade treatment has been reported as well by Conrath et al. This
study was performed in a Dutch group of genotyped patients having a mutation in
either locus LQTl or LQT2 [110]. The question has been raised whether pre-
symptomatic carriers of a genetic defect should be treated by medication. Vincent et al
recommended medical treatment of asymptomatic patients if they were under age 40
at the time of clinical diagnosis [ i l l ] . If therapy fails, a less frequent used therapy is
left stellate ganglion block or ablation. This treatment was based on the Sympathetic
Imbalance Theory [112]. Adrenergic stimulation increases the heart rate and by
blocking the autonomic nervous system by left cardiac sympathectomy (left stellate
ganglionectomy) this arrhythmogenic substrate may be circumvented [113].
Nowadays the application of an implantable defibrillator may be indicated if patients
maintain symptoms despite medication [24].
The influence of pregnancy among patients with LQTS was investigated in a large
study by Rashba et al. They showed that the postpartum interval (± 40 weeks) was
associated with a significant increase in risk for cardiac events and they proposed that
during pregnancy and postpartum intervals the prophylactic treatment should be
continued [114].
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Abstract
Congenital Long-QT Syndrome (cLOTS) is electrocardiographically characterized by a
prolonged QT-interval and polymorphic ventricular arrhythmias (torsade de pointes).
These cardiac arrhythmias may result in recurrent syncopes, seizure or sudden death.
The LQTS can occur either as an autosomal dominant (Romano Ward) or as an
autosomal recessive disorder (Jervell and Lange-Nielsen syndrome). Mutations in at
least five genes have been associated with the LOTS. Four genes, encoding cardiac ion
channels, have been identified. The most common forms of LOTS are due to mutations
in the potassium channel genes KCNOl and HERG. We have screened 24 Dutch LOTS
families for mutations in KCNQl and HERG. Fourteen missense mutations were
identified. Eight of these missense mutations were novel: three in KCNQl and five in
HERG. Novel missense mutations in KCNQl were Y184S, S373P and W392R and novel
missense mutations in HERG were A558P, R582C. G604S, T613M and F64OL The
KCNQl mutation G189R and the HERG mutation R582C were detected in two families.
The pathogenicety of the mutations was based on the segregation in families, the
absence in control individuals, the nature of the amino acid substitution and the
localization in the protein. Genotype-phenotype studies indicated that auditory stimuli
as trigger of cardiac events differentiate LQTS2 and LOTSl. In LQTSl exercise was the
predominant trigger. In addition a number of asymptomatic gene defect carriers were
identified. Asymptomatic carriers are still at risk to develop life threatening
arrhythmias, underlining the importance of DNA analyses for unequivocal diagnosis of
patients with LQTS.
Introduction
Congenital familial Long QT syndrome (cLQTS) can occur either as an autosomal
dominant or as an autosomal recessive disorder (respectively, Romano Ward and
Jervell and Lange-Nielsen syndrome; OMIM 220400). Both syndromes are characterized
by a prolonged QT-segment on the standard 12 lead electrocardiogram and
polymorphic ventricular arrhythmias known as torsade de pointes [l-3]- These
arrhythmias often occur in relation to exercise or emotional stress and may result in
recurrent syncope, seizures or sudden cardiac death [4]. In addition to the prolonged
QT interval the Jervell and Lange-Nielsen syndrome is associated with bilateral
sensorineural deafness [5).
The Long-QT syndrome is a genetically heterogeneous disease with 5 loci mapped (LQT
1-5) and 4 genes identified. As families have been described unlinked to these loci,
other chromosomal locations must exist [6]. Pathogenic mutations in the potassium
channel gene KCNQl (previously named KVLQTi; OMIM 192500) on chromosome
I l p l 5 5 [7], Human Eag Related Gene (HERG; OMIM 152427) on chromosome 7q35-36
38
[8] and the potassium channel regulatory gene KCNEl (minK; OMIM 176261) on
chromosome 2lq22.1-22.2 [9. 10] were identified in LQTl. LQT2 and LQT5 families,
respectively. A sodium channel gene SCN5A (OMIM 600163) located on chromosome
3p21-24 is associated with LQT3 [ l l ] . An as yet unidentified gene, located on
chromosome 4q23-24. is associated with LQT4 (OMIM 600919) [12]. Genes involved in
cLQTS encode proteins which form (part of) ion channels. These ion channels have
distinct functions in the regulation of cardiac action potential duration. Mutations in
the potassium channel genes KCNQl. HERC and the accessory subunit KCNEl lead to a
loss of channel function which diminishes the K+ current resulting in a prolonged
action potential duration. Mutations in the sodium channel gene SCN5A affect the
inactivation rate of the channel resulting in an increased Na+ current and a prolonged
action potential duration. Mutations in all four genes can result in the Romano Ward
syndrome. The Jervell and Lange-Nielsen syndrome has only been associated with
mutations in the KCNQl and/or KCNEl genes [10. 13-16]. The clinical diagnosis of the
LQTS can be difficult, due to the incomplete penetrance and variable clinical
manifestations of the syndrome. Asymptomatic patients and gene defect carriers with
normal or borderline QTc values (QTc=QT corrected for heart rate using Bazett
formula) are not uncommon in LQTS families. Untreated LQTS has a 10-year mortallity
of 50% [17]. Cardiac arrest can be the first symptom (in up to 10% of the affected
children) [18, 19]- Moreover cardiac arrest may occur in 4% of LQTS family members
without a prolonged QT interval [17]. In addition recently a very mild mutation in
KCNQl has been described, which only becomes manifest (Romano Ward syndrome) in
the homozygous state [20]. Therefore it is of clinical importance to identify both the
genetic defect and the carriers in a family.
A group of 24 Dutch Long QT index patients and families was studied to identify the
genetic defects for LQTl-5. If the family was large enough we used linkage analysis to
identify the locus involved or to exclude the other loci. Because the majority mapped
to the LQTl or LQT2 locus, we performed mutation analysis in the KCNQl and HERG
genes. Here we report 7 KCNQl mutations, of which 3 have not been described
previously and 5 novel HERG mutations, accounting for the disease in 14 of the 24
LOTS families. The pathogenicity of the mutations was established by genetic analyses.
Genotype-phenotype studies were performed to analyse the impact of the mutations
identified.
Subjects and Methods
LQTS patients
Patients were selected for genetic screening using criteria according to Schwartz et al
[4]. All LOTS index patients had an abnormal standard electrocardiogram (ECG) with
prolonged QTc values >440 msec. Syncopes were common and sudden cardiac death
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occurred in some families, most often in relation to either physical or emotional stress
and sometimes after an auditory trigger (Table l). None of the patients had hearing
problems and the segregation pattern in the familial cases was autosomal dominant.
Linkage or the triggers for arrhythmias were used as criteria to select the gene most
likely involved: physical stress for LOTl, acoustic trigger for LQT2 [21] and prolonged
QTc without physical stress for LQT3. If no indication for the involvement of LOTl, 2 or
3 locus was found, the LQT5 gene (KCNEl) was amplified and directly analysed by
sequencing.
Haplotyping
Genomic DNA was extracted from peripheral blood lymphocytes by the high salt
extraction method [22]. DNA haplotyping for loci LQTl-4 was performed by using a set
of 10 polymorphic microsatellite markers as described in detail by van den Berg et al.
[23] and included: D11S1318, TH01, D11S86O (LOTl); D7S483 and D7S636 (LQT2);
D3S1298 and D3S1100 (LQT3) and D4S193, D4S406 and D4S402 (LQT4). Primer
sequences were derived from the Genome Database (GDB). For microsatellite analysis
the forward primers were 5' labeled with fluorochromes HEX, TET or 6-FAM. DNA
fragments were amplified by the PCR reaction according to procedures optimized for
analysis on the ABI-377 automatic sequencer using gene-scan software 2.0 (Perkin
Elmer). Two intragenic polymorphic sites in HERG were used as additional markers in
linkage analysis. Primer set 3L and 8R for S3 (1489) and primer set 5L and 11R for S5 (L564)
were used for SSCP polymorphism [8].
Mutation screening
Genomic fragments coding for the six transmembrane domains and the pore region of
the KCNQl gene were amplified using the primer sets described by Wang et al [7]. The
S1-S6 regions, the pore region and the nucleotide binding domain (NBD) of HERG were
amplified by PCR using primer sets according to Curran et al [8]. Additional PCRs were
developed to amplify the S4S5 region (primer set 4L and 10R), the S1S2S3 region (356
bp, primer set 1L-9R) and the S4S5poreS6 region (449 bp, primer set 4L-12R) of HERG.
Using primer set 15L and 17R an intron, disrupting the NBD coding region in HERG, of
approximately 1000 bp was amplified. An intron primer int9F (primer sequence: 5'
CCC-CGG-GGC-TGA-GCT- CCC-TGT-C 3) was used in combination with primer 17R to
generate a 191 bp PCR product of the terminal part of the NBD region in HERG. PCR
conditions: 100 ng forward and reverse primer, 0.2 mM deoxyribonucleotides, 1 U Taq
DNA polymerase (Life Technologies), 1.5 mM MgCL and 100 ng genomic DNA (volume
50 ul). The coding region of KCNEl was amplified by PCR using primer sets as described
bySplawskietal [26].
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Table l .
Family
number
2164
1597
1855
2814
2379
1538
2362
1669
1602
1599
1656
2270
2475
2148
KCNQl and HERC mutations in Dutch LQTS families
Familial Sudden death
/trigger of syncope
One child died at age 6 in
swimming pool/
emotion; physical stress
One person died at age 28
physical stress/ playing
soccer
No sudden death/
physical stress
No sudden death/
physical stress;
swimming pool
No familial history; de
novo mutation; physical
stress
One person died at age 6
/physical stress
Two children died in
swimming pool at age
5'/i and 8/physical
stress
No sudden death/
physical stress,
swimming pool,
emotion
One person died before
age 40 after arousal/
acoustic
One person died during
sleep at age 27/acoustic
No sudden death/
acoustic
No sudden death/
acoustic
Father died during sleep.
Brother died before age
40/Acoustic
Uncle +aunt died before
41. Sister died at age
18/ acoustic
Gene
KCNQl
KCNQl
KCNQl
KCNQl
KCNQl
KCNQl
KCNQl
KCNQl
HERG
HERG
HERG
HERG
HERG
HERG
Domain
S2S3
S2S3
S2S3
pore
pore
S6
distal to
S6
distal to
56
S5
loop S5
pore
loop S5
pore
loop S5
pore
pore
S6
Mutation
codon '
Y184S
C189R
G189R
C314S
Y315S
C345R'
S373P
W392R
A558P
R582C
R582C
G6O4S
T613M
F64OL
Family
Members
tested
22
37
S
3
3
8
11
8
15
11
8
1
1
1
Carriers
10
17
3
2
1
5
7
5
3
6
4
1
1
1
Asympt.
carriers
S
2
1
_
_
_
1
3
_
4
2
_
_
_
' KCNQl codon numbering was according to sequence Yang et al [24] and Chouabe et al [25] Genebank
accession numbers: AFOOO571 and U86146. HERG codon numbering was based on sequence Genebank
accession number: UO427O.' published by van den Berg et al [23]
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Figure 1. Rsa I restriction analysis of the Y184S missense mutation in S2S3 region of KCNQi. The A->C
mutation results in loss of a Rsal restriction site. Mutation carriers show an additional fragment of 145
bp on Nusieve-agarose gel 2:1. Asymptomatic carriers in lane 2, 4, 6,12 and 15 (age 44,19,14, 9 and 9;
QTc values at rest were resp. 455, 450, 465. 457 and 468 msec). The undigested PCR product 242 bp is
PCR fragments were screened for single-strand conformation polymorphism (SSCP)
using the genePhor system (Pharmacia) and CeneGel Excell gels 12,5/24. Gels were run
at 5" C and 15" C according to manufacturers recommendations. The gels were silver
stained (Pharmacia PlusOne kit using an automatic stainer) and air dried. Amplified
products with aberrant SSCP bands were purified with a PCR purification kit (Qiagen).
The purified PCR products were sequenced with both amplification primers, forward
and reversed, using the Dye Terminator Cycle sequencing Kit (Perkin Elmer) and
analysed on an ABI-377 sequencer. Some fragments were sequenced directly without
prior SSCP analysis.
Tests for specific mutations
R582C mutation in HERC.
We used primer 12R and mismatch primer R582CmmF (primer sequence 5'
GAGCAGCCACACACATGGACGCA 3') to generate a PCR product. This mismatch primer
generates a Sphl restriction site if the mutation C->T (R582C) is present (PIRA=primer
induced restriction analysis). Incubation of the PCR product with Sphl endonuclease
results in fragments of 245 bp (wild type) and 225 bp + 20 bp (mutant). The bold
sequence is the generated Sphl site 5-GAGCAGCCACACA TGGACCCATCCAT-3'
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HERG S6 polymorphism Y652.
A 561 bp fragment, containing the region S6-intron-S6. was generated by PCR using
primer set 6L and 13R [8]. After Rsal endonuclease incubation the product was
analyzed on a Nusieve Agarose gel 2:1. Frequency of the T/C polymorphism is 0.47 [27],
Results
A total of 24 unrelated LQTS patients and families were available for DNA analysis. In
50% (12/24) of the LQTS families, linkage analysis could be performed and in these
families a role for either locus LQTl or LQT2 was likely (data not shown). The other
families were either too small, affected family members had died or the clinical data
were not complete. Mutation analysis was performed in KCNEl and in either the
KCNQl gene or HERG. as established by linkage or in both, if the data were
inconclusive. The pathogenicity of novel mutations was based on the location of the
substitution, the evolutionary conservation of the altered amino acid in related K+ ion
channel proteins of different species, the segregation with the disease in the family
and finally, by the absence of the mutation in 55 healthy control individuals.
Mutation analysis of the KCNQl-gene
The six transmembrane spanning segments including the pore region of the KCNQl
gene were screened by SSCP. We found different aberrant SSCP conformers in eight
different index patients, three in region S2S3, three in the pore forming region
S5-pore-S6 and two in the intracellular region distal to S6. All resulted from missense
mutations, four of them had been reported previously.
Family 2164 was analysed after the sudden death of a six year old girl while diving in a
swimming pool. Linkage analysis excluded the LQT2 and LQT3 loci. In this family a
novel missense mutation was found in the S2S3 region. The mutation results in loss of
a Rsal restriction site (Fig. l). By screening all available family members for the Y184S
mutation, nine additional carriers were identified. Five carriers, 3 male and 2 female,
were asymptomatic and one of the carriers did not show QTc prolongation. In family
1597 and family 1855 an identical missense mutation C189R was found. This missense
mutation located in the S2S3 region was published previously by Wang et al [7] as G60R.
Genealogical research demonstrated that these two families had a common ancestor
six generations ago ( ± 1780). Family 1597 was a large family with 37 members. In this
family 17 carriers of the G189R mutation were identified. Carriers showed mild
phenotypes with (sometimes borderline) prolonged QT values after physical stress,
although one exercise related sudden cardiac death occurred. In family 2814 we could
identify the mutation G314S. A de novo mutation Y315S was found in family 2379. The
child had clinical symptoms during physical stress and emotion. Both parents were not
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affected and non paternity was excluded by testing a set of highly polymorphic
markers (data not shown). The mutation G314S as well as the mutation Y315S were
previously reported by Donger et al. 1997 in two French families. Finally we found two
novel missense mutations S373P and W392R in family 2362 and family 1656. These
mutations are located in the intracellular part of the ion channel, distal to the S6
transmembrane spanning region. Seven gene defect carriers in family 2362 showed
QTc values ranging from 422 to 540 msec (at rest). One of these seven carriers did not
show a prolonged QTc value, but he was using ß-blockers for many years. In this family
two children (age 5Vi and 8) died in a swimming pool while diving. In family 1656 all
children (3 male and 1 female) inherited the maternal gene defect. The mother (QTc
452 msec) had no specific clinical complaints. Two of her children (QTc 503 and 450
msec) showed clinical symptoms during physical stress (in a swimming pool) and
emotion, respectively, and two did not show clinical symptoms (QTc 518 and 475
msec). The reported QTc values were determed at rest.
Table 2. Evolutionary conservation of substituted amino acids in HERG
Genbank
Species number A558P RS82C G6O4S T613M F640L
1 Homo sapiens Erg ÜÖ427O A R C T F
3. Rattus Norvegicus Erg- U422O4 A K G T F
4. Rattus Norvegicus Erg- AFO16191 A K G T F
5. Rattus Norvegicus Elk-1 AJOO7628 A L G T F
6. Rattus Norvegicus Elk-2 AJOO7627 A E G T F
7. D Melanogaster Eag M61157 M Q G T F
8. D. Melanogaster Erg QO228O I N G T F
Similar to KCNQl we screened the six transmembrane spanning regions including the
pore and the putative nucleotide binding domain (NBD) of HERG, using primers sets as
described by Curran et al [8]. Because not all intron sequences were available to
generate PCR primers, we started amplifying and sequencing the small 328 bp intron,
that disrupts the S6 spanning region of HERG, with primers 6L and 13R. For screening
the nucleotide binding domain, which is also interrupted by an intron, a new forward
primer (intron 9F) was designed. Six missense mutations were identified. The
pathogenicity of the novel HERG missense mutations were based on the location of the
substitution, the evolutionary conservation (Table 2) of the altered amino acid in
related K+ ion channel proteins of different species, the segregation with the disease in
the family and finally, by the absence of the mutation in 55 healthy control individuals.
Mutation analysis of HERG
Family 1602 was initially misdiagnosed and treated for epilepsy. A young woman (age
22) died suddenly upon arousal from sleep by an alarm clock. We found an aberrant
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SSCP pattern in region S4S5. The SSCP pattern was rather complex due to the
additional A->C polymorphism (L564) in the S5 domain of HERG. This silent mutation
in the S5 region was only 20 bp away from the novel A558P missense mutation. A loss
of a Hhal restriction site, generated by the novel missense mutation, was used to
screen family members. Only one person in generation II was carrier of the A558P
mutation, although some of his brothers and sisters shared the same haplotype (Fig.
2).This strongly suggests that the mutation was de novo. Family 2148 (Surinam
background) and family 2475 were individual gene carriers directly analyzed for HERG
mutations as the trigger for their arrhythmias (auditory stimuli) and the ECG were
indicative for the LQT2 locus [21].
Several families linked to the HERG locus by haplotyping did not show aberrant
conformers by SSCP analysis. Therefore, the transmembrane segments were
sequenced to test whether we had missed mutations. Using this strategy two
additional missense mutations in three families were identified. In two apparently
unrelated families, family 1599 and family 1656 we identified a new missense
mutation R582C. This mutation did not result in an aberrant SSCP with any
combination of primers used in this study. Therefore a mismatch primer was designed
to prove the mutation by generating a restriction site. In the families 10 carriers were
identified, of which 6 were asymptomatic carriers (no clinical symptoms). In family
2270 the G604S was at first not detected by SSCP analysis, as the mutation was
located within primer binding site 6L, initially used to generate a PCR product for SSCP
analysis. By using a different primer 1883F, located 6 bp 3' to the S5 polymorphism, the
mutation could easily be detected by SSCP analysis.
Discussion
Since the recognition that the KCNOl (KVLOTl) and HERG genes were involved in cLQT
syndrome, many mutations in these two genes have been published. Together with
the SCN5A and KCNEl gene they form a group of transmembrane proteins involved in
cardiac ventricular repolarization. An abnormal repolarization rate is the main cause of
ventricular arrhythmias known as torsade de pointes leading to syncope and
occasionaly sudden cardiac death. A gene described in a single French LQTS family and
linked to chromosome 4 (LQT4) is still unknown. Until now 42 KVLOTl [28, 29, 30] and
24 pathogenic mutations in HERG (Table 3) have been described. As suggested by
Curran et al. [8] and Wang et al. [7] mutations in the genes KCNQl and HERG are the
most prevalent in families with cLOT syndrome, which is supported by the linkage data
in our families. Therefore we have focused on genetic analysis of these two genes. In
14 LOTS families we have identified 12 different missense mutations, eight of which
have not been described before. The pathogenicity of the mutations was based on
genetic criteria. In five families with linkage to either the LOTl or the LQT2 locus, no
mutations were found as yet. These mutations may be present in exons which have
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not been screened, or in introns or regulatory sequences.
In two families we found an identical missense mutation C189R in KCNOl. In our case,
a common ancestor was likely by genealogical studies. This mutation has been
described by Wang et al [7]. The novel missense mutation Y184S is located within the
same S2S3 area as the C189R mutation in KCNOl. In this family 8 carriers were
identified of which 5 were asymptomatic and l did not show an increased QT interval.
Mutations in the region S2S3 have in general been associated with a less severe
phenotype than mutations in the S4S5 loop and pore domain [28]. However, one has
to be careful in drawing conclusions for individual patients, as examplified by the
death of a 6 year old girl (while diving in a swimming pool) from a family with the
Y184S mutation.
A de novo mutation Y315S and a missense mutation G314S were found in the pore
region of KCNQl. Identical missense mutations have been reported in two French
families by Donger et al [28]. These patients, comparable to our patient, had their first
syncope before age of 10. This missense mutation is associated with a high risk of
sudden death if untreated. De novo mutations in LOTS were previously reported for
HERC [8]. The novel missense mutations S373P and W392R occurred in highly
due to the change of the amino acid serine into the more rigid proline which has the
ability to disrupt alpha helixes. In case of the W392R mutation, the hydrophobic amino
acid tryptophan changes into the strong basic and hydrophylic arginine. Mutations in
this intracellular part of the ion channel distal to S6 were described by several authors [28,31].
In contrast to the KCNQl mutations, the HERC mutations reported in this study were
exclusively found in the pore forming regions. Some of the previously reported HERC
mutations have been tested in physiological experiments. Similar physiological
properties might be expected if comparable amino acid substitutions occur in the
same region. The A558P mutation is located in the vicinity of the A561V and A561T [8,
31, 32]. Sanguinetti et al [33] and Smith et al [34] reported a strong dominant negative
effect in a cotransfection study of the A561V missense mutation and wild type HERC
The novel missense mutation R582C is located in the extracellular loop between S5
and the pore forming unit. Although the arginine at codon 582 is not a well conserved
amino acid, the substitution to a cysteine may result in conformational changes and
loss of function due to the formation of disulfide bonds. A novel missense mutation
T613M is located in an area where missense mutations occur frequently, like Y611H,
V6l2LandA6l4V[31, 38],
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Table 3
Codon
del 1261
N470D
T474I
1489
Y493X
del 1500-
F5O8
F513
R534C
A558P
A561T
A561V
L564
C572C
R582C
N588D
I593R
S600S
C601S
C6O4S
Y6UH
V612L
T613M
A614V
C628S
N629D
N629S
V63OL
V63OA
N633S
F64OL
M651del
AT
M 1
Y652
Q725X
Int9-3nt
V822M
Summary of HERC mutations
Region
SI
S2
loopS2-S3
loopS2-S3
loopS2-S3
S3
S3
S4
S5
S5
S5
S5
S5
loop Ss-pore
loop S5-pore
loop S5-pore
loop S5-po«
loopS5-pore
loopS5-pore
pore
pore
pore
pore
pore
pore
pore
pore
pore
pore
S6
S6
S6
S6
NBD
NBD
E847/E857 NBD-ter
del
Exon
6
6
6
6
6
6
6
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
8
8
9
Intron S
10
10
Location'
1261
1408
1421
1476
1488
1498
1539
1599
1671
1681
1682
1692
1714
1743
1762
1777
1799
1800
1809
1831
1833
1837
1840
1881
1884
1885
1888
1889
1898
1919
1950-1951
1956
2172
1 2398-3nt
2463
2539-2569
Mutation
lbpdelA
aac->gac
acc->atc
atc->att
tac->tag
27bpdel
ttc->ttt
cgc->tgc
gcg->ccg
gcg->acg
gcg->gtg
eta•>ctg
ggc->tgc
cgc->tgc
aac->gac
ata->aga
ggc->agc
ggc->agc
tat->cat
gtg->ttg
acg->atg
gcg>gtg
ggc->agc
aac->gac
aac->agc
gtc->ctc
gtc->gcc
aac >agc
ttc->tta
2 bp del at
tat->tac
cag->tag
g->c
gtg>atg
31 bpdup
Reference
Curran et al [8, 35]
Curran et al [8]
Tanaka etal [31]
Curran et al [8]
Itoh et al [36]
Curran etal [8]
Schulze-Bahr [27]
Itoh etal [36]
This study
Dausseet al [32]
Curran etal [8]
Tanaka etal [31]
Curran et al [8]
Splawski etal [26]
This study
Splawski etal [26]
Benson et al [37]
Akimoto et al [39]
This study
Tanaka etal [31]
Satler etal [38]
This study
Tanaka [31] Satler [38]
and Splawski etal [26]
Curran et al [8]
Satler etal [38]
Satler etal [38]
Tanaka etal [31]
Splawski et al [26]
Satler etal [38]
This study
Itoh etal [36]
Schulze-Bahr [27]
Itoh et al [36]
Curran et al [8]
Satler et al [40]
Itoh et al [36]
Remarks
truncated protein
prot. A,
phosphorylation
site
polymorphism 37%
polymorphism 47%
polymorphism
44%
change in K+
selectivity and
permeability
cryptic spVice srte m
frame deletion 50
AA
de novo mutation
frameshift
polymorphism
22%
frameshift
' A of the ATC start codon is nucleotide position l(Cenebank accession number UO427O)
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The missense mutations T613M and A614V are situated in a CpC sequence, which are
known as mutational sensitive spots due to deamination of 5 methylcytosine at the
CpC dinucleotides. Finally, the novel missense mutation T64OL is located in the
terminal part of the pore region (outermouth) and is a highly conserved amino acid in
different species. Although the functional effect of this mutation has not been
determined, physiological tests demonstrate that mutations in this region show an
increased inactivation rate and loss of selectivity for K+ [34].
In conclusion a total of 24 Dutch LQTS families were screened for mutations in the
KCNQl and HERC genes. In 14 families missense mutations were found. In addition a
number of asymptomatic gene defect carriers were identified. Asymptomatic carriers
are still at risk to develop life threatening arrhythmias, underlining the importance of
DNA analysis for unequivocal diagnosis of patients with LQTS.
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CHAPTER 4
Abstract
Congenital Long QT Syndrome (LOTS) is electrocardiographically characterized by a
prolonged QT interval and polymorphic ventricular arrhythmias (torsade de pointes).
As a result of these arrhythmias patients suffer from recurrent syncopes, seizures or
sudden death as the most dramatic event. Mutations in five genes, encoding cardiac
ion channels, have been identified in LQTS. Two potassium channel genes (KCNOl and
KCNH2) are frequently involved in LOTS. Potassium channel defects account for
approximately 50-60% of LQTS. As patients benefit from preventive medication, early
detection of a genetic defect is desired to identify the family members at risk. Speed
and sensitivity of mutation detection was improved by applying the denaturing high
performance liquid chromatography (DHPLC) technique for analysis of the entire
KCNQl and KCNH2 genes and the protein encoding part of the KCNEl and KCNE2
genes. By using this methodology, seven missense mutations in the KCNQl gene and
nine mutations (four missense, two nonsense, one insertion and two deletions) in the
KCNH2 gene have been identified in a total number of 32 index patients diagnosed
with LQTS syndrome. We conclude that this method is suitable for rapid identification
of LQT gene defects due to the combination of automation, high throughput,
sensitivity and short time of analysis.
Databases: KCNQl • OMIM: 192500; GDB: 741244; Cenbank: AFOOO571
KCNH2 • OMIM: 152427; GDB: 138126; Genbank: UO427O
Introduction
Congenital Long-QT Syndrome (LQTS) is an inherited cardiac disorder caused by an
abnormal cardiac repolarization time. A prolonged QT-interval on standard 12 lead
ECG, T-wave abnormalities, and occasionally polymorphic ventricular arrhythmias
known as Torsade de Pointes (TdP) characterize the disease [ l ] . These arrhythmias can
result in recurrent syncope or sudden death as the most dramatic event [2-4]. Two
clinical forms of LQTS exist; the Romano Ward syndrome (RWS) and the Jervell and
Lange-Nielsen Syndrome (JLNS; MIM# 220400). The segregation pattern of the cardiac
symptoms is autosomal dominant for both the Romano Ward syndrome and the
Jervell and Lange-Nielsen Syndrome (JLNS) while the bilateral sensorineural deafness is
unique for JLNS and is inherited as an autosomal recessive trait [5, 6]. Six chromosomal
loci have been shown to harbor genes causing LQTS (LQTi-6), two of which are
involved in JLNS (JLNSl-2) [7, 8]. Until now many mutations have been identified in five
of these genes, encoding ion channels proteins [9], leaving only one locus (LQT4; MIM#
600919) unresolved at this point (io).
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Two genes KCNQl (LQTl; MIM# 192500) and KCNH2 (LQT2; MIM# 152427) encode the
alpha-subunits of cardiac potassium ion channels [11. 12] regulating cardiac
repolarization in the late phase 3 of the cardiac action potential. A cardiac sodium ion
channel, important for initial depolarization of cardiac myocytes is encoded by the
gene SCN5A (LQT3; MIM# 603830) [13). Mutations in the SCN5A gene also have been
associated with Brugada syndrome (MIMft 601144), Idiopathic Ventricular fibrillation
(tachycardia) and Lenegre-Lev's disease or Progressive Cardiac Conduction Disease
(PCCD; MIM# 604559) [14-16], Sudden Infant Death Syndrome (SIDS; MIM# 272120)
(17] and sudden unexplained nocturnal death syndrome (SUNDS) [18]. Two minor
genes KCNEl (MinK; MIM# 176261) and KCNE2 (MiRPl; MIM# 603796) encode
potassium channel regulatory proteins or ion channel ß-subunits. Both are located on
chromosome 21 and associated with LQT5 and LQT6. Co-assembly of the auxiliary
protein MinK and MiRPl with ion channel gene products of KCNQl and KCNH2, form
functional ion channel currents IK, and IK, respectively [7. 19]. The vast majority of
mutations associated with LQTS. have been identified in KCNQl and KCNH2 [9].
Mutations are registered in the Long QT database (address:
www.ssi.dk/en/forskning/lqtsdb/lqtsdb.htm).
Mutation detection has mainly been performed by Single Strand Conformation
Polymorphism Analysis (SSCP) which has a maximum detection sensitivity of 80% [20].
To improve the speed and sensitivity of mutation analysis, which is important to
detect treatable carriers of potentially lethal disorders like LQTS, we developed a
Denaturing High Performance Liquid Chromatography (DHPLC) based protocol to
screen the KCNQl and KCNH2 (HERG) genes. Although KCNEl and KCNE2 are not
frequently involved in LOTS, the protein encoding part of the two minor genes KCNEl
and KCNE2 was additionally screened to exclude their involvement. DHPLC is an easy
and non-destructive detection method with a nearly 100% detection rate in blind trials [21].
The method is based on different melting temperatures between hetero- and
homoduplexes of mutated and wild type DNA fragments, generated by Polymerase
Chain Reaction (PCR). Unpurified fragments are injected and attached to the solid
phase of the DHPLC column. At a temperature just below melting temperature,
fragments are eluted from the column by using a linear acetonitrile gradient. The
reduced affinity of melting DNA for the solid phase ensures that the less stable
heteroduplexes are eluted prior to homoduplexes [22]. Until now several investigators
have reported the implementation of DHPLC for diagnostic screening purposes. Genes,
like BRCAl and BRCA2, Notch3 with a high GC-content, MepC2, and TSCl and the
entire mtDNA have been analyzed successfully [23-27]. The DHPLC system allows
automatic analysis of DNA fragments within minutes. For a detailed review we refer to
XiaoandOefner[28].
Here we report the optimized protocol for screening the potassium channel LOTS
genes by DHPLC analysis and mutations identified in the KCNQl and the KCNH2 gene,
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in individuals with clinical symptoms of Long QT syndrome. Additionally we report a
number of single nucleotide polymorphisms (SNPs), additionally identified in exon and
intron sequences of KCNQl, KCNH2 and KCNE2 genes identified in the 32 families
analyzed by this method.
Materials & methods
Patients
Thirty-two blood samples of index patients from Dutch (# 30) and Belgian (# 2)
families, diagnosed with congenital Long-QT syndrome, were sent to our genetic
center. In one family linkage was found with the LOTl (KCNQl) locus, but no mutation
was detected by SSCP analysis. DNA samples from 13 individuals, with a previously
identified genetic defect in either the KCNQl (8 mutations) or KCNH2 (5 mutations)
gene, were used as positive controls to verify the efficacy of the DHPLC mutation
detection system. These mutations were identified in our laboratory by using SSCP and
sequencing analysis and have been described previously [29, 30].
Amplification of the KCNQl gene
DNA fragments were generated by using combinations of primers as described
previously by several investigators [12, 31, 32]. All exons, numbered according to
Splawski et al.,[33] and encoding four isoforms of the KCNQl gene, were amplified.
Primer sequences and PCR conditions are presented in Table 1. Exon l of the KCNQl
gene was amplified in two overlapping fragments (exon l . l and exon 1.2) by using a
TouchDown PCR technique (TD-PCR) [34]. Genomic DNA was diluted to 50 ng/pl and
amplified in a total volume of 50 ul. For PCR reactions a Perkin Elmer 9700 PCR thermal
cycler (Applied Biosystems, Foster City, CA), lOx reaction buffer and 50 mM MgCI^
solutions, provided by Life technologies (Breda, The Netherlands), 100 ng forward
primer and reversed primer, 0.2 pM dNTP (Amersham Pharmacia Biotech, Uppsala,
Sweden), lUnit Taq DNA polymerase (Qiagen, Leusden, The Netherlands) were used.
Amplification of the KCNH2 gene
All exons, encoding the entire sequence of the KCNH2 (HERC) gene, were PCR
amplified. Primer combinations (Table 2) were selected from previously described
reports [11, 29, 31, 32, 35]. PCR reactions were performed as described for the KCNQl
gene, except that 40 cycles of amplification were used for exon 5- To amplify exon l , a
final concentration of IM betaine was supplemented to the reaction mix in a final
volume of 25 n'
Amplification of the KCNEl and KCNE2 genes
Mutation detection was performed for the protein encoding part (exon 3) of the
KCNEl gene and the KCNE2 gene. PCR conditions and primer sequences, selected from
previous reports, are presented in Table 3 [19. 3l].
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DHPLC analysis
Prior to DHPLC analysis, a re-annealing step was introduced after DNA amplification.
PCR products were denatured at 95°C for 5 minutes and cooled down to 65°C
(l°C/min). Amplified fragments of KCNH2 exon l were purified by using the Qiaquick
PCR purification kit protocol (Qiagen, Valencia, CA) to avoid betaine loading on the
column.
DHPLC analysis was performed on an automated DNA fragment analysis system
(Wave™ , Hitachi model D-7OOO version 3.0, Transgenomics, San Jose, CA). The PCR
product (5-10(jl) was injected on a preheated column packed with alkylated nonporous
polystyrene-divinylbenzene particles (DNASep. Transgenomics). DNA was eluted from
the stationary phase by using a linear acetonitril gradient formed by mixing buffer A
(0,1 M triethylamine acetate TEAA. pH7O) and buffer B (0,1 M TEAA, pH70 with 25%
v/v acetonitrile; Biosolve LTD, HPLC grade). The increase of buffer B was 2% per minute
at a flow rate of 0,9ml/min. Buffers were prepared with milliQ water (18,2 MOcm).
Optimization was initiated by deducing the optimal %B (based on the retention time
at 50°C) for each amplified fragment by using a nondenaturing universal gradient
(buffer B gradient: 40-72%; 16 min running time). Subsequently the appropriate
gradient %B and column temperatures, ranging from 56°C to 70°C (2°C interval), were
used to construct the DNA melting curve. From these empirically determined data the
oven temperature for optimal mutation detection was obtained and compared with l)
the theoretical data calculated by the melting algorithm freely available at the
Stanford DHPLC website http://insertion.stanford.edu/melt.html and 2) the melting
program provided by WAVEmaker 4.0 utility control software (Transgenomics, Inc). By
combining these results, temperatures for successful heteroduplex separation were
achieved. Some fragments showed distinct melting domains. In those cases additional
analyzing temperatures were used.
The analytic conditions were optimized for 6.7 minutes total running time. The initial
and final concentrations of buffer B (2% per minute for 5 minutes) were adjusted to
obtain retention times between 3 and 4 minutes. After each run the column was
cleaned with 100% buffer B and equilibrated (1.5 min) at the starting conditions. If
available, positive controls were run at temperatures preferably 1-2 degrees above and
below the empirically calculated running temperature. The elution profiles were
independently judged by two technicians. Also a reduced peak signal or peak
broadening was considered to be suspicious if equal amounts of DNA samples had
been loaded to the stationary phase. The optimized elution profiles and melting
temperatures of the entire coding sequences of KCNOl and KCNH2 are presented in
Table l and 2 respectively. Analyzing conditions for KCNEl and KCNE2 are presented in
Table 3.
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TaMe 1. Conditions for amplification and DHPLC analysis of KCNQl (KvLQTl)
KCNQl
exon
1.1
12
l b
lc
2
2a
3
4
5
6
7
8
9
10
11
12
13long
13short
14
15
16
Region
Sl
Isoform2
Isoform3
S1S2
Isoform4
S2S3
S3S4
S4
S5-pore
pore-S6
S6
[MgCIJ
1.0 mM (")
1.0 mM (")
15 mM
15 mM
1.0 mM
1.5 mM
1.5 mM
1.0 mM
l.SmM(')
1.0 mM
1.0 mM
1.0 mM
mM(')
1.0 mM
1.0 mM
1.5 mM
1.0 mM
1.5 mM
1.5 mM
0.5 mM
1.0 mM
Tan °C
PCR
TD 70-60
TD 70-60
56
56
56
56
56
60
TD 70-60
62
62
62
TD 70-65
56
60
64
62
60
64
64
60
Product
base pairs
334
244
238
228
210
397
242
171
123
236
195
191
267
295
248
233
236
170
161
217
390
Primer forward S'-3"
ctcgccttcgctgcagctc
cgccgcggccccagttgc
ttactcagcccacatcacg
ccttccatgcatgctttca
gtgcatctgtgggatgggca
ccgagcaccattcaacataagtc
cagggtctgaagccactcaag
ctcttccctggggccgtggc
gggcatccgcttcctgcaga
tcctggagcccgacactgtgtgt
tggctgaccactgtccctct
gctggcagtggcctgtgtgga
gggaacagggagggggagct
agggcctggcagacgatgtc
cctggccctgggagctcaca
gcaggggcagtgaggggatg
tggggcacagggaggagatg
tggggcacagggaggagatg
gcagtgccagggccaggtgt
cccggcccaccccagcactt
gttggcaccttcccttctctg
Primer reversed 5'-3"
gcgcgggtctaggcttacc
cagagctcccccacaccag
cacccataactgaccacaattc
gacacgtgggcagctcaagg
agggagatgccagcttccaa
ctgaaatgagtgcctcgag
cttcctggtctggaaacctggg
tgcgggggagcttgtggcacag
ctgggccccgcacccctaaccc
tgtcctgcccactcctcagcct
ccccaggaccccagctgtccaa
aacagtgaccaaaatgacagtgac
ggcctccccacctgctagca
cacagcccaagggagaaa
cctccagcccagcccttcac
ggcaggagagaacccaggag
caccctccccgctgccgttt
ctcagcccctccctcctccg
agggcagaggtgcgggagag
gggaggcctgcaggagcttc
ctcttggcctcccctctcact
Gradient
% B;Temp °C
55%-65%; 66
52V62%; 66
52%-62%;59
52%-62%;56
49%-59%; 64
57%-67% ; 61
52%-62% ; 66
48%-58% ; 65
45%-55%;64
56%-66%;6l
50%-60% ; 62
50%-60%; 62
53%-63%;63
54%-64% ; 60
52%-62%;62
52%-62%;62
54%-64%; 63
49%-59%; 64
47%-57%;63
50%-60%; 65
55%-65%;66
Gradient
* BJemp »C
55%-65%;71
52%-62%; 64
52%-62%;64
57%-67%; 64
45%-55%;65
54%-64X;63
54%-64%; 66
Primer sequences are according to Splawski et al., [1998]. The
reaction mix. The DHPLC gradient is setup for 5 minutes which
an increase of 2%B per minute. Tan = annealing temperature
symbols (•) and (") indicates
indicates that the gradient v,m
final concentration of 5% DMSO and 10% DMSO is added to the
start at low %B (buffer B) and increase to high %B (buffer B) with
Table 2. Conditions for amplification and OHPLC analysis of KCNH2 (HERC)
HERG-A
Exon
1
2
3
4.1
4.2
5
6
7
8
9
10
11
12.1
12.2
13
14
15
HERG-B
l b
Region
PAS
S1-S3
S4-S6
S6
NBD
NBD
[MgCIJ
2.0 mM(")
0.5 mM
1.0 mM
1.0 mM(")
1.0 mM(")
0.5 mM
1.5 mM(")
1.0 mM
1.0 mM
1.0 mM
0.5 mM
1.0 mM
0.5 mM
0.5 mM
0.5 mM
0.5 mM
0.5 mM
0.5 mM
Tan°C
PCR
TD 62-50
TD 70-65
TD 68-58
642
677
TD 65-55
64
64
62
62
62
TD 70-65
49
58
TD 65-55
62
62
TD 70-60
Product
basepairs
144
305
215
267
319
279
505
400
327
331
291
189
271
209
274
287
251
200
uso 1.0 mM 62 532
Primer forward 5- 3'
ccgcccatgggctcagg (l)
cgcactctcctcaccgcccc (l)
tgcccactgagtgggtgc (2)
acgaccacgtgcctctcctctc (2)
ccctggacgaagtgacagccatgg (2)
gcctcaccacgctgcctct (2)
gtcccatggcctgcctcacc(3)
tgccccatcaacggaatgt (l)
ctgacctggtgcggggcctg (3)
ccaagggagggtgtgctgag (2)
ccccggggctgagctccctgtc (3)
aagggecctgatactgatttt ( l)
tgaggcccattctctgtttcc (4)
tgagagcagtgaggatga (2)
ctgacccagctctgctctctg ( l)
atcccggtggaggctgtca (2)
tgcccatgctctgtgtgtattg (l)
Primer reversed 5'- 3'
catccacactcggaagaagt (2)
ccctcttgaccccgcccctg (1)
tgaccttggacagctcacag (2)
gggacccaccagcgcacgccg (2)
ggctggggcggaacgggtcc (2)
cctccaaggtgagaggaga (2)
ctacaccacctgcctccttgctgac (1)
gcccgcccctgggcacactca (1)
cccagcctgccacccact (3)
ggcatttccagtccagtgc (2)
tccagctcagggcagccaa (2)
ttccagctcccagcctca (2)
cttctcgcagtcctccatca (2)
tagacgcaccaccgctgcc(2)
caccaggacctggaccagact ( l )
gaacaagcgggccacggtac (2)
acgtgtccacactgggcag (2)
Gradient
%B;Temp"C
5l%-61%; 66
59%-69%; 65
57%-67%; 63
57%-67%; 68
56%-66%; 63
58%-68%, 63
6l%-71%;63
62% 72%; 63
62%-72%;64
59%-69%; 65
58% 68%; 64
56%-66%; 63
54%-64%;
57%-67%;
55%-65%;
57%-67%;
58%-68%. 64
57%-67%; 62
62
63
65
65
Gradient
%B; Temp "C
44%-S4%; 70
53% 63%; 68
57%-67%; 64
56%-66%; 69
56%-66%; 71
57%-67%;66
60%-70%; 64
62%-72%;65
62%-72%; 66
59%-69%; 66
58% 68%; 65
56%-66%; 64
55% 65%; 64
55%-65%; 66
52%-62%; 68
55%-65%; 66
55%-65%; 66
S4%-64%; 66
ggtgcaggtgaggcagtgg (1) cggccccagaaagaagaggaa (l) 54%-64%;64 52%-62%;68
agcactgcaaacccttccgag tagtgaaaccaaatgccgagc 62% 72%; 60
62%-72%; 64
58%-68%. 66
Primer sequences are according to Splawski et al.,1998 (l); Itoh et al., 1998 (2); Jongbloed et al„ 1999 (3); Janssen Pharmaceutics (4) (personal communication).
The symbols (') and (") indicate a final concentration of 5% DMSO and 10% DMSO is added to the reaction mix. The DHPIC gradient is setup for 5 minutes which
indicates that the gradient will start at low %B (buffer B) and increase to high %B (buffer B) with an increase of 2%B per minute. For the amplification of KCNH2
exon 5 a total number of 40 cycles were used. Tan = annealing temperature. 3
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noncoding region intron 13 (IVS13+36 g>a). The disease causing mutation is situated
in the intracellular C-terminal protein part of the KCNQl ot-subunit. It creates an
additional 'unique' Taql restriction site. This was used to identify carriers of the gene
defect in this family. Subsequently we developed a more 5' upstream primer
(exl3short) to avoid the intronic polymorphism (Figure ID). All mutations mentioned
in this report have been identified in the Dutch families except for the mutations,
Ala34lVal (1022 C>T) and Cly3l6Arg (946 C>C), which originated from Belgium.
»ildtvpc LI 14P wildl>pe 0JI6R A34IV wild typo I.27H
15 JO 4 < I ^ 4 0 4 S 40 n 111 4 \ 4 0 4 \ M 4(1 * * 4<>
KCNQl exon I 2 64%B-66X KCNQl exon 7 62%B-62*C KC NQI cxorWi 6l"!'aJ-65f
»ildtype K557K M<7I- • S546
,„, KCNQl exon 13 61 %B-64T KCNQl ex H 60%B-65°C
Figure 1. DHPLC elution profiles of five out of seven KCNQl missense mutations identified in families
with LOTS. The first elution profile in each block refers to the wild type of the exon analyzed. The DHPLC
condition (Gene, exon, %B and temperature) is indicated below the elution profiles. At the X-axis of the
elution profiles, a time scale (minutes) indicates the elution time of the DNA fragments. The Y-axis (not
shown) the absorption at 260 nm wavelenght indicates the amount of DNA. Note the decrease in
absorption if additional peaks are present indicating a DNA variant. For this reason the subdivision of
the Y-axis was kept constant for each block (A-E). An arrow indicates the DNA-heteroduplex fragments
that are eluted prior to the DNA-homoduplexes. D: The elution profiles in exon 13(short) of the
nucleotide variant S546S and the missense mutation K557E and a combination of both S546S + K557E.
Analysis of KCNH2
All positive controls were also readily detected by DHPLC analysis in the KCNH2 gene.
Next, we identified 16 elution profiles that were different from wild type DNA samples
(Figure 2). Sequencing analysis revealed eight novel mutations, one previously
reported missense mutation and seven single nucleotide variants (SNPs) within the
KCNH2 gene (Tables 4 and 5).
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Table 3. Conditions for Amplification and DHPLC analysis of KCNEl and KCNE2
Region , , J " Product Primer Primer Gradient Gradient
Gene ° MgCI,] C % B;Temp % B;Temp
exon ° p£g bp forward 5 - 3 reversed 5-3 „^ o^
KCNEl 3 I S m M 62 446 cct-gca-gca-gtg- agg-tgt-cca-gtt- 57%-67%;
KCNEl 3 1.5 ml» 62 44b gaa-cct-taa-tg tag-cca-gtg 64
KCNE2 3 1 0 m M 53 2 470 ccg-ttt-tcc-taa- tgt-ctg-gac-gtc- 47%-57%; 47%-57%;
KCNE2 3 1.0 mM 53 2 470 cct-tgt-tcg aga-tgt-tag 66 70
Primer sequences are according to Splawski et al., 1998 (KCNEl; Mink) and Abbot et al., 1999 (KCNE2;
MiRPi). Tan • annealing temperature.
Sequencing analysis
PCR fragments were purified with Qiaquick PCR purification kit (Qiagen) and
sequenced using the Big-Dye termination cycle sequencing kit (Applied Biosystems).
Sequencing reactions were purified using ethanol precipitation and applied on a
automatic sequencer (ABI3100; Applied Biosystems).Results
Analysis of KCNQl
Without exception, all positive controls were readily identified in the KCNQl gene as
abnormal DHPLC profiles. Next, within the group of 32 individuals we observed 20
different elution profiles by DHPLC analysis (Figure l). After sequencing analysis we
identified seven disease causing missense mutations and fourteen single nucleotide
polymorphisms (SNPs) within the coding and noncoding regions of the KCNQl gene
The disease causing missense mutations are presented in order of amino acid
numbering in Table 4 and the single nucleotide polymorphisms in Table 5. Some of the
DHPLC elution profiles demonstrating profiles of wild type and missense mutations are
presented in Figure 1 (A-F). Three of the missense mutations mentioned above were
novel and had occurred in exon 1 (Leull4Pro; 34lT>C), exon 7 (Gly3l6Arg; 946 G>C)
and in exon 13 (Lys557Glu; 1669 G>A). These mutated amino acids were highly
conserved in several species, segregated with the disease in the family and were
excluded in at least 100 control chromosomes from a group of healthy individuals,
thereby strongly supporting a pathogenic role. The mutation Leull4Pro is located in
the initial intracellular part of the N-terminus of the KCNQl protein. The mutation
Gly3l6Arg occurred in the pore-S6 domain and is surrounded by several, previously
reported, missense mutations identified in LQTS patients. The final novel mutation
Lys557Glu resides in the C-terminal part of the potassium ion channel. A member of
the family, previously linked to KCNQl, showed an abnormal elution profile in exon 13
(exl3long) after re-analyzing by DHPLC that had not been detected as an aberrant
conformer by SSCP analysis. Within this amplified product, using sequencing analysis,
three nucleotide substitutions were identified. Besides the novel missense mutation
Lys557Glu two additional polymorphisms were present in the same PCR fragment, the
previously reported silent mutation Ser546Ser G>A [36] and a g to a transition in the
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Examples of elution profiles are presented in Figure 2 (A-E). Four mutations cause
amino acid substitutions and five mutations result in a stop codon which causes a C-
terminal truncated u-subunit of the KCNH2 protein. Two novel missense mutations
Leu87Pro (260 T>C) and Tyr99Ser (296 A>C) have been identified in exon 2 and are
located within the PAS domain of KCNH2. DHPLC analysis of exon 6 indicated the
presence of a nonsense mutation Tyr447stop (1341 A>C) and a novel missense
mutation AspSOlAsn (1501 C>A) in 2 unrelated patients. They are located in the Si
and S3 transmembrane spanning segments respectively (Fig. 2E). A nonsense mutation
Glu698stop (2092 G>T) was identified in exon 8 which encodes the S6-II domain and
creates a premature stop in the intracellular region S6-NBD (nucleotide binding
domain) of KCNH2. In exon 10 the insertion of one nucleotide at position (247linsG;
L824fs828) and in exon 11 a deletion of one nucleotide at position 2616 codon 872
(26l6delC; P872fs877) were identified. Finally a deletion of 5 nucleotides
(578_582delCCGTG; Glyl92fs328) in exon 4 was detected. The resulting frameshift
predicts a truncated protein, which contains only the N-terminal part of the protein
and completely lacks the transmembrane part S1-S6 and C-terminal part.
Table 4- Pathogenic LQTS mutations Identified by DHPLC analysis
Cene
KCNQl
KCNH2
Nucleotide change
c 341 T>C
C5O2C>A
C.775OT
c 946 C>C
C.1022OT
C.1669C>A
c,178lG>A
c26OT>C
c.296A>C
c.578 582delCCCTC
c 1039 C>T
C.1341C>A
C.15O1C>A
c.2O92C>T
c2471insC
c.26i6delC
Coding effect
p.Leull4Pro*
p.Clyl68Arg"
p.Arg259Cys
p.Cly3l6Arg
p.Ala341Val
p.Lys557Glu*
pArg594Cln
p.Leu87Pro*
p.Tyr99Ser"
p.Clyl92fs/328*
p.Pro347Ser
pTyr447stop*
p.AspSOlAsn"
p.Glu698stop*
p.Leu824fs/828*
p.Pro872fs/877*
Position
N-terminal
S2
S4-S5
Pore
S6
C-terminal
C-terminal
PAS
PAS
N-terminal
N-terminal
S1-S2
S3
S6-NBD
NBD
C-terminal
Exon
1
3
5
7
7
13
15
2
2
4
5
6
6
8
10
11
The nucleotide numbering starts from the ATC start codon. Cenbank accession numbers; AFO00571
(KCNQl). UO427O (KCNH2). Novel mutations are indicated with an asterisk The missense mutation
Arg259Cys has been reported previously in a Japanese family with LQTS by Kubota et al. [37].
Analysis of KCNEl
DHPLC analysis of exon 3 showed complex elution profiles due to the occurrence of
three SNPs. Almost all fragments had to be sequenced. Apart from the three
polymophisms Ser28Ser G>A, Ser38Gly G>A and Asp85Asn G>A, sequencing analysis
did not reveal any nucleotide substitutions in our group of patients. The allele
frequency of SNPs identified in this cohort study are presented in Table 5-
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Figure 2. DHPLC elution profiles of seven out of nine pathogenic KCNH2 mutations identified in families
with LOTS. For details we refer to the legends of Figure 1. An arrow indicates the DNAheteroduplex
fragments that are eluted prior to the DNA-homoduplexes. A: Note the dramatic decrease in absorption
and the absence of an additional peak in exon 2 in the presence of the mutation L87P. D shows the
elution profiles of the single amino acid polymorphism K897T and in combination with 26l6delC. E
shows the different elution profiles of KCNH2 exon 6 with two highly polymorphic variants (1489 and
F513). These two variants were also present in one individual carrying the mutation Y42OX and one
individual carrying the mutation D501N.
Analysis of KCNE2
By DHPLC analysis of exon 3 we identified two abnormal elution profiles. Sequencing
analysis indicated an a to g transition which had occurred 28 basepairs upstream the
initial ATC codon (ATG-28 a>g) and an A to C transition at position 22 (Thr8Ala) of the
KCNE2 gene. The amino acid variant Thr8Ala (22 A>G) has been associated with an
acquired form of LOT [38]. The Thr8Ala variant was identified twice in a group of
thirty-two individuals. The 5'UTR polymorphism has been identified in 5 individuals.
SNPs identified in this study are presented in Table 5-
Discussion
Congenital Long QT syndrome is characterized by abnormal ventricular repolarization
and associated with cardiac arrhythmias and sudden death. Mutations in 5 genes have
been identified as disease causing defect. However 87% of the mutations have been
identified within two potassium channels KCNOl (LOTl) and KCNH2 (L0T2). Although
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the KCNEl (LQT5) and KCNE2 (L0T6) genes are not frequently involved in LOTS (3% and
2%) as such, their involvement should not be excluded as they co-assemble with the
gene product of the LQTl and LQT2 locus to form the KCNOl/MinK and tie
KCNH2/MiRPl complex [9].
Table 5- Single Nucleotide Polymorphisms (SNPs) Identified in the KCNQl, KCNH2,
KCNEl and KCNE2 Genes
Gene
KCNQl
KCNEl
KCNE2
Nucleotide change
c.l 5 T>C
c.387+2l7C>T
c.8llC>T
c,1110G>A
C.1131C>G
c.1394 39T>G
c.1394 14C>T
c.1476 A>G
C.159O+14T>C
c.l638G>A
c.l685+36G>A
C.1732+43T>C
C.1794+32G>T
C.1986C>T
c 307+22 G>C
01467OT
C.1539T>C
C1692 A>G
C.1956T>C
c.269OA>C
C.3152+22G>A
c84G>A
d l 2 A>G
c2S3G>A
c.l 28A>G
C.22A>G
Effect
Kozak variant
Unclassified
p.Leu271Leu
p.Ala37OAIa'
p.Thr377Thr
Intronic variant
Intronic variant
p.Glu492Glu
Intronic variant
p.Ser546Ser
Intronic variant
Intronic variant
Intronic variant
p.Tyr662Tyr
Intronic variant
p.lle489lle
p.Phe5l3Phe
p.leu$64Leu
p.Tyr652Tyr
pLys897Thr
Intronic variant''
pSer28Ser
p.Ser38Gly
p.Asp85Asn
Intronic variant"
p.Thr8Ala
Intron/exon
5'UTR
exon 2a
exon 6
exon 8
exon 9
intron 10
intron 10
exon 11
intron 12
exon 13
intron 13
intron 14
intron 15
exon 16
intron 2
exon 6
exon 6
exon 7
exon 8
exon 11
intron 13
exon 3
exon 3
exon 3
intron 2
exon 3
Percentage of heterozygotes h
the patients group
0.10
0.12
0.01
0.01
0.01
0.07
0.01
0.01
0.20
0.12
n.a.
0.19
0.06
035
0.01
0.45
0.43
0.50
0.65
0.41
0.48
0.02
0.69
0.03
0.10
0.03
The nucleotide numbering starts from the ATG start codon. Genbank accession numbers; AFOOO571
(KCNQl). UO427O (KCNH2), M26685 (KCNEl) and NMOO5136 (KCNE2). Heterozygosity is based on the
frequency in the patient population (n*32), which is not unbiased. 'A37OA was found in a Japanese
population freq.0.03 by Iwasa et al [39] "Intronic variants previously reported by Larsen et al. [40].
To establish gene specific therapy, it is of major clinical importance to identify the
gene defect involved. Due to reduced penetrance [41], gene defect carriers with
normal QTc values do exist and these people may be at risk to develop life threatening
ventricular arrhythmias. If the gene defect has been identified, drug administration
can be used to protect gene defect carriers against these dangerous arrhythmias and
sudden cardiac death might be prevented [42]. The incidence of LOTS is estimated at
1:10,000- 15,000 of live births [43]. This indicates that in the Netherlands (with 16
million inhabitants), the incidence of LQTS will be more than 1000 individuals. Within
two diagnostic centers (Maastricht and Amsterdam) we identified about 500 gene
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We conclude that the DHPLC analysis is a rapid, reliable, and highly sensitive mutation
detection method which has been proven to be extremely useful to identify sequence
aberrations in DNA samples even with a high CC content. We were able to identify
several DNA alternations in the KCNOl gene, including a pathogenic missense
mutation in a LOTS family, which was previously missed by SSCP analysis. This
indicates an improvement in sensitivity of the mutation detection analysis (SSCP
versus DHPLC) which is accordance with other investigations [23, 24, 25, 26, 27, 28].
However, when several SNPs are present in the tested fragment, DHPLC is perhaps not
the method of choice.
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GENE SPECIFIC TRIGGERS IN LQTS
Auditory stimuli as a trigger for arrhythmic events differentiate HERC-
related (LOTS,) patients from KVLOTl-related patients (LOTSJ
A.A.M. Wilde MD, R. J.E. Jongbloed, P.A. Doevendans MD, D.R. Düren MD, R.N.W. Hauer
MD, I.M. van Langen MD, J.P. van Tintelen MD, H.J.M. Smeets PhD, H. Meyer PhD and
J.LM.C. Geelen PhD.
Journal of the American College of Cardiology 33:327-332 (1999)
CHAPTER 5 -1
ABSTRACT
Objective. This study was performed to identify a possible relationship between
genotype and phenotype in the congenital familial long QT syndrome (cLOTS).
Background. The cLOTS, which occurs as an autosomal dominant or recessive trait, is
characterized by QT-interval prolongation on the electrocardiogram and torsade de
pointes arrhythmias, which may give rise to recurrent syncope or sudden cardiac
death. Precipitators for cardiac events are exercise or emotion and occasionally
acoustic stimuli. Methods. The trigger for cardiac events (syncope, documented cardiac
arrhythmias, sudden cardiac death) was analyzed in 11 families with a familial LOTS
and a determined genotype. Results. The families were subdivided in KVLOTl-related
families (LQTS,, n = 5) and HERC (human ether-a-gogo-related gene)-related families
(LQTS,, n = 6) based on single-strand conformation polymorphism analysis and
sequencing. Whereas exercise-related cardiac events dominate the clinical picture of
LQTS, patients, auditory stimuli as a trigger for arrhythmic events were only seen in
LQTS, patients. Conclusions. Arrhythmic events triggered by auditory stimuli may
differentiate LQTS, from LQTS, patients.
The congenital familial long QT syndrome (cLOTS), which can occur as an autosomal
dominant or recessive trait, is characterized by QT-interval prolongation on the
electrocardiogram (ECG) and polymorphic ventricular arrhythmias (torsade de
pointes). Torsade de pointes, syncope or sudden death usually occurs in relation to
exercise or emotion, but occasionally also acoustic stimuli have been reported to elicit
torsade de pointes [ l - 3]. Based on linkage analysis, cLOTS is a genetically
heterogeneous disease. Five loci have been identified [4- 9]. As LQTS families have been
described that are not linked to these loci, additional loci must exist. Four genes have
been identified: all these genes encode proteins that form (part of) ion channels [10,
l l ] . On chromosome I lpl5.5 the gene KVLQTl (or in the novel nomenclature KCNOl)
is located that encodes 1^, the slowly activating component of the delayed rectifier
(LQTS,; [4, 8]). On 7q35-36 HERG (human ether-a-gogo-related gene) resides encoding
I*,, the rapidly activating delayed rectifier (LQTS,; [5]) and on 2lq2l.l-22.2 the KCNE
gene is located whose product co-assembles with that of KVLQTl to form the 1^
channel (LQTS,; [9]). On chromosome 3p21-24 the gene for the Na' channel ot-subunit,
SCN5A involved in LQTS,, is found [6]. Mutations in these genes result in abnormal
prolonged repolarization, either by diminishing the repolarizing outward K' currents or
by an increase in the plateau inward (Na-) current [10, l l ] .
As ion channels have different time and voltage characteristics, the ECG-phenotype
may be indicative for the gene involved. In particular, the late-appearing T-wave
preceded by a long isoelectric segment in LQTS, patients can be distinguished [12]. The
ECGs of HERG-related LQTS, patients are characterized by low-amplitude T-waves in
the extremity leads (12, 13]. In addition, preliminary data from the LQT international
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registry demonstrate that the precipitator for arrhythmic episodes may also be
genotype-specific [14). Exercise-related events seem to dominate the clinical picture in
LQTS. [14]. In contrast, cardiac events during sleep predominantly occur in LQTS, and
are very rare in LQTS, [14. 15] The LQTS., patients display a mixed pattern of triggers
for arrhythmic events [14]. Acoustic stimuli have not separately been implied in these
analyses. It is feasible that these clinical features correlate with the characteristics of
the ionic currents affected.
In this study we analyzed the trigger for cardiac events (syncope, documented cardiac
arrhythmias, sudden cardiac death [SCD]) in 11 families with a familial LQTS and a
confirmed genotype. Whereas exercise-related cardiac events dominate the clinical
picture of LQTS, patients, auditory stimuli as a trigger for arrhythmic events were only
found in LQTS, patients. Hence, auditory stimuli may differentiate LQTS, from LQTS,
patients.
Methods
Patients. The study was performed according to a protocol approved by the local ethics
committee. Informed consent was obtained from all patients. All families came to our
attention after unexpected cardiac death at a relatively young age (<40 years) in one or
more family members. Both ECGs and peripheral blood samples for genotype analysis
were obtained from all symptomatic individuals and from as many family members as
possible. In all symptomatic patients cardiac evaluation revealed prolonged QT-
intervals, and Romano-Ward syndrome was diagnosed because of normal hearing.
Individuals with a positive genotype (see below) and individuals within these families
who died suddenly and unexpectedly under the age of 40 years were defined as LQT
patients (no ECGs were available in any of these patients). The trigger for eventual
cardiac events (syncope, documented cardiac arrhythmias, SCD) was analyzed in all
individuals. Triggers were subdivided into three categories: l) (physical) exercise; 2)
stress, emotion and anger; and 3) auditory stimuli (alarm clock, telephone ring,
ambulance siren, and others).
Genotype analysis. Genomic DNA was extracted from peripheral blood lymphocytes by
a high-salt extraction method [16]. Genomic fragments coding for the S1-S6
transmembrane domains (including the pore region) of the KVLQTl gene [8] and the
S1-S6 domains of HERG, including the pore and putative nucleotide binding domain,
were amplified [5] on a Perkin-Elmer 96OO PCR (polymerase chain reaction) thermal
cycler in the presence of 100 ng forward and reverse primers, 0.2 mmol/liter
deoxyribonucleotide, 1 U Taq DNA polymerase (Gibco/BRL), 1.5 mmol/liter MgCI, and
100 ng genomic DNA (volume 50 ul). Subsequently, PCR fragments were screened for
single-strand conformation polymorphism (SSCP) variants using the GenePhor system
(Pharmacia) and GeneGel Excell gels 12.5/24. Gels were run at 10°C using
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manufacturer's standard conditions. The gels were silver-stained (Pharmacia PlusOne
kit using an automatic stainer) and air-dried. Amplified products with aberrant SSCP
bands were purified with PCR purification kit (Qiagen). The purified fragments were
sequenced in both directions using the amplification primers. They were analyzed on a
ABI-377 automatic sequencer (Perkin-Elmer) using Dye Terminator Cycle sequencing
kit (Perkin-Elmer). For a detailed description of the methods employed, see Van den
Bergetal. [17].
Statistical analysis. The presence of a specific trigger between the two groups of
patients was compared by the Fischer exact test. Values of p < 0.05 were considered
significant.
Results
Out of the 18 families controlled in our centers, the genotype could be determined in
11. This analysis revealed five KVLOTl-related families (16 male and 26 female gene
carriers; mutations identified Y184S, G189R in two families with a confounder in
±1780, R130C and C345R) and six HERG-related families (8 male and 15 female gene
carriers; mutations identified: A558P, R582C in two apparently unrelated families,
C6O4S, T613M and F640L). The precipitator for syncope was evaluated in these
genotyped families (Table 1). In 9 out of 15 symptomatic gene carriers in all six HERG-
based families, acoustic stimuli were related to syncope. Although common, these
auditory stimuli were not exclusively related to arousal. Figure 1 shows one of the
episodes, triggered by an alarm clock. The arrhythmia is preceded by a "long-short"
sequence based on ventricular extrasystoles. Five individuals in these HERG-related
families died during sleep, one directly preceded by an acoustic stimulus and four
without a known trigger (from one of them it was told that she could faint upon
hearing the doorbell). In contrast to HERG-related patients, none of the 23
symptomatic carriers of a mutated KVLQTl gene reported syncope related to auditory
stimuli (p < 0.0001). Instead, in LQTS, patients, exercise was the predominant trigger (p
< 0.0002) and directly related to SCD in three young individuals (Table 1).
In one of the HERG families (genotype A558P) acoustic stimuli triggered loss of
consciousness in three first-degree relatives; one of them died suddenly at the age of
22 upon arousal from sleep by an alarm clock. Figure 2 shows the onset of a rapid
polymorphic ventricular arrhythmia shortly after arousal by an alarm clock in one of
these individuals. Prior to the onset of the arrhythmia a slight increase in heart rate
was noted. The quality of the registration does not allow careful description of the T-
wave morphology or duration measurement. The arrhythmia degenerated into
ventricular fibrillation (VF) and the patient could be successfully defibrillated.
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Table 1. Precipitator of Cardiac Events in Symptomatic
KVLQTl (LQT5,)
n = 23
(5 families)
HERC (LQTS,)
n = 15
(6 families)
Exercise
18
78%
2
13%
Stress-Emotion, Anger
9
39%
3
20%
LQTS, and LQTS,
Acoustic
0
0%
9
60%
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Carriers
Unknown
2
9«
4
27%
Precipitator of syncope as derived from the patients' history. Exercise relates to physical exercise. In one
individual, more triggers and/or more than one type of acoustic stimulus might be present. Male-to-
female ratio was 9/14 in KVLQTl carriers and 4/11 in HERC carriers. The precipitator is unknown in six
patients. Six LQTS., patients died suddenly, five of them during sleep (see text). Three young LQTS,
patients died suddenly while exercising. Note that acoustic stimuli (in five patients an alarm clock, in
five the doorbell, in three the telephone, and in one an ambulance siren) are only reported by LQTS,
patients (p < 0.0001) and that exercise-related events predominantly occur in LQTS, patients (p <
0.0002).
.^L~~J_^Lj^J^i^_A^^--A^^
Figure 1. . Extremity leads of a ventricular arrhythmia upon sudden arousal at 3:00 by an alarm clock.
The HERC mutation in this patient was C604S.
Figure 3 shows recordings (lead II, V2 and V5) of these three sibs (111-2, -3 and -4) and
their father (11-5). No ECC had been recorded from the deceased patient. Markedly
prolonged, terminally negative T-waves in the precordial leads were observed in
patients 111-2 and 111-4. Individual 111-3 and all other family members (not shown) were
asymptomatic, and QT-intervals were all within normal range. Without exception,
affected individuals met the criteria of a high probability for LQTS [18].
Treatment with beta-blockers was installed in 10 LOTS, patients and was successful in 8.
Two patients developed torsades de pointes after many years (>1O years) of successful
treatment (while being heavily symptomatic before treatment was installed). Seven
(asymptomatic) patients were not treated at all. Fourteen LOTS, patients were treated
with beta-blockers, and in all of them treatment has thus far been successful; 24
patients were not treated (or refused treatment). One patient (female 84 years) has
been treated for more than 30 years with diphantom, and this treatment has not been
changed after the genotype was established.
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1 mV
400m f
Figure 2. Ventricular arrhythmia upon sudden arousal at 300 by an alarm clock in a HERC patiert
(A558P). The leads given are (approximately) V I and II. See text for discussion.
11-5
1112
III-3
JU-JU, -
iii ±._± .
Figure 3. ECG recordings of the three sibs 111-2. -3 and -4 and their father (11-5)
Recordings from lead II. V2 and V5 have been selected Abnormal, prolonged
QT segments are present in patients II- 5. Ill - 2 and 111-4 Calibrations are
standard. The recording in Figure 2 is from patient 111-2.
Discussion
cLQTS-related polymorphic ventricular arrhythmias most often occur in relation to
exercise and emotion. The recent molecular analysis of the LQTS indicates that both
the electrocardiographic repolarization pattern and the conditions during which
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arrhythmias develop might be genotype-specific [12- 14]. All identified genes involved
in the congenital LQTS code for (part of) ion channels involved in the repolarization
process. They include KVLQTl (LQTS,), KCNE (LQTSJ and HERG (LQTS.) encoding
subunits of the slowly activating delayed rectifier (I.J and the rapidly activating
delayed rectifier (I,,), respectively, and SCN5A (LQTS,) encoding the Na' channel a-
subunit [4-9]- A mutation in an unknown gene on chromosome 4 is responsible for
LQTS, described in a single French family [7]. Both LQTS, and LQTS., are the most
prevalent subtypes.
Genotype-phenotype relationship
Preliminary data on the relation between genotype and the trigger for arrhythmic
events in patients included in the international LQTS registry (14] reveal that, in
agreement with our data (Table 1), LQTS, arrhythmic events were frequently related to
exercise [14. 19. 20]. Inadequate and transmurally nonuniform action potential
shortening by ß-adrenoceptor stimulation may underlie the associated high
prevalence of arrhythmic events in these patients [21]. In contrast, LQTS, patients, not
included in this study, experienced events during sleep [15]. In these patients cardiac
repolarization may be fairly normal during fast rates due to the presence of normal K'
currents. However, at rest, the incomplete inactivation of 1 ,^ (as a result of the
mutation in the SCN5A gene) leads to abnormal repolarization [15]. Indeed, in
experimental models mimicking LOTS, a fairly steep APD- and QT-rate relationship has
been observed [22, 23]. The LOTS^  patients have an equally distributed pattern of
precipitators (i.e., exercise, fright and emotion, and sleep). Acoustic stimuli as a trigger
for arrhythmic events are not specifically cited in any previously mentioned study.
In this study we report on HERC-related cLOT families in which SCD, ventricular
tachyarrhythmias and repeated syncope were preceded by auditory stimuli. In the
patients with an auditory stimulus-related cardiac event, described in the literature,
the genotype is unknown. In light of the available data on genotype specific ECG
characteristics [12, 13], the markedly low T-wave amplitude in the extremity leads in
the patients described by Wellens et al. [ l ] and by Shimizu et al. [2] might indicate a
HERG-related defect.
Low T-wave amplitude in the extremity leads was also observed in our patients with
HERG mutations (e.g., Fig.l). Documented arrhythmic episodes followed arousal by an
alarm clock at 3 a.m. (Figure l and Figure 2). These episodes and those described
previously [ l and 3] demonstrate that arrhythmias follow the stimulus within 10 s.
Between the alarm signal and the onset of the arrhythmia the T-wave might invert [ l
and 3] and ventricular extrasystoles may appear ( [l, 3]; Fig. 1) giving rise to a "long-
short"sequence resulting in more serious arrhythmias. This sequence is a common
finding in LOTS patients [24].
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Figure 2, however, shows that ventricular extrasystoles are not a prerequisite for tie
onset of potentially lethal arrhythmias. Further similarity in these patients is tie
predominant occurrence at night. In apparent conjunction, five individuals in HER3-
related families experienced nocturnal death. A similar high incidence of noctunal
death has been observed in other HERG-related families [25, 26, 27]. We found m
LQTS, patients no acoustic stimuli in relation to disease-related events.
Based on the preceding evidence it is tempting to speculate that acoustic stimuli asa
precipitator for arrhythmic events may differentiate LOTS^  from LOTS, patients, n
physiological terms an unexpected auditory stimulus is presumably equal to suddtn
fright, and a role for catecholamines is suggested. The sudden onset of the arrhythma,
within seconds after the stimulus, precludes a systemic catecholamine effect or a
catecholamine-related shift in the extracellular environment as basis for tfe
arrhythmia. In agreement is the lack of changes in heart rate variability parametes
just prior to the arrhythmic events [3]. The arrhythmic events occur at a relatively lov
rate and not necessarily after a preceding sudden significant change in rate (Fig.2; EG
recordings in [ l - 3]). Hence, it seems fair to state that rate-dependent effects on the
respective currents are not involved either.
.Ratrwr .i*,«flnvinure Witeiy xrlat a sudden release of local catecholamines triggers the
event. Indeed, the sudden onset of ventricular extrasystoles originating from the
terminal part of the grossly deformed T-waves is compatible with catecholamine-
induced early afterdepolarizations (EADs) at a cellular level. The EADs have been
recorded in LQTS patients upon exposure to (systemic) catecholamines [2 and 28].
Whereas in control patients isoproterenol shortens the (monophasic) action potential,
a lengthening is observed in LQTS patients [28].
Electrophysiologkal background
Functional studies with HERC mutants expressed in Xenopus oocytes reveal complete
loss of function for some mutants and dominant negative suppression of HERC
function for others [29]. In an experimental cellular model mimicking a HERG defect
(guinea pig ventricular cells exposed to a selective I*, blocker), ß-adrenoceptor
stimulation initially further lengthens the action potential and EADs develop [22].
After several minutes the action potential shortens, presumably due to catecholamine-
induced 1^ activation.
In contrast to 1^, l„, is insensitive to catecholamines [30]. In control cells and in cells
pretreated with anthopleurin aimed to mimick a SCN5A defect by blocking 1^
inactivation, isoproterenol shortens the action potential from the onset of exposure
[22]. The KVLQTl mutants similarly exert a dominant negative effect on I,, current
[31]. Preliminary experimental data, using the specific [32] 1^ blocker chromanol 293B,
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reveal evidence that ß-adrenoceptor stimulation results in a dramatic increase of
transmural dispersion of repolarization and the development of ventricular
arrhythmias most likely as a result of a large augmentation of residual 1^ in epicardial
and endocardial cells, but not in M-cells where I», is intrinsically weak (21). Computer
simulation studies on the role of 1^ and I*, in cardiac repolarization in a guinea-pig
ventricular cell-based model reveal that a decrease in 1^ conductance of >80% prevents
cardiac repolarization completely [33]. The I*, reduction does lengthen the action
potential but does not result in EADs [33].
Based on these results, obtained in a model in which compared to human cells several
important repolarizing currents are not present (among which the transient outward
current), it is postulated that the ratio l^/l», is of particular importance with regard to
the development of EADs [33]. Although both currents have been shown in isolated
(right) ventricular myocytes [34], no detailed information is available on its ratio and
distribution.
Conclusions
The presence of acoustic stimuli as a trigger for arrhythmic events may differentiate
LOTS, from LOTS, patients. The absence of SCN5A- and KCNE-related patients
precludes a statement that acoustic stimuli can be considered characteristic for LQTS,.
Although this observation ought to be confirmed by larger studies, it seems that,
based on the prevalence of the LOTS subtypes, the presence of auditory stimuli should
direct molecular genetic analysis toward HERG.
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Abstract
Background. Genotype-phenotype relations have recently been described in patients
with the long QT syndrome (LOTS). Therefore we analysed the triggers for cardiac
events in our patients. Methods. We studied the triggers for cardiac events in a
genotyped population, consisting of 15 families and two solitary cases. Eight families
(61 patients) and one solitary patient were affected with LOTS,, seven families (35
patients) and one isolated case with LOTS,. In individual patients more than one
trigger could be present. Furthermore, the age of onset of symptoms was determined.
Results. In the LQTS, group, 29 of 62 mutation carriers were symptomatic. Five of these
patients died suddenly. Physical stress was a trigger for cardiac events in 25/29
patients. This was related to exercise in 21 patients and to diving or swimming in 15
patients. In 9/29 patients emotional stress was a trigger for cardiac events. One
patient showed symptoms at rest, and in one patient the trigger was unknown. In the
LQTS; group, 18 of 36 mutation carriers were asymptomatic. Six died suddenly, five of
them at night. Events related to physical stress occurred in 2/18 patients (related to
exercise in both patients, not to swimming), and to emotional stress in 6/18 patients.
Sudden arousal was a trigger in 14 patients. An acoustic stimulus was mostly present,
but not obligatory. In 12 patients an acoustic stimulus was related to cardiac
symptoms, solely in combination with sudden arousal in at least five patients. In 3/18
patients, the trigger was unknown. In LQTS,, four children became symptomatic under
the age of five, 11 at five or six years of age, and 11 patients between the ages of 7 and
13. In 13 of 18 LQTS., patients in whom the age of onset of symptoms was known, no
patients became symptomatic under 9 years of age. Four children became
symptomatic between the ages of 9 and 13. In LQTS, patients events predominantly
occurred in relation to exercise and emotion, whereas in LOTS., patients events often
triggered by sudden arousal, mostly due to an acoustic stimulus, and by emotion.
Furthermore, LQTS, patients became symptomatic at a younger age than LOTS,
patients. Conclusion. Clinical presentation of patients with long QT syndrome is largely
genotype specific, and clinical criteria may be used for specific molecular testing.
Congenital familial long-QT syndrome (cLQTS) is characterized by QT-interval
prolongation on the ECC and polymorphic ventricular arrhythmias (torsade de pointes)
which may lead to syncope and sudden cardiac death. There is a classic subdivision of
cLQTS into Romano-Ward syndrome with a (usually) autosomal dominant inheritance,
and Jervell and Lange-Nielsen syndrome, inherited as a autosomal recessive trait and
associated with congenital deafness. In recent years it has become clear that the
molecular basis of cLQTS is heterogeneous. Until now, five chromosomal loci and four
genes have been identified [1-6], This genetic information forms the basis of the
present subdivision in LQTS,, LQTS,, etc. KVLQTl (or KCNQl in the novel nomenclature)
is the gene involved in LQTS,, and, amongst others, in Jervell and Lange-Nielsen
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syndrome. Its chromosomal location is the distal end of the short arm of chromosome
11 (in code I l p l 5 5 . p=short arm). HERC, the gene involved in LQTS.,, is located on the
long arm of chromosome 7 (7q35-36; q=long arm). Together, KVLQTl and HERG
account for about 70% of affected families. The proteins encoded by these genes
assemble into tetramers to form functional potassium channels, with or without other
(regulatory) units encode by different genes. One of these regulatory units has been
shown to be involved in LQTS,, (the KCNEl gene on chromosome 21q21.1-22.2)[6]. The
gene for the cardiac Na* channel ot-subunit SCN5A, involved in LQTS,, is located on
chromosome 3p2l-24 [3]- Mutations in these genes may result in decreased
repolarizing outward K' currents (LQTS, . J or in an increase in the plateau inward
current (LQTSJ. Te final common pathway is an abnormally prolonged repolarization
as evidenced by the log QT interval on the ECC [7, 8]. Based on different characteristics
of the ion channels involved, the phenotype of the patients and/ or families may be
indicative of the gene involved. Indeed, preliminary evidence suggests that both the
ECC and the trigger for arrhythmic events may be genotype-specific [9-12].
In this study we tested the hypothesis that the clinical presentation of patients with
LQTS is indicative of the type of LQTS. Therefore the trigger for cardiac events (syncope,
documented cardiac arrhythmias, sudden cardiac death) was analyzed in 15 families
with a familial LOTS and in two individual patients with LOTS (in whom a specific cause
for the LOTS other than the genetic defect could be excluded). Our data suggest that
the clinical presentation is indeed indicative of the specific gene involved in the
disease.
Methods
Patients. The study was performed according to a approved by the local ethic
committee. Written informed consent was obtained from all patients. All genotyped
families followed to our centers were included. The families (n=l5) and isolated
patients (n=2) came to our attention after unexplained cardiac death at a relatively
young age (<40 years) in one or more family members, or after LOTS was diagnosed in
a symptomatic individual. All symptomatic patients had normal hearing, hence Jervell
and Lange-Nielsen syndrome could be excluded. When no ECC was available for an
individual within these families, they were defined as having LOTS if they had died
suddenly and unexpectedly under the age of forty. Symptomatic individuals with a
prolonged QT interval and a negative family history (n=2) were classified as congenital
LOTS whenever a specific reason for prolongation of the QT interval could be excluded
(i.e. no QT-prolonging drugs, electrolyte disturbances, mitral valve prolapse, acute
cerebrovascular accidents, etc.). A careful history, an ECC, and peripheral blood
samples for genomic analysis were taken from all symptomatic individuals and from as
many family members as possible. Cardiac events were determined by history for all
proven mutation carriers, obligate carriers (family members that by pedigree analysis
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were determined carriers of the mutated gene), deceased family members. The
distribution of triggers within the genetically distinct groups was studied. Only the
gene involved was related to the distribution of triggers. The specific mutations that
were found in our patients were not analyzed for genotype-phenotype relations, as our
patient group was not large enough to discriminate between possibly distinct
phenotypes of the mutations involved. Events could be related to physical stress,
which was subdivided into exercise and diving and/ or swimming, to emotional stress,
to sudden arousal, to an acoustic stimulus, or they could have occurred at rest. In some
patients, cardiac events occurred in relation to multiple stimuli. The average age of the
symptomatic patients was computed. Furthermore, the age at onset of symptoms was
determined for the genetically distinct groups.
Genotype analysis. Blood samples were collected from all patients. The genomic DNA
was extracted from peripheral blood lymphocytes." PCR amplification was performed
of the coding regions of the KVLQTl gene and the HERC gene (Perkin Elmer 9600 PCR
thermal cycler). These fragments were analysed for SSCP variants, using the CenePhor
system (Pharmacia) and GeneGel Excell 12.5/24. Gels were run at two different
temperatures, 5 °C and 15 °C, silver stained and air dried. Fragments displaying
aberrant SSCP bands were purified using Qiagen PCR purification kit, and sequenced
on an ABI-377 automatic sequencer (Perkin Elmer), using the amplification primers as
sequencing primers. The Dye Terminator Cycle sequencing kit (Perkin Elmer) was used
for this purpose.
Results
The pedigree of one of the families is given in figure 1. This family came to our
attention in 1997, shortly after the death of a 6-year-old girl (W-7). After one syncopal
episode shortly after diving the swimming pool in May 1997, she died in June 1997
under swimming circumstances. Post-mortem examination revealed no specific cause
for her death. Several weeks after this tragic event a ten year-old cousin (III-4)
experienced a syncope during exercise. Subsequent in-hospital evaluation revealed a
prolonged QT interval and a familial LQTS was suggested. The family history further
revealed that the mother of the deceased child (11-7) had been treated for an aspecific
epilepsy during childhood until adolescence. Symptoms started at the age of six. Her
brother (11-4). the father of the symptomatic boy, recalled three syncopes in his youth
related to exercise. The first episode took place at the age of 14. Their eldest sister (11-3)
had suffered from syncope since childhood, which became exercise dependent later in
life. Prolonged QT intervals were present on the ECGs of these three individuals. The
other first-degree relatives had no complaints and both parents (1-1 and 1-2) appeared
healthy at old age. Genetic analysis in family revealed a mutation in the KVLQTl gene,
resulting in an amino acid substitution at position 184 (Tyrl84Ser).
84
CHAPTER 5-2
The trigger for syncope was further evaluated in 14 other congenital LQTS families and
two individual patients followed in our centres (Figure 2). In some patients, symptoms
were triggered by multiple stimuli. In eight families (including the family described
above), consisting of 6 l mutation carriers, and in one individual patient a mutation
was found in the KVLQTl gene (LQTS,). In seven families, consisting of 35 mutation
carriers, and in one individual patient we found a mutation in the HERC gene (LQTS,).
Symbol definitions
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Figure 1. Pedigree of a family affected with LOTS,. In this family a mutation was found in the KVLQTl
gene, leading to an amino acid substitution at position 184 (Tyri84Ser). QT intervals corrected for heart
rate were added. See text for further details.
The LOTS,, -related KCNEl gene was analysed in all index patients, except for one LQTSj
patient, by sequencing analysis. No mutations were found in this gene. (Jongbloed,
personal communication). The LOTS -^related gene has not yet been identified, but
linkage data provided no evidence for involvement of this gene in our families. Of 62
mutation carriers with LOTS,, 29 (47%) were symptomatic (14 male, 15 female;
average age of patients alive 35±19 years) Twenty-five patients (25/29) showed
symptoms in relation to physical stress, related to exercise in 21 patients and to
diving/swimming in 15 patients. An example is given in figure 3. In 9 patients (9/29)
emotional stress was a trigger for cardiac events, and one patient had an event at rest.
No patients showed cardiac symptoms in relation to sudden arousal or to acoustic
stimuli. The trigger for arrhythmias was unknown in one patient. In 36 individuals with
genotyped LOTS^ , 18 patients (50%) were symptomatic (5 male,13 female; average age
of the patients alive 37±12 years, the age was unknown in two patients). Six of the
symptomatic family members died, five of them reportedly at night. Cardiac events
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related to physical stress were present in 2 of 18 symptomatic patients (related to
exercise, not related to diving/swimming), to emotional stress in 6 patients (6/18), and
to sudden arousal in 14 patients (14/18) mostly due to an acoustic stimulus. An
acoustic stimulus was identified as a trigger in 12 patients, only in combination with
sudden arousal in at least five of them. In three patients (3/18) the trigger for cardiac
events was unknown. The number of asymptomatic patients seems rather high, 53%
in the LQTS, group and 50% in the LOTS^  group. This would indicate a rather low
penetrance in our LQTS population.
Distribution of symptoms
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Figure 2. The distribution of symptoms in a genotyped LQTS population is graphically displayed. In an
individual patient multiple stimuli may lead to cardiac events. The Y axis displays the number of
patients involved. On the X axis different stimuli that lead to arrhythmic events are represented. The
number of patients who died suddenly is also shown here (SCD=sudden cardiac death) Physical stress as
a trigger for symptoms was subdivided into exercise and diving/ swimming. In at least five patients who
had symptoms in relation to an acoustic stimulus, events only occurred when that stimulus was
associated with sudden arousal. In other patients the sound of e.g. a ringing telephone or an ambulance
siren could be a trigger for cardiac events as well.
The median of the age of onset of symptoms in the LQTS, group (known in all 29
patients) was 6 years (mean 9-2 years, SD 8.6 years). In four patients, symptoms started
under the age of five, in 11 patients at the age of five or six, and in 11 patients
between the ages of 7 and 13. In 13 of 18 LQTS., patients in whom the age of onset as
unknown, the median of the age at which symptoms occurred for the first time was 17
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years (mean 155 years, SD 4.1 years). None of the patients showed symptoms before
the age of 9 Four patients became symptomatic between the ages of 9 and 13.
Discussion
LQTS is a syndrome characterised by the prolongation of the QT interval and by
polymorphic ventricular arrhythmias (torsade de pointes) type, figure 3), giving rise to
recurrent syncope and sudden cardiac death. Recently, multiple functionally related
genes have been identified [2,3,5,6]. These genes encode for proteins involved in the
depolarisation process. LQTS,.,, are based on mutations in the KVLQTl, HERG, and
KCNEl genes which encode for (subunits of) potassium channels in the cell membrane.
Mutations in the SCN5A gene encoding the a-subunit of the cardiac Na" channel, are
involved in LQTS,. The gene related to LQTS,, that has been mapped to chromosome 4,
has not yet been identified [4].
Because ionic currents have different time and voltage characteristics, it may be
speculated that the phenotype is characteristic for the underlying gene defect, indeed,
clinical differences in genetically distinct forms of long QT syndrome were found. In
our LOTS, population, cardiac events were mainly triggered by exercise, in particular
diving/swimming. In patients with LOTS;, cardiac events also occurred at night, most
often in relation to sudden arousal. (The data presented in this paper include the
patients described in the paper by Wilde et al [14]. Differences in patient statistics are
due to an enlargement of the patient group.) Although most often present, a loud
acoustic stimulus was not obligatory. Occasionally the acoustic stimulus alone (not
leading to sudden arousal at night) was sufficient to elicit cardiac arrhythmias.
Further, emotion and stressful events frequently triggered loss of consciousness in
LOTS; patients. Preliminary data from the LOTS registry involving larger numbers of
affected patients are in accordance with our findings [11]. Patients suffering from
LOTS, became symptomatic at an earlier age than patients suffering from LOTS,. In
four LOTS, patients the age of onset of symptoms was <5 years of age, in 11 patients 5
or 6 years of age, and in 11 patients between 7 and 13 years of age. In 13 of 18 LQTSj
patients in whom the age at onset was known, no children under the age of 9 had
suffered from cardiac events. Between 9 and 13 years of age, 4 children became
symptomatic. Zareba et al [15]. found a similar difference in the age of onset of
symptoms. Finally, Moss et al.' showed genotype specific ECG patterns for LOTS,, and LQTSj.
Exercise is a particularly important trigger for cardiac events, especially linked to
mutations in KVLQTl (LOT, and Jervell and Lange-Nielsen syndrome; this study,) [ l l ] .
IKS, the current related to the channel of which components are encoded by KVLQTl
and KCNEl, is responsible for the final repolarization phase. This current is highly
sensitive to catecholamines. An increase in heart rate requires an enhanced
repolarization rate, and increased amplitude of I*, is likely to account for this.
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Inhomogeneous adaptation of the action potential duration to an increase in rate,
secondary to dysfunctioning mutant l„, channels, may account for the enhanced
propensity for arrhythmias during exercise. Swimming, and in particular diving, is an
important Stressor in LOTS, patients (Figure 2). It may be postulated that diving is
equivalent to a Vasalva manoeuvre, with an increase in heart rate, following the initial
bradycardia. Once again, the improper adaptation of the action potential duration may
lead to heterogeneity in repolarisation with subsequent triggered arrhythmias. A
common denominator of all these conditions is catecholamine release, locally and / or
systemically.
LQTS, patients exhibit cardiac events related to exercise as well, but also to stress,
emotion, anger, and particularly acoustic stimuli with or without sudden arousal.
Typically, an acoustic stimulus is followed by the arrhythmia within seconds [14].
Hence, local catecholamine release of systemically released catecholamines seems
pertinent to the initiation of arrhythmias in these patients. In a HERG experimental
model (cardiac myocytes exposed to pharmacological HERG inhibition, i.e. most 'class
III' drugs), catecholamine exposure leads to a biphasic response: an initial marked
prolongation of the action potential duration is followed by sustained shortening [16].
This initial prolongation, in particular when it occurs inhomogeneously, may, underlie
the arrhythmogeneity in HERG-mutated patients. In SCN5A patients, events
predominantly occur at rest [ l l ] . It is postulated that at slow heart rate, repolarisation
is hampered by a sustained inward current secondary to incomplete inactivation of the
mutant sodium channels. At a faster heart rate, the increased contribution of (normal)
K' currents may overcome the persistent inward Na' current.
In conclusion, this study showed a genotype-phenotype relation in patients with LQTS.
The trigger for symptoms may indicate the genetic origin of the disease. Occurrence of
cardiac events after sudden arousal was only found in LQTS^  patients, whereas events
related to physical stress occurred predominantly in LQTS, patients. In the latter
patient group, events related to physical stress were often common denominator of all
these conditions is catecholamine release, locally and/or systemically related to
swimming. In addition, LQTS, patients showed symptoms at a younger age than LQTS,
patients, which indicates that early treatment may be more important in children
affected with LQTS,.
Analyzing the genotype-phenotype relation in patients with LQTS may eventually lead
to a more efficient search for the underlying genetic defect, as the presumably
affected gene will be the first target for mutation analysis. In addition, a gene specific
treatment, i.e.ß-blockade in LQTS, (and LQTS,) patients, and sodium channel blockers
or pacemaker therapy in LQTS, patients, may be indicated. Gene specific treatment is
the subject of clinical trials currently being performed in patients included in the LQTS
registry.
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Figure 3- ECG recorded at rest (panel A) and during exercise (panel B) in a 10-year-old girl affected with
LQTS, Tyrl84Ser). The ECG in panel A shows an atrial rhythm, 82 beats per minute, PR interval 100 msec,
QRS duration 80 msec, heart axis + 60°, and a QT interval of 500 msec, when corrected using Bazzet's
formula (QTC=OT/(RR)') 585 msec. Panel B shows an ECG recorded in the same patient during exercise.
An ectopic atrial heart beat is followed by two sinus beats. The heart frequency is 90 beats per minute.
The QT interval is not measurable accurately, but appears prolonged. A polymophic ventricular
tachyarrhythmia of the 'torsade de pointes' type is triggered by a premature complex with a coupling
interval of 480 msec. Calibration and lead-switch artefacts are present in both panels. Paper speed was
25mm/sec. On the vertical axis, 10 mm represents 1 mV.
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CHAPTER 6
Abstract.
Background: Gender differences have been reported in patients with the congenital
long QT syndrome (LQTS). We analyzed whether electrocardiographs differences
existed in females, males, girls and boys in response to ß-adrenoceptor blockade.
Methods: 12-lead ECCs before and during ß-adrenoceptor blockade were collected in
87 genotyped LQTS patients (48 women, 14 men, 12 girls and 13 boys). Per ECC, up to
three QTc intervals were determined in each lead. Difference between longest and
shortest QT interval was taken as a measure for dispersion. V4 was used for further
analysis. Results: 1) Adult males had the largest shortening of QTc interval upon
treatment. During treatment adult males with LOTS, were found to have shorter QTc
intervals than adult females, whereas this difference did not exist in LOTS; patients. 2)
Female LQTS^  patients had a 50% larger dispersion than female LOTS, patients both
before and during treatment. 3) In adult females a combination of a long QTc interval
and large dispersion was found to be related to occurrence of symptoms, and
sustentation of symptoms during treatment. 4) Adult male LOTS, patients constitute
the only patient group with a marked decrease in both QTc interval and dispersion
associated with a 100% efficacy of treatment in response to ß-adrenoceptor blockade.
Conclusions: These findings indicate that in addition to underlying differences in
repolarization between men an women, also response to ß-adrenoceptor blockade is
modulated by gender-related factors.
Keywords: Adrenergic (ant)agonists; ECC; Gender; Long QT syndrome; QT dispersion
Introduction
The QT interval is known to be influenced by gender [1-3]. Young boys and girls have
similar QT interval durations. During puberty, the QT interval in boys shortens, leaving
adult women with a longer QT interval than adult men [2]. In the congenital Long QT
Syndrome (LQTS) adult women have longer QT intervals than adult men [4,5].
Therefore they are more often clinically affected by this syndrome than men, in spite
of the equal sex-distribution of the disease genotype. This is not restricted to
electrocardiographic parameters. Female gender is an important risk factor for cardiac
events in patients with this syndrome [6]. Furthermore, there is a different time-
dependent distribution of initial cardiac events [4.7] In males, the probability of a first
cardiac by age 15, is higher than in females, and decreases after puberty, which it does
not in females [7]. However, the first cardiac event is more often fatal in males than in
females [7]. Thus, gender is a major determinant in the course and clinical
presentation of patients with the Long QT Syndrome .
Women are more at risk than men of developing arrhythmias in response to QT
prolonging drugs than men as well [8-10]. However, it is unknown whether there are
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differences in electrocardiographic response to purely ß-adrenergic blocking agents
between male and female carriers of long QT mutations. We have analyzed a
genotyped population for sex linked differences in response to (J-adrenoceptor
blockade, with a distinction between adults and children. In addition, we analyzed
whether these differences were specific for patients with mutations in the KCNQl
gene (LQTSl) or the HERC gene (LQTS2). leading to changes in 1^ and I,, current,
respectively.
We found that during treatment with ß-adrenoceptor blockade, men with LQTS, have
shorter QTc intervals than women; this was not seen in LQTS; patients. Furthermore,
female LQTS, patients showed more dispersion than female LQTS, patients. No
difference in the genetic subgroups was found among adult males. Patients remaining
symptomatic during treatment showed a positive relation between the amount of
dispersion and the duration of the QTc interval, in line with basic concepts of
arrhythmogenesis.
Methods
The study was performed according to a protocol approved by the local ethics
committees in the academic hospitals of Utrecht, Amsterdam and Maastricht, and
conforms with the principles outlined in the Declaration of Helsinki ( l l ) . Written
informed consent had been obtained in all patients. All genotyped LQTS, and LQTS,
patients in whom no more than one mutation had been found and who were treated
with ß-adrenoceptor blockade were included in this study.
Genotype analysis
Patients were genotyped as previously described [12]. Briefly, genomic DNA was
isolated from anticoagulated blood samples. Exons, encoding the complete sequence
of the KCNQl and HERC (KCNH2) gene, were amplified by using PCR analysis (Perkin
Elmer 9700 thermal cycler). Subsequently, amplicons were analyzed by SSCP analysis.
Gels were run at 5 and 15 °C, silver stained and air-dried. DNA fragments showing
aberrant bands were purified (Qiagen PCR purification kit), sequenced by using the
BigDye cycle sequencing kit (Applied Biosystems) and analyzed on an ABI-377
automatic sequencer (Applied Biosystems). In this study mutations were classified in
both the gene involved (KCNQl or KCNH2) and the effect of the mutation i.e.
mutations leading to a stop-codon or a frameshift (truncating) and mutations leading
to an amino acid substitution (missense). Three kinds of mutations were identified, i.e.
LOTS,/missense ( l l mutations), LOTS/truncating (6 mutations) and LQTS /^missense (9
mutations).
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Electrocardiography
In 12-lead ECGs before and during treatment up to three consecutive RR and QT-
intervals were measured in all leads. QTc intervals were calculated using Bazett's
formula (QTc=QT/VRR). All intervals were measured manually. The intersection of the
line through steepest part of the downslope of the T-wave and the isoelectric line was
defined the end of the T-wave. The end of the U wave was used in case fusion of T and
U waves made distinction of the end of the T-wave impossible. In a minority of cases
(mostly concerning the right precordial leads) the highest point of the second part of a
biphasic T-wave was determined the end of the T-wave, based on T-wave morphology
in subsequent leads. QT intervals were always determined similarly on the ECC before
and the ECC during treatment in one patient. The difference between the longest and
the shortest QT interval in any lead was used as a measure for dispersion.
^ CMv>»ar« io icMn« i ih>»«Mniwu> iu» _^  Figure 1. Chances in QT and QTc intervals
» . -r- -i- I during ß-adrenoceptor blockade are shown
in boys, girls, males and females. #,
Statistically significant change. In QT
intervals this change was 2O±72 (P<0.02),
18±1O.7 (NS), -3±12.4 (NS), and 25±6.7 (P
^ ^ <0.O0l) in the four groups, respectively. The
"*" ^ ^ « difference between males and females was
I statistically significant (ANOVA; P <0.05).
rens^U~'T Changes in QTc were -24±8.4 (P <O.O2). -
[ i io.«»~. J, i2±93(NS). -45110.3 (P <0.0Ol) and -24±75
I
***" «""» " • " '•*•'•• (P <0.0l), respectively.
Symptomatology
Symptomatology before and during treatment was determined. Patients who
presented with cardiac arrest, registered torsades de pointes, a history of syncope, or,
during treatment, pre-syncope that required alteration in their medication were
defined as symptomatic. Follow-up during treatment was 55 ± 57 years (average ±
S.D.). Three patient categories were defined based on clinical presentation:
symptomatic before treatment and symptomatic during treatment (S-S), symptomatic
before treatment and asymptomatic during treatment (S-A) and asymptomatic before
and during treatment (A-A).
Statistical analysis
Differences between variances among the groups of boys, girls, males and females
were tested by the F-test. In case of similarity of variances this was followed by one-
way ANOVA before and during treatment. Changes in QT or QTc intervals following
treatment were analyzed by the Student's t-test for paired observations to test
differences from zero. Differences between changes in QT or QTc intervals between
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boys, girls, males and females were tested by one-way ANOVA. Values are given as
mean ± SEM. Levels of 0.05 or less were considered statistically significant.
Results
Change in QT and QT(c) intervals by ß-adrenoceptor blockade in females, males, girls
and boys
A total of 87 patients was included in this study: 48 women, 14 men, 12 girls and 13
boys (1-15 years). Fig. l shows that in boys (P<0.02) and females (P<0.00l) QT intervals
increased upon ß-adrenoceptor blockade. Such an increase was not observed in males,
whereas there was an insignificant increase in girls. Moreover, the difference between
males and females was significant (ANOVA; P <0.05) Because RR intervals increased
even more than QT intervals, QTc intervals decreased ß-adrenoceptor blockade (Figure
l). This decrease varied from 12 ± 93 (NS) in girls to a largest value of 45 ± 10.3 in
males (P<o.OOl).
QTc intervals in men, women and children with LQTS, and LQTS,
QTc intervals were similar in all groups (Figure 2A). During treatment, adult males had
significantly shorter QTc intervals than adult females in LOTS,, but not in LOTS^
patients (Figure 2B; Table 1). Both males and females showed shortening of the QTc
interval during treatment (compare Figure 2A and B). No differences in response to ß-
adrenoceptor blockade existed between LOTS, and LOTS., in the four subgroups. In
adult LOTS, males shortening of the QTc interval upon treatment was 49±13.1 ms. In
adult males with LOTS, the QTc interval decreased 42 ± 159 ms during treatment. In
both groups shortening was statistically significant (P <0.02 and P <0.05, respectively).
Women with LOTS, had a shortening of 37 ± 16.7 ms, and those with LOTS, of 19 ± 8.2
ms, which was in both groups significantly different from zero (P <0.05). In children the
changes in QTc interval were less pronounced (compare Figure 2A and B).
Gender differences in dispersion
In women dispersion differed significantly between LOTS, and LOTS, patients (Figure
3). In men however, the two genetic groups did not differ. Dispersion in females was
41 + 6.2 ms in the LOTS, group and 62 ± 3.7 ms in the LOTS> group (P <0.0l). Ithe
difference in dispersion between adult female LOTS, and LOTS, patients was also
observed when girls were included in the female group. The larger dispersion in female
LOTS; patients proved to be independent of age (linear regression analysis; data not
shown).
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Symptomatology
Table 2 shows the efficacy of treatment in the LOTS, and LOTS; patient groups divided
into boys, girls, males and females. Efficacy was defined as the percentage of S-A
patients within the (S-A + S-S) groups. Of course, the numbers are very small in most of
the subgroups. In adults, the efficacy of treatment was 100% in male and 89% in
female LQTS, patients. In adult LOTS^  patients, efficacy of treatment was 67% in males
and 70% in females.
(A) (B)
Figure 2. QTc Intervals in boys, girls, males and females with LQTS, and LQTS, are plotted before (A) and
during (B) ßadrenoceptor blockade See Table 1 for numerical data. Before treatment, QTc intervals
were similar in all groups. During treatment, significantly shorter QTc intervals were found in male than
In female LQTS, patients, while no such difference was seen in LQTSj patients. #, Statistical significance
atP<0 01.
Table 1. QTc intervals in females, males, girls, and boys with LQTSl and LQTS2
females
males
girls
boys
LQTS,
LQTS,
LQTS,
LQTS,
LQTS,
LQTS..
LQTS,
LQTS,
n
13
35
6
8
6
6
9
4
Before treatment
QTc
502*19.3
4911105
472199
4941125
485191
4621179
504110.4
48918.8
dispersion
4116.2*
62137*
p<0.01
56HO.5
53195
49176
62136
5017.8
661I6.9
During treatment
QTc
463185
472176
422191
4491154
460127
4621160
474112.0
4791108
dispersion
40153'
6314.4*
p<0.005
47178?
5016.9
38i64*
6417.6"
P<0.05
50156
56139
Symptomatology, QTc intervals and dispersion
A positive relationship existed between the length of the QTc interval and the amount
of dispersion in the adult S-S patients (seven women, one man) (Figure 4). In addition,
in this figure the type of LQTS is stated as well as the type of the mutation. Patients
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with a truncating LQTS., mutation had the shortest QTc intervals and the least
dispersion. Patients with missense mutations had larger dispersion and a longer QTc
interval, and the only LQTS, patient that remained symptomatic during treatment also
had an extremely long QTc interval and a large dispersion (655 and 100 ms,
respectively before treatment (see Figure 4) and still 513 and 73 ms during treatment).
During treatment QTc intervals were shorter and dispersion was smaller in the four
groups with the highest efficacy of treatment (89-100%) compared with the other four
groups with lower efficacy (50-70%) (Figure 5). In male LQTS, patients both reduction
in dispersion were the largest compared to all other patient groups.
Discussion
Patients with the congenital Long QT Syndrome demonstrate electrocardiographic
differences during treatment with ß-adrenoceptor blockade between adult males,
females, and children (Figures 1 and 2). Although no differences exist in QTc intervals
before treatment among these groups, during treatment adult men in the LQTS, group
IJ . . J ' . i l
Figure 3. Dispersion in QT intervals is
shown in males and females before
treatment. In women, LQTS, patients
have significantly more dispersion
than LQTS, patients, whereas in men
no difference is found between LQTS,
and LQTS, patients See Tablel for
numerical data.
display the shortest QTc intervals (Figure 2B). Woman with LOTS; have a significantly
larger dispersion than women with LOTS,, both before (Figure 3, Table l) and during
treatment (Table l). In addition in women that remained symptomatic during
treatment, LOTS;, patients with a missense mutation had longer QTc intervals
combined with a larger dispersion than those with a truncating mutation (Figure 4). In
patient groups with highest efficacy of treatment, QTc intervals were shorter and
dispersion was smaller during ß-adrenoceptor blockade (Figure 5). This study is the
first to show gender differences in electrocardiographic response to ß-adrenoceptor
blockade in LOTS patients.
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QTc intervals in females, males, girls and boys
Differences in cardiac repolarization between men and women have been reported in
healthy subjects and in LQTS patients [l-5, 7]. Healthy women have longer QTc
intervals and a higher heart rate. Stramba-Badiale et al [3] showed QT differences to
be more profound during low heart rates due to a steeper QT/RR relationship in
women than in men. Also in the Long QT Syndrome women and children were
reported to have longer QTc intervals than men [4, 5], while female gender has been
shown to be an independent risk factor for cardiac events.
700
'«50
§600
550
500
&450
400
Pjf/enfs sympfomaf/c dunnjr freaf/nenf (S-
2-mls
2-mu
2-m*
2-mi«
• Adult females
• Adult males
40 50 SO 70 80
D/$pers/on toe/tore
SO 100 no
Figur« 4. Patients symptomatic during treatment show a positive relationship between the length of the
QTc interval and amount of dispersion. 1, LQTS,, 2, LQTS,; Mis, missense mutation; trunc, truncating
mutation As indicated, LQTS., patients with a truncating mutation have a relatively short QTc intervals
and little dispersion. LQTS, patients with missense mutations had a longer QTc interval and larger
dispersion, as had the only (female) LQTS, patient that remained symptomatic during treatment.
Table 2. Efficacy of treatment in females, males, girls, adn boys with LQTS, and LQTS,
Females
Males
Girls
Boys
LQTSl
LQTS2
LQTSl
LQTS2
LQTSl
LQTS2
LQTSl
LQTS2
A-A
4
IS
3
3
3
4
3
3
S-A
8
14
3
2
3
1
4
1
S-S
1
6
0
1
0
1
1 (+1 AS)
0
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To be able to understand differences in response to treatment in male and female
subjects, it is necessary to understand the physiological background of gender
differences in cardiac repolarization. Unfortunately, little is known about the influence
of sex hormones on cardiac repolarization. In humans, androgens may shorten the QTc
interval [2, 4, 5]), whereas the effect of estrogens in humans is equivocal. Most studies
addressing this issue have been performed in castrated rabbits treated with either
estrogen or dihydrotestosteron (DHT). Pham et al [13] showed that the duration of the
first 30% of the action potential (APD30) was significantly shorter in castrated males
than in castrated females, indicating a hormone-independent factor in differences in
cardiac repolarization. An increase in QT interval was found in oophorectomized
rabbits treated with estrogens compared to DHT, especially at long cycle lengths, due
to a steeper QT/RR relationship [14]. In contrast, Drici et al [15] found a lengthening of
the QT interval in explanted hearts both from animals treated with male and from
those treated with female sex hormones. In addition, they found a downregulation of
the HK2 (human Kvl.5 [(16] and IsK (minK, a subunit to KCNQl that encodes the
protein associated to I,, [17] in both groups. The similar QT intervals in this study are
not in conflict with other studies as QT intervals were measured at a short cycle length,
while differences in QT interval are more pronounced at long cycle length. Besides a
lower Im, Liu et al [18] identified a lower I*, current density in female than in male
rabbits, which they held responsible for the steeper QT/RR relationship in female
animals These studies might form a rationale for the occurrence of longer QTc
intervals in females. In our population, men and women had similar QTc intervals
before treatment. This can be explained by the fact that we only studied treated
carriers. Upon treatment with ß-adrenoceptor blockade, males had a greater
shortening of the QTc interval than females. This was due to a shorter QTc during
treatment in male than in female LOTS, patients. This difference was not found in
LOTS, patients. Figure 2A shows that before treatment women with LOTS, had slightly
larger QTc intervals than men. If findings in rabbits [18] hold true for the human
species as well, this could be due to less I*, in the female ventricle.
Gender differences in dispersion
We recently reported that LOTS, patients in general display larger dispersion than
LOTS, patients [19]. However, no differences in dispersion were found between males
with LOTS, and LOTS,, whereas women with LOTS; had significantly larger dispersion
than those with LOTS,. A decrease of homogeneously distributed repolarizing I*,
current may uncover a larger inhomogeneous contribution of I,, [20] to repolarization
in LQTS^  patients, and thus lead to larger dispersion of action potential duration over
the ventricular wall. Our data suggest that the inhomogeneous transmural
distribution of I*, is larger in females than in males. This is supported by the fact that
QT/RR relationship is steeper in women than in men [5], which might be due to more
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I*, in the latter. To our knowledge there are no experimental data available to settle
this issue. However, the fact that this difference between female LOTS, and LOTS^
patients was similar in adult females and in girls and was independent of age excludes
an important role for estrogens and suggests a hormone independent difference
between the male and female heart.
In conclusion, gender differences exist in response to ß-adrenoceptor blockade in
patients with types 1 and 2 of the congenital long QT syndrome. During treatment
males with LQTSl have shorter QTc intervals than females and adult patients with
LQTS2. Also treated females with LOTS, exhibited less dispersion than those with
LQTS,. Furthermore, an association was identified between efficacy of treatment and
the relationship between QTc interval and dispersion. Studies to elucidate the
underlying mechanisms of gender differences in response to ß-adrenoceptor blockade
will be needed to settle these issues.
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Figures. Efficacy of treatment, (S-A/(S-A+(S-S))»1OO, is shown in the 4 groups subdivided into LQTS, and
LQTS... in relation to the average QTc interval and the average dispersion for these patients in each
group. B indicates boys, G girls, M males and F females 1 and 2 indicate LQTS, and LQTS,. Pre= before
treatment, post- during treatment. The percentage represents the efficacy of treatment in each group
(compare Figure 5). Shorter QTc intervals, less dispersion or a combination of both were related to a
larger efficacy. In LQTS, males, absence of symptoms during treatment was associated with a reduction
in both dispersion and QTc duration. Efficacy of treatment tends to be larger in adult LQTS, patients
than in adult LQTS. patients.
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CHAPTER 7
HYPERTROPHIC CARDIOMYOPATHY
7.1 Introduction
Up till a decade ago, diagnostic identification of acquired or hereditary cardiac diseases
was based upon clinical observations and pedigree analysis and supported by instru-
mental and biochemical diagnostic tests. The molecular basis of the majority of these
disorders was grossly unknown or speculative. In the last ten years, rapidly evolving
and innovative strategies in molecular biology and genetics have completely changed
this scenario. Families with well-documented hereditary disorders, sometimes known
for several decades, appeared very attractive to start the search for the causative
molecular defect. Using linkage analysis with DNA markers (DNA variants scattered
along the genome), it became possible to search for linkage of particular markers and
the disease-causing locus in a given family. Once the risk locus was identified, several
strategies to identify the gene defect could be applied. By comparing families with
identical genetic defects and by an inventory on the clinical features of all affected
individuals it may be possible to establish genotype-phenotype correlations, which in
turn can lead to an exact diagnosis.
In this chapter we discuss clinical and genetic guidelines to identify the familial form of
primary HCM. HCM includes a group of primary myocardial disorders of previously
undefined etiology, which are characterized by a high incidence of morbidity and
mortality. Observations of myocardial diseases that can reasonably be interpreted as
HCM were made in the middle of the last century at the Hospital La Salpetriere in Paris
by A. Vulpian, who called what he saw at the macroscopic level a "retrecissement de
I'orifice ventriculo-aortique" or « sub-aortic stricture » [ l ] . It was however only in the
late 1950s that the unique clinical features of HCM were systematically described [2,
3]. Hypertrophy can occur in either ventricle although usually there is involvement of
the interventricular septum, with or without involvement of either the anterior wall or
the posterior wall in continuity. A particular form of regional involvement affects the
apex but spares the upper portion of the septum (apical hypertrophy) [4]. Typically, the
left ventricular volume is normal or reduced. Systolic gradients are common. Typical
morphological changes include myocyte hypertrophy and disarray surrounding the
areas of increased loose connective tissue. Arrhythmias and premature sudden death
are common [5]. Sudden death accounts for about 50% of the mortality in HCM.
Sudden death may be the first clinical manifestation in some affected individuals.
Previous reports estimated its incidence to 2 to 4% annually in adults and 4 to 6% in
children and adolescents [6-8] but these numbers are certainly overestimated because
they are based on referral populations. Annual mortality rate in unselected patients
has been reported to be 0.5 to 1.5% [9].
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HCM is the most common cause of sudden death in young athletes, accounting for
36% of cases. Although HCM has been regarded largely as a relatively uncommon
cardiac disease, the prevalence of echocardiographically defined HCM in a large cohort
of apparently healthy young adults selected from a community-based general
population was reported three years ago to be as high as 0.2% [10].
7.2 Familial Hypertrophie Cardiomyopathy (FHC)
Familial disease with autosomal dominant inheritance predominates, and the first
large pedigree of familial hypertrophic cardiomyopathy (FHC) was reported in I960
[ l l ] . None of the previous hypotheses on the pathophysiological mechanisms would
have predicted that defects in sarcomeric genes could be a possible molecular basis for
the disease. The results of molecular genetic studies have nevertheless shown that all
mutations found thus far concern nine different sarcomeric proteins (figure 1, Table 1):
three myofilament proteins, the beta-myosin heavy chain (ß-MyHC), the ventricular
myosin essential light chain (MLC-ls/v) and the ventricular myosin regulatory light
chain (MLC-2s/v); four thin filament proteins, alpha cardiac actin (alpha-cAct), cardiac
troponin T (cTnT), cardiac troponin I (cTnl), and alpha-tropomyosin (alpha-TM); one
myosin-binding protein, the cardiac myosin binding protein C (cMyBP-C), and finally
the third filament protein, titin (TTN).
So, FHC is caused by a structural and/or functional impairment of the sarcomere, which
is the contractile unit of striated muscle (Figure l). Sarcomeric gene mutations may also
be associated to either the transition between hypertrophic and dilated cardiomyopathy
[14] or to primary dilated cardiomyopathy [15, 16]. This finding suggests that the
position of the mutated amino acid triggers the development of either hypertrophic or
dilated cardiomyopathy by impaired force generation versus impaired force
transmission, respectively. The molecular mechanism by which the mutations lead to
FHC and the basis for the diversity of the phenotypes is not completely elucidated. It has
been generally accepted that cardiac hypertrophy is influenced by a dominant-
negative mechanism, which can be explained by either production of a poison
polypeptide or failing to incorporate a defective protein into the sarcomere leading to
haploinsufficiency.
In 1999, 143 mutations have been entered in the FHC database (Table 2) [17] The two
major genes appear to be A^ VH7 and /WVßPO, but one should note that not obligatory
all the genes were screened to find the mutation in previous reports. Most of the FHC
mutations are missense mutations or deletions that do not disrupt the reading frame
with the exception of/VIV6PC3 in which most are frame shift mutations.
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Figure 1. Schematic organization of the sarcomeric proteins associated with FHC (adapted from [18]).
These genes certainly do not represent the whole spectrum of FHC disease genes since an additional
locus was reported on chromosome 7q [12] and one might reasonably hypothesize that disease genes
yet to be identified include additional components of the sarcomere Indeed, recently a mutation has
been reported in MW-i6. the strongly A1VH7 homologous gene encoding the o-MyHC in a FHC proband
{13]
Mutations in the beta-MyHC gene, MYH7 (CMHl locus)
Jarcho et a/, opened this field in 1989 by studying a large Canadian HCM family which
had been previously reported by Pare et al. in I96l [ l9, 20]. Linkage analysis showed
tight association of a disease locus with marker D14S26, and therefore identified the
first locus for FHC, CA^Hl. Among the possible candidate genes involved in HCM, the
closely linked cardiac <*- and ß-myosin heavy chain (MyHC) genes - MV7-/6 and A/IVH7,
respectively were suspected. Subsequently, a missense mutation was found in the
MVH7 gene [21]. Several other investigators have confirmed the linkage of HCM
families to CAIHl [22, 23]- Likewise other groups excluded linkage of FHC families to
CMHl indicating genetic heterogeneity [24, 25]. The beta-MyHC consists of 1,939
amino acids and is the major isoform in human ventricular cardiac myocytes and slow
twitch skeletal muscles. It is composed of two parts, a globular amino-terminal part of
150 kDa. the heavy meromyosin (HMM) and the rod or tail of 70 kDa, the light
meromyosin (LMM). HMM can be separated in two domains by papaine digestion, the
subfragments 1 and 2. Subfragment 2 contains the ATP- and actin-binding sites. More
than seventy MVH7 mutations were identified and most of them are located in HMM.
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Table l . Sarcomerk proteins and genes involved In FHC.
Protein Gene
1. Beta myosin heavy chain (ß-MyHC) MYH7
2. Ventricular essential myosin light chain MYL3
(MLC-ls/v)
3. Ventricular regulatory myosin light chain MYL2
(MLC-2s/v)
4. Alpha-cardiac actin (alpha-cAct) ACTC
5. Cardiac troponin T (cTnT) TNNT2
6. Cardiac troponin I (cTnl) TNNI3
7. Alpha-tropomyosin (alpha-TM) TPMl
8. Cardiac myosin binding protein C(cMyBP-C) MYBPC3
9. Titin TTN
FHC Locus
CMHl
14qll-ql2
CMH5
3P
CMH6
12q23-q243
CMH8
15ql4
CMH2
lq32
CMH7
19pl34
CMH3
15q22.1
CMH4
llpll.2
CMH9
2q24.3
Remarks
mainly missense mutations
missense mutations; mid left ventricular chamber thickening
missense mutations and splice donor mutations
missense mutations
missense mutations, in frame deletions, splice donor mutations;
mutations are particularly associated with poor prognosis and with
only mild hypertrophy; low disease penetrance ± 80%
missense mutations and inframe deletion
missense mutations; poor prognosis
missense mutations, deletions, insertions; mostly truncated
proteins; low disease penetrance ± 60% late onset.
missense mutations
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Mutations in the myosin light chain genes, MYL2 and MYL3 (CMH5 & CMH6 loci)
The muscle myosin proteins consist of two heavy chains and two pairs of light chains.
The isoforms of light chains expressed in human ventricles are the ventricular essential
myosin light chain (MLC-ls/v) and ventricular regulatory myosin light chain (MLC-
2s/v). These two proteins are encoded by /WVfJ and /WVL2, which are located on
chromosome 3p and 12q23-q24-3. respectively [26]. Mutations in both genes were first
described to be associated with a particular subtype of cardiac hypertrophy defined by
mid left ventricular obstruction and skeletal myopathy [27]. However, it was later
demonstrated that /V1VL2 is also associated with classical forms of FHC [28].
Table 2. Distribution of the FHC database mutations (from [17])
Mutations in the alpha-cardiac actin gene, ACTC (CMH8 locus)
Actins are involved in various types of cell motility and they are ubiquitously expressed
in all eukaryotic cells [29]. Actins are highly conserved proteins consisting of 377 amino
acids. The polymerization of globular actin (g-actin) leads to a structural filament (f-
actin) in the form of a two-stranded helix. In vertebrates, three main groups of actin
isoforms, alpha, beta and gamma, have been identified. The alpha-actins are found in
striated muscles and are a major component of the contractile apparatus. Two
missense mutations were initially reported in the ACTC gene associated with a dilated
form of cardiomyopathy [15]. Thereafter, Mogessen et a/, reported ACTC mutations in
families with FHC [30]. Recently three novel mutations (E99L. P164A and A331P) were
identified in functionally distinct domains of alpha-cAct that were associated with an
early onset and apical cardiac hypertrophy [31].
Gene locus
MYH7
MYBPC3
TNNT2
MYL2
TNNI3
ACTC
TPMl
MYL3
TTN
# of mutations
70
30
14
8
8
S
S
2
1
It of missense mutations or in frame
deletions
67
8
13
7
8
5
S
2
1
# of frameshift or nonsense
mutations
3
22
1
1
-
-
-
-
-
108
CHAPTER 7
Mutations in the cardiac troponin T gene, TNNT2 (CMH2 locus)
Troponin T is the tropomyosin-binding subunit of troponin, which is required for thin
filament regulation of contraction. It contains several putative functional domains:
phosphorylation sites and protein-binding sites to alpha-tropomyosin, troponin I and
troponin C. The gene 77V/VT2 is composed of 17 exons spread over 17 kb and gives rise to
multiple isoforms by the use of alternative exons and alternative acceptor sites [32].
Thierfelder et al. succeeded to map the rfV/vT2 to chromosome lq32 and presented three
unrelated families with a missense mutation and one splicing site mutation in 77vrvT2
causing cardiac hypertrophy in affected family members [33]. The splice site mutation
was predicted to function as a null allele leading to haploinsufficiency and the authors
suggested that abnormal stoichiometry of sarcomeric proteins caused cardiac
hypertrophy. Watkins et al. identified eight mutations in the lA/A/T^ gene and estimated
that mutations in this gene account for approximately 15% of familial HCM cases [34].
Mutations in the cardiac troponin I gene, TNNI3 (CMH7 locus)
Because all the known FHC disease genes encoded major contractile elements in
cardiac muscle, a Japanese group systematically screened cardiac sarcomere genes,
including cardiac troponin I (7A/A//3), and cardiac troponin C in a large group of
unrelated patients with HCM. They found mutations in the 77v7v/3 in several FHC
patients [35]- Family studies showed that an R145G mutation was linked to HCM and a
L206O mutation had occurred 'de novo' strongly suggesting that 77VA//3 is the seventh
FHC disease gene.
Mutations in the alpha-tropomyosin gene, TPMl (CMH3 locus)
Tropomyosins are rigid rod-like ubiquitous proteins in the thin filament of the
sarcomere. They associate with the actin filaments and contribute to the stability of
the thin filament. The tissue-specific isoforms are generated by alternative splicing of
the oc-tropomyosin pre-mRNA. MacLeod and Gooding identified the sequence of the
gene and Eyre ef a/, assigned the gene to chromosomal band 15q22 [36, 37]- The
tropomyosin gene gives rise to four isoforms. The alpha-tropomyosin gene, 7"P/Ml, has
only io exons, which encode 284 amino acids. Four missense mutations have been
described in IPA^l previously [33, 34]. Watkins et al. concluded that mutations in 77WI1
are a rare cause of HCM, accounting for approximately 3% of the cases. Recently, two
novel IP/Ml mutations have been reported, the E180V mutation being associated to
the transition between hypertrophic and dilated cardiomyopathy [14], and the V95A
mutation showing unique features of mild cardiac hypertrophy with a high mortality
rate [38].
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Mutations in the cardiac myosin-binding protein C gene, MYBPC3 (CMH4 locus)
Cardiac myosin-binding protein C is located in the C-zone of the sarcomere A-bands
and is tightly bound to myosin and titin. The CA^ H4 locus was found in 1993 on
chromosome I lp l3-q l3 [39]- Human /WKßPC3 was then localized by fluorescent /n s/tu
hybridization on chromosome l l p l l . 2 [40]. It was therefore anticipated that
mutations in /M/SPC3 might cause FHC and indeed Bonne et a/, and Watkins et a/,
simultaneously demonstrated splice mutations and a duplication in this gene in
families with HCM [41, 42]. Subsequently, several groups found /ViyßPC3 mutations in
FHC [43-48]. Most of the mutations produce a frame shift leading to a premature
termination during translation, resulting in truncated proteins lacking at least the
major myosin-binding site. MVßPQ is the most frequent mutated gene in French
families with HCM (personal communication). The mechanism by which the truncation
mutations lead to FHC is not fully understood, because neither the truncated protein
nor a decrease of the normal protein was detected in the myocardial tissue of two
patients with a A/IKSPC3 mutation [44, 48]. However, several ex v/Vo analyses and
mouse models with A/IKßPO mutations showed that truncated proteins are present in
the tissue and may act as poison polypeptides in a dominant-negative manner on the
structure and/or the function of the sarcomere [49-53].
Mutations in the titin gene, TTN (CMH9 locus)
Titin is a giant sarcomeric protein, extending from the M-band to the Z-disk of striated
muscle sarcomere [54]- It's the third filament protein of the sarcomere. Titin is
essential in the assembly of the highly ordered sarcomeres of striated muscles and
responsible for the elasticity of relaxed striated muscle. Titin interacts with numerous
sarcomeric proteins and provides a mechanical linkage. Only one missense mutation
(R74OL) has been reported in exon 14 [55]. The substitution occurred in a
nonconservative domain located within the alpha-actinin binding site. The titin
mutation may cause HCM in this patient via altered affinity to alpha-actinin.
7-3 Friedreich's Ataxia
Friedreich's ataxia (FRDA) is the most common autosomal recessive ataxia,
characterized by degeneration of the large sensory neurons and spinocerebellar tracts,
cardiomyopathy and increased incidence of diabetes [56]. Initially, FRDA can be
diagnosed with only an isolated HCM in young children even though additional features
are not obvious, including ataxia, dysarthria and areflexia. The onset of the disease is
before adolescence, most often between the age of 8 and 15 years, and is generally
characterized by pyramidal weakness of the legs, dysarthria, nystagmus, diminished or
absent tendon reflexes. Babinski sign, impairment of position and vibratory senses,
scoliosis, pes cavus, and hammer toe. FRDA is caused by intronic GAA triplet repeat
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expansion in the frataxin gene [57], which is located on chromosome 9ql3. The gene
codes for a 18-kDa mitochondrial protein of unknown function. Frataxin has distant
homology to C e/egons and yeast genes, where it is associated with the mitochondrial
membrane, playing a role in regulating mitochondrial iron transport and in the
stability of DNA structure. FRDA is caused by severely reduced levels of frataxin. This
leads to mitochondrial iron accumulation and to a subsequent defect of respiratory
chain and aconitase, probably due to cellular sensitivity to oxidative stress. In most
patients FRDA is due to GAA-triplet repeat expansions in the first intron of the frataxin
gene but in some cases the disease is due to mutations in the coding region. Most
patients are homozygous for the expansions of a CAA triplet repeat within the frataxin
gene but a few patients are compound heterozygotes with a point mutation and the
GAA-repeat expansion. Recently, the first conditional mouse models for FRDA were
generated by homologous recombination, and they exhibit important
pathophysiological and biochemical features of the human disease [58]. These mice
represent the first mammalian models to evaluate treatment strategies for the human
disease.
7.4 Genetic analysis
For diagnostic DNA analysis of FHC it is crucial first of all that the diagnosis is
unequivocally made without including any false-positives. This is one of the most
important steps for the following genetic analyses. It is important that the clinician
distinguishes a primary form (only cardiac symptoms) from a secondary form (associa-
ted with non-cardiac symptoms). Another important criterion is the age of onset.
Primary HCM is rarely symptomatic in infants and children while secondary HCM can
disclose at any age. If HCM is diagnosed in infants and children, clinicians should
always add biochemical evaluation and investigation of the neurologic system and
skeletal musculature. Careful analysis of the family history and examination of the
patient, and, if possible of relatives provides additional information. A sporadic case of
HCM can be acquired (non-genetic) or can arise from a "de A7ovo" mutation. In case of a
positive family history the transmission mode can indicate whether the familial
disease is inherited as an autosomal dominant, autosomal recessive or X-linked trait.
An exclusively maternal transmission is suggestive for a mitochondrial defect.
Because FHC is very heterogeneous, linkage analysis is mainly the first option to
initiate DNA analysis. A number of informative markers, closely linked to candidate
genes, are used to investigate whether the disease gene co-segregates with a distinct
locus. It should be emphasized that in FHC (with at least three affected and some
unaffected relatives), it is much easier to establish the genetic etiology than in
sporadic patients. Yet there are some limitations. Sometimes families are too small to
perform adequate linkage analysis. In addition, a late clinical presentation of the
disease (late-onset) or the presence of asymptomatic patients may obscure linkage
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analysis. In that case, the known disease genes are directly screened for mutations. For
linkage analysis, it is very important to choose highly informative microsatellite
markers with a high degree of heterozygosity. If linkage is obvious, a putative
candidate gene can be located and a switch to the identification of the gene defect is
made. DNA analysis is initiated by screening the complete coding sequence including
intronic flanking regions. Depending on the strategy of DNA analysis and the
laboratory equipment, identification of a mutation may take quite some time.
Sometimes the large size of the gene hampers large routine screenings. If no linkage
can be established a genome-wide screen is a next option to investigate whether a
novel locus is involved. When a mutation is found in a proband, its disease-causing
effect should be confirmed. Mutation should segregate in the family and should be
absent in at least 200 normal control chromosomes to exclude low rates of
polymorphisms.
7.5 Genotype-Phenotype relationships in familial hypertrophic cardiomyopathy
Before genetic analyses, it was well known that the pattern and extent of left
ventricular hypertrophy varies greatly from one individual to another and even in first-
degree relatives, and that J high incidence of st/ddert deaths occurs in some families
[59]. Genetic studies have provided insight into the heterogeneity of FHC clinical
features. However, the results must be seen as preliminary, because the available data
relate to only a few hundred individuals, and it is obvious that although a given
phenotype may be apparent in a small family, examining large or multiple families
with the same mutation is required before drawing unambiguous conclusions. Several
concepts nevertheless have emerged, at least for mutations in the /WVH7, 77v7Vr2 and
MV8PCJ genes. For A/I/H7, it is clear that prognosis is very variable from one patient to
the other (Category A) [60, 6 l . 8]. For example, the R4O3Q and R723C mutations
appear to be associated with markedly reduced survival [60,62], whereas some others,
such as the V606M, appear more benign [6l]. The disease caused by TNA/72 mutations
is usually associated with a 20% incidence of non penetrance, a relatively mild and
sometimes subclinical hypertrophy but a high incidence of sudden death which can
occur even in the absence of significant clinical left ventricular hypertrophy (category
A) [34, 63, 64]. In one family with a 7/VA/72 mutation, however, penetrance is complete,
echocardiographic data show a wide range of hypertrophy and there was no sudden
cardiac death [65]. Mutations in ArfVBPC? seem to be characterized by specific clinical
features with a mild phenotype in young subjects, a delayed age at the onset of
symptoms and a favorable prognosis before the age of 40 [66, 46]. Genetic studies
have allowed the identification of patients with double mutations who develop a more
severe form of the disease: compound heterozygous for MVH7 mutations [67], double
heterozygous for MVH7 and MVWCJ mutations [68] and homozygous for a A1VH7
mutation [69]. In addition, a detailed analysis of a "de novo" mutation in a French
112
CHAPTER 7
family with HCM allowed the description of the first case of germline mosaicism in
FHC [70]. This mosaicism had been inherited from the mother but did not affect her
somatic cells. Genetic studies have also revealed the presence of clinically healthy
individuals carrying the mutant allele, which is associated in first-degree relatives with
a typical phenotype of the disease. Several mechanisms could account for the large
variability of the phenotypic expression of the mutations: the degree of functional
impairment caused in the sarcomere by the mutation (that may vary markedly with
the position of the mutation in the molecule and the type of protein involved), the role
of environmental differences and acquired traits (e.g., differences in lifestyle, risk
factors, and exercise) and finally the existence of modifier genes and/or
polymorphisms that could modulate the phenotypic expression of the disease. The
only significant results obtained so far concern the influence of the angiotensin I
converting enzyme insertion/deletion (ACE I/D) polymorphism. Association studies
showed that, compared to a control population, the D allele is more common in
patients with HCM and in patients with a high incidence of sudden cardiac death [71-
73]. It was also shown that the association between the D allele and hypertrophy is
observed in patients with a MVH7 R403 codon mutation, but not in MVWC3 mutation
carriers [74], raising the concept of multiple genetic modifiers in FHC. The genetic
status begins to be used as the criterion of reference to reassess diagnostic criteria and
penetrance. The diagnosis of FHC is usually based on ECG and echocardiography, and it
is generally accepted that echocardiography is a more accurate technique than ECG for
the diagnosis in adults [5]. Analysis of a large genotyped population showed that, in
fact, ECG and echocardiography have similar diagnostic values for FHC in adults, with
an excellent specificity and a lower sensitivity [75]. As for penetrance, it was a much-
debated issue. Before molecular genetics analyses, several studies have indicated
either a full penetrance [76], or an incomplete one [77, 78]. The penetrance of FHC has
been re-assessed in a large French genotyped population, and it was found that it is
incomplete, age-related and greater in males than in females [79]- This latter data has
very important implications for genetic counseling especially for women under the age
of fifty. One of the transgenic mouse models of FHC also shows a gender difference
[80] and it provides now a good genetic model to look for a direct role of sexual
hormones on myocardium and to study the role of putative modifier genes on sexual
chromosomes.
7.6 Therapy in HCM
Two separate therapeutic approaches can be followed in HCM patients. One aimed at
blocking the progression of hypertrophy and alleviating cardiac symptoms. The second
target is prevention of arrhythmias [80]. There are three groups of individuals that
should be distinguished: 1) Patients with complaints related to HCM, 2) Patients with
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hypertrophy, but no complaints, and 3) Carriers without disease characteristics and
symptoms:
1) The need to treat patients with complaints is obvious, although the optimal
treatment is not known. The wide range of therapeutic options going from
pharmacological, pacing, alcohol ablation, to surgical tissue resection in an attempt to
improve cardiac function and reduce complaints is indicative for the confusion. All
studies have different inclusion and assessment criteria, making comparisons between
reports an arduous task. Different drugs have been tested, including Ca'-entry
blockers, beta-adrenoceptor blockers and ACE inhibitors. Early studies with Ca^'-entry
blockers indicate beneficial short-term effects on diastolic function, but only minor
improvement after 6 month (considered to be long term in this study) [81]. Many
studies focus on the reduction of the outflow tract obstruction, but it is questionable
how important this is for symptoms and prognosis [81-84]- A retrospective study in the
UK concluded improved survival in HCM children treated with high dose beta-
adrenoceptor blockers [83]. It has been shown that the outflow tract gradient can be
reduced by left or biventricular pacing, septal alcohol injection or partial septal
resection, with short term relieve of symptoms. These treatment modalities can be
beneficial for the individual patient. With respect to arrhythmias, it is obvious that
amiodarone has been drug of choice in this disease to relieve anginal complaints,
prevent and treat atrial arrhythmias and prevent and control ventricular arrhythmias.
There is little debate on the place of amiodarone in this patient group as shown by
different studies, the question of course is whether implantable cardioverter
defibrillators (ICD) are superior, which seems to be the case [85, 86]. All patients with
an outflow tract obstruction (including the asymptomatic patients) should receive
endocarditis prophylaxis under the usual conditions.
2) Patients with the disease but without complaints will be less motivated to follow a
strict drug regimen. How to attenuate the development of hypertrophy is again not
well studied in this group. Rhythm control and sudden death prevention are
important. Especially, in the setting of a family history with sudden death, or the
identification of a mutation involved with a high incidence of sudden death (see
above) would support prophylactic ICD placement. Again indicating the importance of
the appropriate genetic diagnosis in this disease (Category A). The role of a
preimplantation electrophysiological study is less obvious [85].
3) If you carry a mutation, does that make you a patient, in the absence of any signs of
cardiac disease? For most individuals the answer is no. There are no reports on sudden
death in gene carriers, without left ventricular disease. However, in the setting of
troponin T mutations the situation is different as the signs of hypertrophy can be
minor or absent, while a high incidence of sudden death has been reported [34, 63,
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64]. Therefore, in these individuals, implantation of an ICD should be considered in the
absence of any sign of disease.
Conclusions
It has become clear that the genetic basis of this group of cardiac disorders is
extremely heterogeneous, thus complicating successful and fast identification of the
causative molecular defect. During the differential diagnostic ways it is of crucial
importance that the cardiologist establishes the type of cardiomyopathy and that the
clinical geneticist adequately determines the mode of inheritance. In this respect it
should be realized that cardiac tissue - paraffin-embedded or liquid nitrogen frozen,
which is obtained from a deceased HCM patient is as suitable for genotyping as blood
from alive subjects. The availability of this material can greatly accelerate adequate
genotyping. Once the detect has been characterized it will be possible sometimes to
offer patients or asymptomatic gene-carriers adequate therapeutic advice and suggest
interventions to slow down further progress of the disease. Identification of the
disease causing genes will be the basis for cell-biological studies, which may give
insights into the pathogenesis of this group of cardiomyopathies. A fast method to
screen multiple genes for pathologic mutations can be implemented in the new
"microarray" technology. Soon, genotyping will be a mature and indispensable
diagnostic tool to reveal the true nature of these cardiac disorders.
The aim for the near future is not only to identify new genes - major or modifiers -
involved in HCM but also to better understand the molecular mechanisms by which
the mutations lead to FHC. The analyses of human myocardial tissue, the ex v/Vo and /n
Wfro studies, and the development of animal models by homologous recombination
strategy will all help to investigate the pathogenesis of human FHC mutations.
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Abstract
Aims. Generate and test an efficient screening protocol for identification of MYH7
mutations associated with SCD. Background. Mutations in the beta-Myosin Heavy
Chain gene (MYH7) cause a familial form of cardiac hypertrophy. Clinical
manifestations of these mutations vary and have been classified as either benign or
malignant depending on the occurrence and age of sudden cardiac death (SCD) in
patients or families. A protocol was set up to rapidly identify malignant mutations
associated with SCD. Methods and Results. A screening program was initiated by
using a limited set of six exons, in which published malignant mutations have been
shown to be clustered. Three novel missense mutations (Asn444Ser, lle736Thr and
Val965Leu) and 4 previously reported missense mutations (Arg4O3Trp, Arg453Cys,
Arg7l9Cln and Val6O6Met) were identified in 9 out of 60 families with cardiac
hypertrophy and SCD. Conclusions. In 15% of the FHC families with a history of SCD,
the disease-causing defect was identified. Some of these mutations were previously
described as being benign, not associated with sudden death, indicating the
complexity of strict genotype-phenotype predictions for risk stratification and
treatment of individual patients.
Introduction
Sudden cardiac death (SCD) is a major cause of mortality in the western world. Among
young (< 35 year) athletes SCD occurs in the setting of hypertrophic cardiomyopathy
(HCM) in about 36% of cases [ l ] . In a large cohort of apparently healthy young adults
selected from a community-based general population, the prevalence of
echocardiographically defined HCM was estimated at 0.2% [ l ] . The predominant form
is Familial Hypertrophic Cardiomyopathy (FHC) which has an autosomal dominant
mode of inheritance and is genetically heterogeneous. Major clinical features include
an increase in left and/or right ventricular muscle mass with often asymmetric
thickness of the septum. On echocardiography an increased wall thickness of >13 mm
is considered abnormal. Morphological features of HCM are myofibrillar disarray and
interstitial fibrosis leading to impaired relaxation and an altered contraction force, a
hallmark of the disease. Typical complaints include exertional chest pain (angina
pectoris), dyspnea, fatigue, palpitations and syncope. At physical examination a cardiac
systolic murmur can be present (2]. SCD may be the first dramatic symptom of the
disease. The overall annual mortality in adults with FHC is estimated to be 1%,
compared to 0.13% (age 34-75y) in the normal population [3.4].
At present mutations in 10 genes, encoding sarcomeric proteins, have been identified
that may cause FHC. with titin (TTN) as the most recent addition to the list [5]. Up to
now more than 150 mutations within these genes have been listed in the FHC
database [6]. Because FHC is such a genetically heterogeneous disorder, the most
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straightforward strategy to identify the genetic defect is linkage analysis followed by
mutation analysis. However families are generally too small to perform linkage
analysis, especially families with a high incidence of SCD in which genetic testing could
be very helpful for early identification of individuals at risk. Since it is not feasible to
completely screen all 10 genes simultaneously in a diagnostic setting we designed an
efficient screening protocol aimed to specifically identify malignant, SCD correlated
FHC mutations. This protocol focussed on the beta-myosin heavy-chain gene (MYH7)
on chromosome 14. which contains about 33% of the reported FHC mutations [6]. As
the impact of genetic diagnosis is most relevant in families with SCD, we only included
SCD families in this first genotyping effort. By using this protocol we identified a
missense mutation in 9 out of 60 unrelated small families with a history of SCD. Three
mutations were novel and four mutations were reported previously. Some mutations
previously considered benign and not associated with sudden death, were now
identified in families with SCD at early age.
Materials and methods
Diagnosis
The clinical diagnosis of HCM was based on two dimensional echocardiography and
Doppler recordings. The diagnosis was made if an unexplained ventricular wall
thickness >13 mm was found in the absence of other cardiac or systemic disorders [7].
The disorder was considered familial in the presence of a positive family history. In the
Netherlands several academic centers have an outpatient clinic for inherited
cardiovascular diseases. In these outpatient clinics a clinical geneticist and cardiologist
collaborate in consulting individuals or families. If the diagnosis of FHC is made,
informed consent is requested for obtaining medical information on family members
and if possible, autopsy records of deceased patients. Furthermore, permission is
obtained for genotyping. Pedigree information and blood samples are sent to the
Genetic Department for genomic DNA extraction and genotyping. We selected index
patients from 60 consecutive families with HCM (mean age 42y) and occurrence of at
least one case of SCD in a family member before the age of 55 years.
Cenotyping
Although the MYH7 gene consists of 41 exons, most of the malignant mutations are
clustered within exons 13, 14,16,19, 20 and 23 encoding the globular head and hinge
or neck domain (Figure 1; S1-S2). These six exons were selected for the initial screening
protocol. Peripheral blood samples were taken from patients and if available from their
first degree family members. Cenomic DNA was extracted by using high salt
extraction method [8]. The target exons of the MYH7 gene were amplified by using
intronic primers (Table l). Primer pairs were based on the genomic sequence [9]. Exon
16 was divided in two separate amplification reactions (16a & 16b). To detect
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differences in folding of denatured PCR products, Single Strand Conformation
Polymorphism (SSCP) analysis was performed at 5°C and 15°C and amplicons with
aberrant conformers were purified and analyzed by sequencing as described previously
[10,11].
K383N
R403W
R«3Q
R « 3 l
ATG
R7Z3C
R723G
G584R
D587V N6965
N602S G716R
V606M R719Q
K61SN R719W
173*1
G741R
G741W
G741A
1906V
E 9 2 *
E93CK
E939C
E 9 4 *
V965L
UM I II II I 111 IIP
1314 16 1920 23
N H 2 - * - -» -C00H
Globular head Neck-Hinge region Filament backbone
.Fjjuire *• _S«h«"t»t't *tfurture of the MYH7 j{ene and locations of the _ß-MyHC protein domains. The
translation start codon ATC (exon 3) is indicated and exons analyzed in this study are numbered and
represented by gray boxes. Above the corresponding exons the mutations reported in this study (bold
face) and mutations registered in the FHC database (www.angis.org.au/databases/) are indicated.
Mutation Specific Restriction enzyme analysis
Some of the previously described "malignant" missense mutations alter the DNA
sequence, creating an additional or abolishing a specific restriction site. Following
amplification the products were incubated with the appropriate restriction enzyme.
Wild type and mutant DNA samples were discriminated by size fractionation using gel
electrophoresis. In this study we used mutation specific restriction fragment analysis
to identify the missense mutations Arg4O3Leu (exon 13) and Gly7l6Arg (exon 19) by
using PflMI and Bsmal restriction endonucleases (Biolabs; Westburg) respectively [12,
13]. The missense mutations Arg4O3Trp, Arg453Cys and Arg719Cln presented in this
study can be identified with restriction endonucleases Aval, Nlalll and Mspl (Biolabs;
Westburg) respectively. Digested PCR products were analyzed by electrophoresis on
3% agarose gels. The pathogenicity of the novel mutations was based on the
evolutionary conservation of the altered amino acid in the MYH7 of vertebrate striated
muscle from different species, on the segregation in the family in relation to the
disease and on the absence of the mutation in 110 alleles from healthy individuals
[14].
124
Table 1. MYH7 primer combinations and PCR conditions
Region
Exon 13
Exon 14
Exon 16a
Exon 16b
Exon 19
Exon 20
Exon 23
Primers
13F
13R
14F
14R
l6F-a
l6R-a
l6F-b
l6R-b
19/2OF
19R
20F
19/2OR
23F
23R
Sequence 5'-> 3'
TTACACCCATCAACCACACACC
CTCAACTTCAAAACTCTCATCCC
TCACTCTTCCCAACAACCC
TCATTCTTCTCCCACTCCC
TCAAGCACACTCACTCATCC
CCCCCCATAGTGCATCACCC
CAAGGGGAAGCCTGAAGCCC
CTGTACCGGGAGCCTCAGTC
CTCCTCCTACTTCCTTCTTG
CCCCTGTTCTATGAGCTTCT
CAGAGCATGGGTGACTCTGG
GAGGAGTCAATGGAAAAGAG
CCTCCCCTCTGTTCCTCACC
CGGGCTGGAGCCAAAGGGAG
Position (14)
8708-8729
8952-8974
8971-8988
9190-9208
1018110201
1O3741O393
10348-10367
1054010559
12011-12030
12174-12194
12267-12296
12464-12483
13941-12960
14221-14240
Temp
"C
64
64
64
64
60
60
64
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PCR product
266 bp
237 bp
212 bp
211 bp
183 bp
216 bp
299 bp
Results
In 9 out of 60 probands (15%) from HCM related SCD families, we identified 7 distinct
missense mutations in the MYH7 gene (Figure 2). The limited number of living patients
(1-3, average 2) is obvious from the pedigrees presented and limits the genetic linkage
analysis approach followed by genotyping. DNA results and main clinical features of
the genotyped families are presented in Table 2. From most SCD cases (1-2 per family)
no tissue or DNA was available for analysis. Three mutations were novel (Asn444Ser,
He736Thr and Val965Leu) and four mutations had been reported previously
(Arg403Trp, Arg453Cys, Val6O6Met and Arg719Cln). Three apparently unrelated
families carried the Val6O6Met mutation which appears be a more common mutation
in the Dutch population.
Novel missense mutations (Asn444Ser, He736Thr and Val965Leu)
In family B the novel missense mutation Asn444Ser (nt9O97 A>C; exonl4) was
identified in a male patient (age 54y). His son suddenly died at age 23 while playing
soccer. A sporadic case in family H concerns a male proband (age 48y) with
hypertrophic cardiomyopathy, ventricular arrhythmia, an aborted sudden cardiac
death (aSCD) and a positive family history for SCD. His brother died suddenly at age
35y and his mother at age 58y. In this family we identified the novel missense
mutation lle736Thr (ntl2347 T>C; exon 20) . Finally, in family I the novel missense
mutation Val965Leu (ntl4177 G>C; exon 23) was identified. In this family two brothers
of the proband (46y), with clinical signs of hypertrophy, died suddenly at age 29 and
50y. Their father had cardiac hypertrophy and died suddenly at age 50y.
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Sex Age years
M SCO at 53
63
59
58
54
SCDat23
SCD at 40
54
21
11
died at 41
SCD at 57
43
M
M
F
M
F
F
F
SCD at 38
17
SCD at 40
SCD at 48
54
48
42
HOW/
Mutation
+ / •
+ / +
+ / +
• / •
+ / -
• / •
Effect of the
mutation
R4O3W
8847C>T
N444S
9097 A>G
R453C
9123 C>T
exon
13
14
14
2D Echocardiography
-
ASH 20mm
dubious septum hypertrophy
outflow tract gradient
ASH, Ml, enlarged LA
LVH, SH 17mm
Electrocardiogram Symptoms
• f / -
V6O6M
10457C>A
V6O6M
10457C>A
16
ASH, Ml, enlarged LA
LVH; outflow tract gradient
l.5m/sec, trace Ml
MVP; LVH
known with HCM
SH 23mm; PW 13mm; outflow
tract 43; SAM
known with HCM
16
abnormal ST-T segment
incomplete RBBB
1st degree AV block, slow R-
progression
dyspnoe exertion
AP?
dyspnoe exertion
collapse at age 28y, AFconduction disturbances.
abnormal ST-T segments
sinus bradycardia, abnormal . , „ . . . ..
ST-T segment, incomplete RBBB * " > while sporting
1st degree AV block, slow PR
progression; large P waves
sinus bradycardia
normal
non sustained VT
AF
no complaints
myocardial infarction
dizziness
o/
ASH 18mm abnormal ST-T segments
SH 15mm; atria dilated LVEF 36% LBBB bradycardias. broad QRS pacemaker, persistent
complex AF
normal (septum 9mm) -
M
F
M
F
F
F
F
F
M
M
SCD at 58
SCD at 48
23
SCD at 40
24
22
19
SCD at 58
SCD at 35
48
-
-
+ / +
+ /-
+ / +
+ / +
+ / +
+ /-
+ /-
+ / +
M
M
M
M
M
SCD at 50
SCD at 50
SCD at 29
46
42
V6O6M
10457G>A
R719Q
12148 C>C
I736T
12347 T>C
V965L
14177G>C
16
19
20
23
wall Th Sl5, PW 13mm; outflow
tract gradient 27
SAM; IVS-EDWT 16-I8mm; PW-
EDWTl2mm;MI
HCM
HCM
known with HCM
no significant LVH
ASH 15mm
ASH 25mm
LBBB, septum Q waves
1st degree AV block, enlarged P
wave; left axis
intermediate axis, mild ST
elevations
septum Q waves, IVH
SCD while sporting;
collapse, souffle
dizzy, collapse,
arrhythmia
decreased stress
tolerance
pacemaker
near collapse, dyspnea
complaints
dyspnea
no complaints
no complaints
*MYH7 codon numbering was according to the genomic sequence of the human cardiac beta-myosin heavy chain gene (12). The age of individuals at time of
the clinical investigation is indicated in years. Symbol definitions: - no information available: 0 / • no hypertrophy, carrier of the MYH7 mutation; + / •
hypertrophy, carrier of the MYH7 mutation; + / - hypertrophy, unknown genotype. Abbreviations: AF= atrial fibrillation; AP« angina pectoris; ASH«
asymmetrical septum hypertrophy; F= Female; LA= left atrium; LBBB= left bundle branch block; LVEF= left ventricular ejection fraction; LVH= left ventricular
hypertrophy; M= Male; Ml= mitral valve insufficiency; MVP= mitral valve prolaps; PW= posterior wall; RBBB= right bundle branch block; SAM» subvalvular aortic
motion; SCD« sudden cardiac death; SH= septum hypertrophy; VT= ventricular tachycardia.
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54y
N444S
63 y 57 y 59 y 58 y
R403W R403W R403W
I
23y
-O D—i-O
40y 54y
R453C
o
21 y 11 y
R453C R453C
41 y 57 y
43 y
V606M
EG
17y
V6O6M
38 y
43 y
-D
•606M
48 y 42 y
V6O6M V606M
ffl
19 y 24 y 20 y
V6O6M V606M V606M
58y
-O
48 y
23y
V606M
D
40 y
24 y 22 y 19 y
R719Q R719Q R719Q
ja-
50y
35y 48 y
I736T
50y
-o
29 y 46 y 42 y
V965L V965L
Symbol definitions
D O no clinical data
• # hypertrophic cardiomyopalhy
ffl <}> no clinical symptoms
Figure 2. Pedigrees of the SCD families. Pedigree symbols: squares indicate males; circles indicate
females, symbols with diagonal slash, deceased family members; filled symbols, individuals with
hypertrophic cardiomyopathy, unfilled symbols, individuals investigated without cardiac hypertrophy;
Crossed symbols, carriers of the genetic defect without cardiac hypertrophy. An arrow refers to the
family proband. Below pedigree symbols the genetic defect and the age of sudden death are indicated.
Only family members with the genetic defect and their spouses are presented within the pedigrees.
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Malignant missense mutations (Arg4O3Trp, Arg453Cys and Arg719Gln)
In family A, a 58-year-old woman was carrier of a previously reported missense
mutation Arg4O3Trp (nt8847 C>T; exon 13). She had mild aortic stenosis and marked
left ventricular hypertrophy. Her brother, diagnosed with HCM suddenly died at age
53y. An elderly brother (age 59y) did not show clear clinical symptoms, although he
had inherited the genetic defect. The mutation Arg4O3Trp was not detected by Pflml
restriction analysis (which is a mutation specific assay for the R4O3Q mutation). The
Arg453Cys (nt9123 C>T; exon 14) missense mutation was identified in family C from
Pakistan origin. A 54-year-old male proband transmitted the mutation to his son (age
21y) and his daughter (age l l y ) who already had clear signs of cardiac hypertrophy. A
brother of the proband died suddenly at the age of 40y. No autopsy was performed.
The proband (age 19y) in family G showed an aberrant SSCP conformer in exon 19 and
after sequencing we identified a previously reported missense mutation Arg719Gln
(ntl2148 G>C; exon 19). Two older sisters of the proband had developed HCM at age
24 and 22y. Their mother died at age 40y. In this family the myocardial hypertrophy is
predominantly located in the septum.
Benign missense mutation (Val606Met)
In three unrelated families (D, E and F) we identified the previously reported missense
mutation Val606Met (ntlO457 G>A; exon 16). The female proband (age 43) in family D
had marked septal hypertrophy. Two family members with HCM died suddenly at age
38 and 57y. There were no biological samples left to confirm the mutation in the
deceased family members or to proof paternal or maternal inheritance. Families E and
F had incidences of sudden death at age 40, 48y; 48y and 58y. The only genotyped
member of family F, had developed cardiac hypertrophy at age 23y.
Discussion
Identification of mutations causing familial hypertrophic cardiomyopathy (FHC) is
important to elucidate the pathogenesis of this complex cardiac disorder. It has
become of major significance for predictive genotype testing and genetic counseling of
family members at risk of carrying a pathogenic mutation, although disease
penetrance is incomplete and clinical manifestations of carriers with an identical
mutation may vary [15]. Because of this phenotypic variability of reported mutations,
it is difficult to predict the clinical manifestations in individual cases and to implement
preventive treatment by genotyping alone. Meanwhile the question has been raised
whether genotyping has a future role in guided risk-factor stratification [16]. This can
only be achieved by analyzing large cohorts of patients with inexpensive, rapid and
sensitive screening methods. By simplifying the genotyping protocol and by
introducing the SCD as risk factor we attempted to improve the identification of
mutations in families at risk of the most severe form of HCM. Based on literature data,
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we expected 11 mutations (6OxO.33xO.55) as 55% of the mutations identified in the
MYH7 gene are located within the limited number of six exons selected for the initial
screening. We have identified 9 mutations which fits with the SSCP approach, which
although being very rapid, may miss up to 20% of the mutations present. Our yield of
mutations of 15% is much higher compared to the results of Ackerman et al who
recently reported a yield of 1% by implementing an even more limited (3 exons)
screening protocol [17]. They identified only one mutation in a total amount of 69
patients with a positive family history and at least one SCD before the age of 40. If we
had used their strategy analyzing only exons 13,14 and 19 we would have identified 4
mutations in 60 subjects (6.7%). The discrepancy between the results may also
originate from the selection criteria of the families included. We believe that the
combination of well chosen clinical selection criteria and a carefully selected gene
screening procedure will be most effective, both from a clinical and a financial point of
view.
Novel malignant missense mutations
The novel mutation Asn444Ser resides, like the previously reported Arg453Cys
malignant mutation, in the vicinity of the nucleotide-binding pocket domain which is
associated with actin binding (Si domain)[l8, 19]. Position 444 is highly conserved in
the myosin heavy chain protein from several species, indicating an important
functional domain. The second novel missense mutation was identified in codon 736
(lle736Thr) and presents a malignant phenotype in this family. Involvement of codon
736 was reported previously in a Japanese family where the amino acid isoleucine (lie)
was altered into methionine (Met) and also presenting a malignant phenotype [20,
21]. Both amino acid substitutions occurred in the same codon which is close to the
binding site of the essential ventricular myosin light chain (MLCl). In a chicken MLCl
deficient model, a decrease of 50% of the velocity at which myosin moves actin was
observed in a motility assay [22]. Similar results were reported in mice lacking the
essential myosin light chain binding domain, demonstrating that alterations in myosin
force transmission were sufficient to trigger the development of HCM in mice [23]- The
third novel missense mutation Val965Leu concerns a highly conserved amino acid
valine. The amino acid substitution occurred in the rod or N-terminal part of the S2
segment of the MYH7 gene. Recently it was demonstrated that mutations in this N-
terminal part, like Arg87OHis and Clu924Lys, drastically reduce binding of myosin
binding protein (MyBPC3). This protein contributes to the structural integrity of the
sarcomere by binding the myosin heavy chain to the cytoskeleton protein titin [24].
Known malignant missense mutations
The three missense mutations (Arg4O3Trp, Arg453Cys and Arg719Gln) identified in
this study, have been reported previously by several other investigators while some of
these mutations have been studied with /n vitro experiments and functional tests [19.
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25]. Codon 403 has been described as mutational "hotspot" and distinct mutations
Arg4O3Leu. Arg4O3Trp and Arg4O3Gln have been reported in several studies [6, 26],
The Arg4O3Leu mutation is correlated with a high incidence of sudden cardiac death
and the mutation Arg4O3Trp showed 100% penetrance for developing hypertrophy
[27]- An early onset of symptoms has been reported for the Arg4O3Trp mutation which
also has been identified in this study [12]. Posen et al. described a large South-African
pedigree of 64 members (31 affected) with the Arg4O3Trp mutation in which no SCD
occurred, concluding that the mutation Arg4O3Trp was benign [28]. In the study
presented here however, the mutation has a malignant phenotype as one family
member died at a relative young age (family A). Watkins et al. constructed a Kaplan-
Meier curve showing a correlation between a mutation at position 403 (Arg4O3Gln)
and a high incidence of death at a young age [18]. In vitro studies in chicken skeletal
muscle myosin and human slow-twitch muscle fibers showed that the Arg4O3Cln
mutation strongly diminishes the motility and ATP-ase activity [19, 25] indicating that
the 403 position is very important for muscle contraction. The second known
malignant missense mutation is Arg453Cys. Watkins et al. suggested that carriers of a
genetic defect, altering the charge of the amino acid as for example the arginine to
cysteine substitution in codon 453, had a significantly shorter life expectancy than
carriers of mutations with no change of charge [18]. The mutation Arg453Cys is
located at the surface of the protein facing towards the putative actin binding region
and might therefore influence the catalytic function of the molecule [19]. Finally, the
Arg719Gln mutation was reported previously in a family of Hispanic origin with an
early age of onset of cardiac hypertrophy but no history of syncope or SCD and normal
ECG's [29]. However, a second mutation that had occurred in codon 719 (Arg719Trp)
was correlated with a high incidence of SCD at young age [13, 30, 31]. These
observations indicate that mutations in codon 719 not always generate a malignant
phenotype, which might depend on the change of charge or polarity of the amino acid
substitution or on the role of modifiers in a different genetic background.
Benign missense mutations
The Val606Met mutation results in a neutral change of charge in the MHC protein and
has often been reported with a favorable outcome and a mild phenotype in previously
reported families labeling the mutation benign [18, 21]. However Fananapazir et al
reported a family with 4 cases of SCD (age l5-27y) and concluded that the Val6O6Met
mutation is malignant in some kindreds [32]. Similar findings have been reported in an
Australian and Japanese family [21, 33]- Later, also Havndrup et al. reported an
unfavorable prognosis/outcome in one family with a high risk for sudden death at
young age [34]. Our families present with a malignant phenotype as well, although it
can not be excluded that in one family (Family D) another fatal inherited cardiac defect
might be involved as the father of the proband died suddenly at relatively young age
(41y) from a myocardial infarction.
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Conclusions
The aim of this study was to generate an efficient screening protocol with a high yield
of malignant mutations in the beta-myosin heavy chain (MYH7) gene by including the
risk factor of sudden cardiac death. By screening only those exons, known to harbor
malignant mutations as well as the majority of the mutations, and by selecting specific
families with reported early SCD, we identified the genetic defect in 9 out of 60
probands (15%) which justifies our strategy. Two malignant missense mutations
Arg4O3Leu (exon 13) and Cly7l6Arg (exon 19) previously reported as being correlated
with a high incidence of SCD were not detected in this study [12, 26, 27, 29, 30].
However, we identified three novel malignant missense mutations (Asn444Ser,
He736Thr and Val965Leu) underlining the importance of DNA testing. In spite of the
limited nature of the protocol, the mutation detection score was high (15%), indicating
the suitability of our rapid pre-screening protocol for malignant mutations in high-risk
families. Being aware of the heterogeneous character of FHC we are developing a
comparable screening protocol for the troponin T (TNNT2) gene which, despite
moderate hypertrophy, has been associated with a high risk of sudden cardiac death
[35, 36]. Initial unpublished results suggest a similar success rate. We conclude that
our genotyping approach allows a rapid identification of the genetic defect in a high
number of patients with HCM with SCD and opens the way to predictive testing of
individuals at risk. For gene carriers identified cardiological follow-up by routine 2D-
Echo, ECC, X-test and Hotter registration can be applied to monitor the progression of
the disease so that clinical interventions can be implemented in time.
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Abstract
Objectives. This study was initiated to identify the disease-causing genetic defect in a
family with hypertrophic cardiomyopathy (HCM) and high incidence of sudden death.
Background. Familial hypertropic cardiomyopathy (FHC) is an autosomal dominant
transmitted disorder that is genetically and clinically heterogeneous. Mutations in 11
genes have been associated with the pathogenesis of the disease. Methods. We
studied a large FHC family, first by linkage analysis, to identify the gene involved, and
subsequently screened the gene, encoding alpha-tropomyosin (TPMl), for mutations
by using single-strand conformation polymorphism and sequencing analysis. Results
.Twelve family members presented clinical features of HCM, five of whom died at
young age, while others had only mild clinical features. Marker analysis showed
linkage for the TPMl gene on chromosome 15q22 (maximal logarithm of the odds
score is 5.16, 8= 0); subsequently, a novel missense mutation (Glu62Gln) was
identified. Conclusions. The novel mutation identified in TPMl is associated with the
clinical features of cardiac hypertrophy in all but one genetically affected member of
this large family. The clinical data suggest a malignant phenotype at young age with a
variable clinical manifestation and penetrance at older age. The Clu62Gln mutation is
the sixth TPMl mutation identified as the cause of FHC, indicating that mutations in
this gene are very rare. This is the first reported amino acid substitution at the f-
position within the coiled-coil structure of the tropomyosin protein.
Abbreviations: cM, centiMorgan; DCM; dilated cardiomyopathy; FHC; familial hypertrophic
cardiomyopathy; HCM; hypertrophic cardiomyopathy; LV; left ventricular; MYBPC; myosin binding
protein C; MYH7; beta-cardiac myosin heavy chain; TNNT2; troponin T; TPMl; alpha-tropomyosin
Familial hypertrophic cardiomyopathy (FHC) is a clinically and genetically
heterogeneous disease with an autosomal dominant mode of inheritance. Main
clinical features are increased left ventricular (LV) and/or right ventricular muscle mass
often in combination with asymmetric hypertrophy of the septum. On
echocardiography, an increased cardiac muscle thickness (13 mm or more) is observed
[ l ] . Typical complaints include chest pain (angina pectoris), shortness of breath
(dyspnoea), fatigue, palpitations, and syncope. Sudden cardiac death may be the first
dramatic symptom of the disease. The motion and contraction force of striated cardiac
muscle cells is generated within the sarcomere by interaction between thick and thin
filaments. Impaired relaxation and contraction force, a hallmark of FHC is generally
caused by mutations in one of the sarcomere encoding genes. Until now, 11 genes
have been reported as being involved in the development of FHC [2-4]. A total of 10 of
the 11 genes encode cardiac proteins that assemble into contractile units (sarcomeres)
of the cardiomyocytes. The genes that encode beta-cardiac myosin heavy chain
(MYH7). myosin binding protein C (MYBPC3), and troponin T (TNNT2) account for
approximately 75% of FHC (based on reported mutations). Recently, the gene PRKAG2
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(gamma 2 subunit of AMP-activated protein kinase) encoding a non-sarcomeric
protein on chromosome 7q was found to be involved in cardiac hypertrophy [5, 6]. In
these patients, a complex of symptoms including conduction disturbances and Wolf-
Parkinson-White syndrome was demonstrated, probably related to glycogen storage
[7, 8]. In this paper we describe a large five-generation FHC family from the
Netherlands. Linkage was identified with the alfa tropomyosin (TPMl) gene, and a
novel mutation Clu62Cln (E62Q) was detected. The TPMl gene is a very rare cause of
FHC (approximately 5%), except for the Finnish population where TPMl mutations
account for > l l % [9]. Until now, only eight missense mutations have been described
within the TPMl gene causing either hypertrophic (FHC) or dilated cardiomyopathy
(DCM) [10-17]- The presence of the new mutation was associated with variable clinical
features, although the mutation should be considered malignant, especially at
younger age.
Methods
Clinical studies
A large five-generation Dutch family with FHC was analyzed in our institute. Family
members were clinically evaluated by physical examination, two-dimensional
echocardiographic examination, and 12-lead electrocardiography (ECC) analysis.
Histopathological data of deceased family members were obtained when available.
The clinical diagnosis of hypertrophic cardiomyopathy (HCM) was made if the
interventricular septal thickness was >13 mm, in the absence of other cardiac or
systemic causes of LV hypertrophy. In some family members, phenotypic assignment
of cardiomyopathy was based on histopathological features of HCM at postmortem
examination. Informed consent was obtained from each family member for genetic analysis.
Genetic studies
Marker analysis
Blood samples were collected from 22 individuals (clinically affected members and
family members with no clinical symptoms of cardiac hypertrophy). Genomic DNA was
extracted according to standard protocols [18]. Marker sets, used to test four
candidate genes, were either located in the 5' and 3' flanking regions of the genes or
were intragenic. D1S2716 and D1S2622 at 2 to 2.5 centiMorgan (cM) proximal of the
troponin T gene (TNNT2; chromosome Iq32), marker D11S1344 and D11S1357 at 0.8
cM of the myosin binding protein C gene (MYBPC3; chromosome l lp l l .2 ) , two
intragenic markers MYOI and MYOII for the ß-beta-myosin heavy chain (MYH7;
chromosome I4ql2), and, finally, D15S159 and D155993 at <0.5 cM for the alpha
tropomyosin gene (TPMl; chromosome 15q22) [19-22]. Markers were derived from the
Genome Database (GDB) and Genethon, labeled with fluorescent dyes and polymerase
chain reaction amplified according to standard procedures. Fragment length analysis
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was performed by using the ABI31OO fragment gene analysis system (Applied
Biosystems Inc., Nieuwerkerk a/d Usel, the Netherlands) and Genescan analysis
software version 37 (Applied Biosystems Inc.). : «/° . • * ^v, *; a«^;
Linkage analysis
Linkage analysis was performed by using the ILINK module of the LINKAGE program
version 5.1 [23]. Disease penetrance was estimated at 75% and disease frequency at 0.2%.
Mutation analysis
Nine exons (la, 2b, 3, 4, 5, 6b, 7, 8, and 9a, b), comprising the entire coding sequence of
the TPMl gene in cardiac muscle, were amplified by using intronic primers as
previously described [10]. Single-strand conformation polymorphism analysis was
performed at 5°C and 15°C, and amplicons with aberrant conformers were purified
and analyzed by sequencing as described previously [24]. For diagnostic analysis, the
mutation detection was performed by Mnll endonuclease (Roche, Almere, the
Netherlands) of the PCR product of exon 2b and analyzed by gel electrophoresis on a
3% Nusieve Agarose gel (FMC, Sanvertech, Boechout, Belgium).
Results
Clinical characteristics
The pedigree of the FHC family is presented in Figure 1, and main clinical
characteristics are presented in Table 1. The family came to our attention because of
the early sudden death of a mother (III.11) and four of her children (IV:l6, IV:17, IV:l8,
and IV:19). The cause of her death was unclear, and no autopsy was performed.
Postmortem evaluation of the two children (IV:l6, IV:17) revealed severe asymmetric
septal hypertrophy. Histology indicated myofibrillar disarray with interstitial fibrosis in
the apical part of the septum and abnormal intramural coronary vessels. The third son
(IV:8) was examined after the death of the oldest two sibs. He suddenly died at age 15.
The youngest son (IV:19) was examined at age 17, and, at that time, he complained
about fatigue. A few months later, he died suddenly. The father of this family
remarried to a younger sister (111:13) of his first wife. Two children (IV:21 and IV:22)
again showed HCM at age 33 and 35 years, respectively. Besides cardiac abnormalities,
both were mentally retarded suffered spastic paralysis. The origin of their mental
deficiency remains unclear. Their mother remained without complaints at age 67
years. She was frequently reinvestigated and did not show any signs of HCM on ECG or
two-dimensional echocardiography. Only on magnetic resonance imaging
investigation a septal hypertrophy (max, 17 mm) was found. In the other branch of
this family, the diagnosis HCM was made for individual IV:9 at routine screening for
military services. At age 7, his daughter (V:3) was investigated for signs of HCM.
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Electrocardiographs examination and echocardiography demonstrated signs of LV
hypertrophy. At present she remains without complaints.
Linkage of the TPMl gene
Because of maternal transmission in the right part of the pedigree (Fig.l), HCM-related
and specific mitochondrial DNA mutations (A3243G. A326OG, C33O3T, A43OOC,
A4269C, A43417G, G8344A, and T8993C/G) were excluded, as well as mitochondrial
DNA deletions (data not shown). Marker analysis of 20 family members and two
spouses of deceased members excluded the involvement of the MYH7, the MYBPC3,
and the TNNT2 genes. Segregation of the alfa-tropomyosin (TPMl) markers were in
line with a possible involvement of the TPMl gene. Linkage analysis software revealed
a maximum LOD score Z(6)= 5.16 (6=0) (for markers D15S159 and D15S993.
Subsequently, nine amplified exons of the TPMl gene were screened by SSCP analysis.
An aberrant conformer was identified in exon 2b indicating a sequence variation.
Sequence analysis showed a GAG to CAG transition at position 184 (complementary
DNA reference sequence of TPMl, Genebank accession number M19713). The
nucleotide substitution changes the amino acid glutamic acid of codon 62 into
glutamine (Glu62Gln). In this family, the missense mutation segregated with the disease.
As the G to C substitution abolishes a Mnll restriction site, we applied Mnll restriction
analysis to identify carriers of the genetic defect in all family members at risk. The
pathogenicity of the mutation was based on exclusion of the mutation within a
control group of 100 unrelated subjects (200 chromosomes) and by the localization of
the substituted amino acid in an evolutionary highly conserved domain of the alpha-
tropomyosin protein.
Discussion
Familial HCM is a clinically and genetically heterogeneous disorder. Incomplete
penetrance and variable age-related clinical expression is often observed within and
between families, even if an identical mutation is involved. At the moment, mutations
in 11 genes have been identified that are involved in FHC, making linkage analysis the
first step in identifying the genetic defect, as has been demonstrated in this family. In
FHC families, however, a major problem is the high incidence of sudden death of
affected family members and, because ofthat, no tissue or DNA is available for linkage
studies. In this study, marker analysis showed statistically significant linkage with the
TPMl gene on chromosomel5q22, and the causative mutation was identified in all
clinically affected family members. The high conservation of the protein domain
involved, and the absence in the control population, indicated that this mutation was
very likely the cause of FHC in this family.
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Figure 1 . Five generation pedigree of the familial hypertrophic cardiomyopathy family. Pedigree symbols: squares = males; circles = females symbols wi th
diagonal slash » deceased family members; filled symbols = individuals with documented hypertrophic cardiomyopathy; dot within symbol = obligate carrier of
the genetic defect; unfilled symbols = individuals without cardiac hypertrophy. Underneath the symbols are indicated the age (years) of sudden death and the
genetically defined carriers of the mutation with E62Q (Clu62Cln). Bars « the haplotypes and numbers the alleles length (in basepairs) of the markers D15S159
(upper) and D15S993 (lower); filled bars »the risk haplotype 165 to 181.
Table 1. Clinical features of the HCM family.
Pedigree
11.2
11.4
111.4
111-3
111.11
111.13
IV.3
IV.7
IV.8
IV.9
IV.ll
IV.16
IV.17
IV-18
IV.19
IV.21
IV.22
V.3
Gender
F
F
F
M
F
F
M
F
M
M
M
M
F
M
M
M
M
F
Age
?
67
46
34
44
34
18
19
17
15
17
35
33
12
E62Q Clinical history
(+)' SCD at 69 yrs
(+)
(+) SCD at 47 yrs
(+) SCD at 45 yrs
(+) SCD at 35 yrs
+t no complaints
+ no complaints
+ Atypical complaints
+ PAF
+ PAF, dyspnea
(+) SCD at 18 yrs,
arrhythmia
(+) SCD at 19 yrs
(+) SCD at 17 yrs
(+) SCD at 15 yrs
(+) SCD at 17 yrs.
fatigue
+ no complaints
+ no complaints
+ no complaints
LVEF
NA
NA
NA
NA
NA
Normal
66%
Normal
64%
70%
NA
NA
NA
>50%
>50%
70%
>50%
SH
16
18
14
31
15
24
18
18
20
2DEcho
PW
14
8
10
10
t
10
13
12
Normal
ESO
23
30
33
24
NA
NA
29
21
EDD OttMH
41
46 SAM, Ml
55 SAM, Ml
38 SAM
NA
NA
49
38 Ml
KG
NA
NA
NA
NA ;.
NA •• ::
Normal
LVH, abnormal ST-segments
NA
LVH, abnormal ST-segments
LVH, abnormal ST-segments
NA
LVH
LVH, abnormal ST-segments
LVH, abnormal ST-segments,
sinus bradycardia
Abnormal ST-segments
LVH, abnormal ST-segments
LVH, abnormal ST-segments
Remarks
Obligate carrier
Obligate carrier;
gynecological cancer at
dec /lyrs
Obligate carrierObligate carrier
Obligate carrier
MRI:ASH17mmt
Died during catheterization
PM: septal hypertrophy,
myofibrillar disarray +
fibrosis
PM: extensive septal
hypertrophy + LVH, RVH,
myofibrillar disarray +
fibrosis
PM: muscle degeneration.
interstitial fibrosis
Mentally retarded spasticity
Mentally retarded spasticity
Hypertrophy at age 5y
"The (+) symbol indicates possible carrier of the mutation Clu62Cln; t the + symbol indicates carrier of the mutation Glu62Cln; tMRI: normal value <l2mm.
Age » age (yr) at cardiac evaluation; ASH = asymmetrical septum hypertrophy; EDD = end-diastolic diameter; ESD = end-systolic diameter; HCM = hypertrophic
cardiomyopathy; LVH = left ventricular hypertrophy; LVEF = left ventricular ejection fraction; Ml « mitral incompetence; MRI = magnetic resonance imaging; NA =
not available: PAF = paroxysmal atrial fibrillation; PM - post mortem; PW = posterial wall; RVH - right ventricular hypertrophy; SAM = systolic anterior movement
of the mitral valve; SCD = sudden cardiac death; SH = septum hypertrophy.
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However, in this pedigree, the penetrance of the Glu62Gln mutation is incomplete, as
one of the carriers with the mutation presents only with very mild hypertrophy at
older age that might be missed by routine echocardiographic screening (Figure l ;
individual 111:13). These findings suggest that other genetic or environmental factors,
yet unidentified, must be involved in modifying the effect of the mutation between
family members. The clinical presentation of the novel mutation points towards a
malignant (high incidence of sudden death) form of FHC with varying hypertrophy
from mild to severe, in particular, asymmetrical septal hypertrophy. An interesting
finding is the coronary abnormalities encountered during autopsy in patient IV:l6.
Despite marked initial thickening, there were no signs of old or fresh myocardial
infarction. In addition, the localization of the fibrosis was not related to the site of
coronary abnormalities. These findings make coronary disease a less likely cause of
sudden death in this patient. In contrast, the extensive disarray combined with fibrosis
and maybe local subendocardial ischemia could provide an arrhythmic substrate.
Unfortunately, no serial measurements or Hotter monitoring were performed in
affected family members. No cases presented with HCM progressing into DCM.
Up to the present, only few TPMl mutations have been reported, causing either
hypertrophic (FHC) or DCM. Two mutations in exon 5, near the Ca '^-dependent
troponin-T binding domain of the alpha-tropomyosin protein, have been associated
with a transition from severe hypertrophy to DCM (Glul80Val) and with mild LV
hypertrophy but poor prognosis (Glul80Gly) [10,15]. Within the same protein domain,
a mutational hot spot at position Aspl75Asn has been identified in five unrelated
families (four Caucasian, one Japanese) with FHC [9, 10, 12, 13]. The Aspl75Asn
mutation was studied in three families with full penetrance and seemed to be
associated with a favorable prognosis [25]. Unique features of mild cardiac
hypertrophy with a high mortality rate were described for the mutation Val95Ala in
exon 3 [16]. The mutations Glu40Lys and Glu54Lys in exon 2b occurred in an area that
may alter the binding of alpha-tropomyosin to actin and have been associated with
clinical features of DCM [17].
The TPMl gene encodes a rigid rod-shaped protein. This protein is abundantly
expressed in the striated muscle cells and various other tissues and forms a double
helix coiled-coil structure by head-to-tail polymerization. Several isoforms result from
the TPMl gene by alternative splicing, and the adult cardiac isoform is encoded by only
nine of the 14 exons. The protein is located within the thin filament of the sarcomere
where it is associated with actin by twisting around the long axis of the actin filament
as a coiled-coil dimer. It can bind seven consecutive actin monomers and, so,
contributes to the stability of the thin filament [26]. Another thin filament component
troponin T also has a binding site for tropomyosin.
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This binding site is thought to be responsible for positioning the troponin complex,
which is composed of three polypeptides, troponin T, I, and C, into the thin filament.
The troponin-tropomyosin complex is Ca^*-sensitive. By raising the level of free
calcium, the position of the tropomyosin-troponin complex is shifted, and the actin
filaments can interact with the myosin heads of the thick filaments, which are active
in the contracting muscle.
Our findings suggest that differences in clinical presentation may depend on the
location of the amino acid substitution in the TPMl helix. The novel mutation
Glu62Gln is the most 5' proximal missense mutation that has been reported in the
TPMl gene thus far, and which is associated with a malignant form of FHC.
Ala63Val (11.13)
Lys70Thrd3)
Asp175Asn(9.10.1Z13)
Glu62Gln
G/u54Lys( 17)
CIUi80Gly(10)
Clu180Val(15)
Figure 2. This figure has been redrawn according to Michele et al. 2000 [26] and represents
the predicted coiled-coil structure of the alpha-tropomyosin gene (TPMl) alpha helix. The
positions a to g represent the amino acids sequence of the heptad repeat that stretches
along the entire alpha-tropomyosin protein. The view starts from the N-terminus (position
a) of the tropomyosin protein going down the axis of the tropomyosin dimer (position g).
The dotted lines represent the stabilizing interaction of charged amino acids between two
tropomyosin molecules to form the coiled-coil dimer. Mutations associated with familial
hypertrophic cardiomyopathy (bold) or dilated cardiomyopathy (italic) are indicated in the
figure. The mutation Clu62Gln identified in this study is underlined.
The negative-charged polar amino acid is replaced by an uncharged polar residue at a
position on the outer surface of the coiled-coil [26]. In the coiled-coil filament of the
tropomyosin molecule, the positions of the amino acids are arranged in an order of
highly conserved heptad repeats along the entire length of the TPMl protein [26, 27].
All mutations that have been reported previously and associated with FHC have
occurred at the g-, d-, or e-position of the heptad repeat (Figure 2). The altered amino
acids, which have been correlated with DCM, only occurred at the e-position. Two of
the DCM-associated mutations change the acidic amino acid residue into a basic
residue. Olson et al. [17] suggested that these mutations create a locally increased
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positive charge in the negatively charged surface of tropomyosin, changing the
electrostatic interactions between actin and tropomyosin filaments. This novel
Glu62Cln mutation is the first reported amino acid substitution at the f-position
within the coiled-coil that changes the polarity of the amino acid and which is
associated with hypertrophy. Further, it should be noticed that the amino acid variants
at the positions 62, 63, and 70 are located within a protein domain with a function yet
unidentified.
Reports of novel mutations within the TPMl gene may help to unravel and define
functionally important domains that are crucial for specific interaction with other
(sarcomeric) proteins. Preliminary data of mutated amino acids in specific regions
might indicate in which way the cardiomyopathy might develop, hypertrophy or
dilation of the cardiac ventricles. By identifying the important domains for either
disorder, better diagnostic and prognostic tools become available. Furthermore, the
knowledge will help to elucidate the complex architecture of the sarcomere.
Supported, in part, by the Interuniversity Cardiology Institute the Netherlands (ICIN)
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Although LQTS and HCM are both clinically and genetically different diseases, they
have in common that carriers of the gene defect can die suddenly from fatal cardiac
arrhythmias. Both disorders are genetically heterogeneous and finding the genetic
defect, explaining the pathology and providing prognostic information to individual
asymptomatic gene carriers is still a major challenge.
DNA-diagnostics LQTS and HCM
The route from the patient to the identification of the gene defect involved can be
based on several criteria as indicated in the diagnostic schemes (Figure 1 & 2). The
choice of the first candidate gene is often determined by the genotype-phenotype
correlation. For LQTS, specific abnormalities on ECG, the trigger of cardiac events, the
frequency of the mutations found in the LQTS genes or linkage studies in families can
guide to the gene involved. For HCM, this is less obvious and the (biased) frequency of
mutations in sarcomeric genes is often the only parameter. A phenomenon like sudden
cardiac death (SCD) for example is not completely gene specific. Furthermore, genetic
linkage studies are often hampered by the lack of living patients.
Genetic screening protocol in LQTS and HCM
Since mutation screening was initiated, it soon became obvious that both LQTS
families and HCM families, have a "private" mutation, which means that most families
have a unique family-specific mutation. This implies that for each "newly diagnosed
LQTS or HCM family", all candidate genes have to be screened to identify the disease
causing gene defect. Yet, a number of unrelated families have the same mutation since
mutational "hot spots" do exist [ l - 4]. These hot spots are CpC dinucleotides, in which
the C nucleotide after methylation can deaminate and change into a T nucleotide. In
rare cases even a founder mutation has been identified, which means that a large
number of (related) families must have had a common ancestor who has been
responsible for the transmission of a specific mutation with reduced penetrance [5, 6].
Because of this clinical complexity and genetic heterogeneity, it is not trivial to fulfill
the diagnostic requests. A common strategy starts with amplification of the exons of
the gene, most likely involved, followed by a pre-screening method and, subsequently,
sequence analysis. Initially single strand conformation polymorphism (SSCP) analysis
was used as a pre-screening method However, mutations may be missed as the
estimated sensitivity of SSCP analysis is 70-80% [7]. To increase sensitivity, Denaturing
High Performance Liquid Chromatography (DHPLC) analysis has been applied, which
has a claimed sensitivity of almost 100% [8]. This prescreening technique was
successfully applied for LQTS index patients [9, chapter 4]. To date, the DHPLC
technique has also been used successfully in the field of cardiovascular diseases to
screen the TNNT2 gene, the PRKAG2 gene (unpublished results) and the entire
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mitochondrial DNA [10]. Soon, DHPLC analysis will also be developed for the screening
of all other HCM candidate genes in an efficient way. In LQTS and HCM families,
candidate genes can be excluded by marker analysis. However, in HCM and often LQTS,
families are generally not large enough to positively identify a genetic locus. This is less
problematic for the LQTS families as only 3 genes are predominantly involved, whereas
more than 11 genes may be involved in HCM.
Efficacy and efficiency of the genetic screening effort
Long QT syndrome
In many prescreening methods, like DHPLC, the identification of a 'disease causing'
mutation is based on PCR amplification and heteroduplex analysis (of the wild type
and the mutated DNA). With respect to this approach, a number of aspects are of
importance. The DHPLC method is PCR based and therefore, large deletions
chromosomal rearrangements can remain undetected. Conventional Southern blot
analysis or quantitative PCR approaches should be pursued in addition to the DHPLC
screening if mutation detection fails. Further, in case of homozygous mutations, the
amplified DNA fragments cannot form heteroduplexes and these mutations may be
missed although, in some cases a mobility shift of mutated DNA-homoduplexes can be
observed. As LQTS is a dominant disorder, this is not a major problem as heterozygosity
is the rule. However, double mutations (homozygous and compound heterozygous) do
rarely exist and have been reported in some severe cases of LQTS [ l l ] . In the past, a
homozygous mutation in the HERG gene (LQT2) gene has been reported to cause intra-
uterine arrhythmia and, in the SCN5A gene (LQT3) a homozygous mutation caused a
2:1 AV block in a 5-year-old boy [12,13]. Homozygous mutations in LQT2 and LQT3 are
rare and are, like homozygous mutations in LQTl (involved in JLNS), associated with
severe ventricular arrhythmias [5, 6]. Additionally, finding a mutation in a certain
gene, the order of the exons that have to be screened can also be time-saving. Because
of the high incidence of mutations that have been reported in exons which encode the
pore and the transmembrane spanning domains (S1-S6), genetic analysis of the
potassium channels KCNOl and KCNH2 is preferentially initiated in these exons (LQTS
database: http://pc4.fsm.it:8l/cardmoc/). The mutation detection in the SCN5A gene
is preferentially initiated at the 3' end of this gene (starting from exon 28 to exon l) as
a large number of mutations has been identified within the final two domains of the
SCNSAgene.
In our study 87 LQTS index patients were analyzed, originating from 34 families with
more than one affected family member and 43 single cases. All families, except two,
originated from the Caucasian population. The two exceptions were Asian families. In
addition, 10 individual cases with an acquired form of LOTS were tested as well. In
families where linkage could be established, only the gene of interest was analyzed.
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If linkage analysis was not informative and even a single gene could not be excluded,
index patients from these families were analyzed for the genes involved in LQTl and
LQT2 as well as the genes involved in LQT5 and LOT6. Screening of the potassium
channel encoding genes was performed to exclude involvement of compound
heterozygosity in some severe cases of LOTS. The KCNJ2 gene, involved in Andersen
syndrome and defined as LQT7 subtype, was not included in this study as no patients
presented clinical features of facial abnormalities or clinodactily [14]. Involvement of
the KCNJ2 gene has already been excluded in a large group of patients with an LOTS
phenotype (Splawski 2001, personal communication).
Up to now the clinical diagnosis of LOTS was confirmed by the identification of a
mutation in 91% of the familial cases (Table l ; 31/34 families with >l patient). The
almost equal distribution of mutations between LQTl and LQT2 (45% and 51%) is in
line with frequencies reported in international studies (41% and 45%) [15]. In only 3
families no mutation was identified. In 2 familial cases an involvement of one of the
known LQTS genes was unlikely by linkage analysis indicating that an as yet unknown
gene might be involved and one small family did not fulfill the Schwartz criteria
(borderline QTc).
In the group of 43 single cases, 7 mutations (7/43 = 16%) were identified but, none in
the 10 cases with an acquired form of LQTS. With respect to the genetic results in the
acquired form of LQTS, only a low frequency (12%) of mutations has been reported in a
large group of aLQTS patients [16]. Two identical KCNH2 mutations identified within
the single cases, turned out to have a familial history and were counted as familial
case. The SCN5A mutation (QTc 657 msec) was identified in a neonate with a ventricle
septum defect (VSD) and a 2:1 atrioventricular (AV) block. The mother and
grandmother were both carrier of the mutation but did not show any symptoms and
had marginally prolonged QT values. Biophysical characterization of the SCN5A
mutation revealed a sustained (non-inactivating) current as well as an increase in Na*
channel current. Both mechanisms are expected to delay the ventricular repolarization
[17]. Four single cases with LQTS turned out to carry a very rare silent mutation of
which the pathogenicity could not be established unequivocally. In our group, the
number SCN5A mutations is low which can be expected since involvement of the LQT3
subtype is reported less frequently. Next to the identification of the pathogenic
mutation in the index patients, follow-up investigations were performed in each
family, leading to an additional number of 485 genotyped individuals, 227 of these
individuals (46.8%) were carriers of the familial gene defect. The mutation detection
screening also provided additional information with respect to "de novo" mutations.
Within the group tested, we were able to identify a "de novo" mutation or the origin of
the mutation in the family in 3 (8%) out of the 29 genetically defined LQTS families.
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Two "de novo" mutations were identified in the single cases as both parents did not
carry the mutation. In each case of "de novo" mutations, non-paternity was excluded
by using a set of autosomal polymorphic markers. It is obvious that, in a disorder like
LQT syndrome, which seriously affects life expectancy, mutations will not be
transmitted neutrally and disappear from the population. The fact that this disorder
still exists means that, due to a mutation rate in the human genome of 10 \ new
mutations will constantly emerge and when affecting germ cells, they may result in
familial diseases (Vlietinck, personal communication). It also indicates that most
families have their own "private" mutation and that a patient, without family history
of syncope or other clinical features of LQTS, may be the first in line.
Table 1. Overview of the genotyped LQTS population
Total number of index patients that were analyzed = 87
„ , „ „ , ... ... „ ... In 31 families the mutation was identified
34 LQTS families with > l patient, positive
family anamnesis, according to the Schwartz
selection criteria |
1SCN5A
In 7 single cases a mutation was identified
43 LQTS single cases with unknown or less
obvious family anamnesis
3 KCNH2
- 1SCN5A '
10 acquired LQTS no mutations were identified
•Wehrensetal. [17]
Hypertrophie Cardiomyopathy
Because of the large number of candidate genes involved in HCM and the limitations
in selective clinical, gene-specific clues, we prefer to perform linkage analysis to
identify and/or exclude candidate loci. An exception is the combined presence of HCM
and Wolff-Parkinson-White syndrome (WPW) in a family with HCM and conduction
defects, which directs to the gene, encoding the gamma2-subunit of the AMP-
activated protein kinase (PRKAC2). In such a family a missense mutation was identified
in the PRKAG2 gene. Until now, linkage analysis has only been successful in one family
to map the genetic defect unambiguously. In this large family, marker and sequence
analysis resulted in the identification of a novel mutation in the TPMl gene [18,
chapter 8-2). The majority of the HCM families were not suitable for linkage analysis,
because of lack of living patients due to a high incidence of SCD or, of a limited number
of participating healthy individuals who are essential for establishing a risk-haplotype.
Therefore, the selection of genes to be tested by SSCP or DHPLC analysis was based on
151
GENERAL DISCUSSION
the frequency of mutations reported, and presumed malignancy as indicated by the
occurrence of SCD. In 165 symptomatic index patients, diagnosed with HCM, a
selected number of six exons, encoding part of the head domain of the ß-myosin heavy
chain (MYH7) were analyzed by SSCP analysis (chapter 8-l). Within these 6 exons,
about 52% of all MYH7 mutations, and most of the malignant mutations have been
reported. In a selected number of families (with a high risk for sudden death) the
systematic screening was continued by DHPLC analysis of the TNNT2 gene and the
TPMl gene. Especially mutations in the TNNT2 gene are known for a limited or absent
hypertrophy and a high frequency of SCD. In addition, all index cases have been
analyzed exclusively for exon 25 of the MyBPC3 gene by DHPLC analysis and a
mutation specific amplification, because of the presence of a Dutch (founder)
mutation which has been identified recently [19].
Until now, blood was collected from 183 patients. The vast majority had a family
history of hypertrophic cardiomyopathy or related cardiac problems. In many cases,
blood of affected relatives was available as well although, in general insufficient for
linkage studies. These patients were tested for mutations as described above, although
not all analyses were performed for the entire group. In 27% (50/183) of the patients a
mutation could be identified (13 MYH7, 5 TNNT2, 2 TPMl (chapter 8-2), 29 MyBPC3
and 1 PRKAG2. Mainly due to the founder mutation in the MyBPC3 gene, this is a high
score, given the limited protocol used. Leaving out the founder mutation, the
percentage of mutations identified is still substantial (19%) and higher than reported
in literature with slightly different protocols. As compound heterozygous and
homozygous mutations have been reported in the HCM population [20-23], we tested
if compound heterozygosity occurred of the MyBPC3 Dutch founder mutation, and
either one of the mutations previously identified in the MYH7, TNNT2 or TPMl genes,
but this was not the case.
Criteria for genetic pathogenicity
The criteria for genetic pathogenicity are according to international recommendations
and have been applied to the mutations which have been identified in the LQTS and
the HCM population in this thesis [24-26]. Regarding the speed of new developments
in genetic technology, the identification of genetic variants or mutations will not be a
major problem in the near future. However, the interpretation of diagnostic value of
the variations will become more challenging. For example the nucleotide substitutions
which lead to an altered amino acid are not necessarily pathogenic and, on the other
hand, apparently silent mutations might in fact be pathogenic. Whether a mutation
will be pathogenic or not is often hard to predict.
Conclusions regarding the pathogenicity of the mutations which have been described in
this thesis were based on:
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1) exclusion of the mutation within a representative control panel of at least 100
chromosomes;
2) co-segregation of the mutation in the family with the disease;
3) conservation of the involved amino acid within the protein domain in several species
4) the nature of the mutation (missense, nonsense, deletion, insertions etc.)
5) the localization of the mutation within specific functional protein domain
Sequences have to be compared with the tissue specific human reference sequence or
tissue specific isoforms which can be obtained from the Genome Databases and
National Center for Biotechnology Information (GDB and NCBI) available on the
internet. The comparison of reference sequences has become easier due to the Human
Genome Project and the increasing number of genome databases of various species
which facilitates the investigation whether protein domains are highly conserved
during evolution.
Besides pathogenic mutations, the genetic screening program has revealed a number
of non coding SNPs, unclassified variants (UV) and amino acid polymorphisms (cSNP)
that have been identified in either intronic or exonic sequences. The question is,
whether these variants are completely neutral. One example is the Kozak sequence
variant (ATG-5, o t ) in the KCNOl gene that has been identified in 3 index patients
with LOTS (Chapter 3). This variant resides in the regulatory sequence and may affect
translation and transcription processes, as has been demonstrated in an in-vitro
transcription/translation system of the glycoprotein(GP)lb-alpha gene. The presence of
this specific Kozak variant exhibited an increased expression and more efficient
translation of the mRNA [27, 28]. Similar findings of pathogenic UVs have been
reported within the BRCAl and PKU genes, where silent mutations or even missense
mutations resulted in alternative RNA splicing events or exon skipping [29, 30]. These
UVs had affected specific short sequences that are present in exons and, either
enhance or silence pre-mRNA splicing. Such specific short oligonucleotide sequences
are termed exonic splicing enhancers (ESEs) or exonic splicing silencers (ESSs) and play
important roles in constitutive and alternative splicing [31, 32]. The alteration of
correct splicing patterns by disruption of an exonic splicing enhancer may be a more
frequent mechanism than previously thought. The aforementioned examples indicate
that one should be careful in classifying these variants as polymorphisms as they may
finally have a pathogenic effect. This implicates that the pathogenicity of mutations
should be demonstrated in functional studies or in a suitable animal model to prove
the disease causing effect of the mutation. Functional assays of novel mutations are
necessary as they may provide novel insights and mechanisms, explaining the
pathophysiology of this dangerous disease. However, within a diagnostic setting this is
often difficult to realize.
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Cenotype-phenotype correlation
The Long QT syndrome
One remarkable and important outcome of systematic genetic screening in the LOTS
population is the possibility to distinguish genotype specific sub-phenotypes. Clinical
evaluation of the genetic defined carriers has resulted in a gene specific trigger for
cardiac events [33, 34, 15]- To date physicians can accelerate genetic analysis by highly
accurate prediction (efficacy is 75%) of the LOT gene involved which is based on the
combined genotype-phenotype relationship (trigger and ECC phenotype)[35, 36]. In
LQTS, missense mutations are predominantly involved (Table 4, chapter 2). Missense
mutations normally result in stable mutated proteins which act by a dominant
negative effect on the functional molecular structure as incorporated "poison proteins"
(poison peptide hypothesis)[37]. However, frame shift mutations, resulting in
premature stop codons, are less frequently involved in LQTS. It is generally accepted
that truncated proteins result in unstable proteins or may lack functional domains and
consequently fail to be incorporated into the ion channel complex [38]. Truncating
mutations also may cause haploinsufficiency by nonsense mediated mRNA decay
(NMD) or. if the mRNA is translated, truncated proteins can be quickly degraded by
proteases (null-allele hypothesis) [39]. In LQTS, one mechanism for haploinsufficiency
has been proposed to be due to ineffective post-translational modifications causing
trafficking defects. However, the aforementioned hypotheses are often based on
predictions without experimental evidence. Recently, functional testing of a novel
missense mutation in the Per-Arnt-Sim (PAS) domain of KCNH2 has demonstrated that
obviously, besides C-terminal mutations, also an intracellular N-terminal mutation
may cause LQTS by deficient trafficking [40].
In young children, seizures may not always be recognized as a cardiac disease and the
QT prolongation may go unrecognized on ECC [41]. During this study we repeatedly
noticed that genetic analysis was requested in families with unexplained fainting or
epilepsy as initial diagnosis. In these families the diagnosis had been mainly assumed
in children carrying a mutation in the KCNH2 (LQT2) gene. This corroborates with the
fact that two genes, KCNQ2 and KCNQ3, have been associated in Benign Familial
Neonatal Epilepsy (BFNE). Both genes are expressed in the brain and belong to the
same potassium channel family as the KCNQl gene and associated with LQTl [42].
Hypertrophie Cardiomyopathy
In HCM a genotype-phenotype correlation is less obvious, except for HCM in relation to
Wolff Parkinson White syndrome (WPW). In order to correlate a more specific
genotype-phenotype relationship, additional genetic analysis of large populations of
HCM patients will be necessary.
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In the ß-myosin heavy chain gene (MYH7) many missense mutations have been
associated with a malignant phenotype and a high incidence of SCD at a young age
(age <40y).
Conflicting results have been reported for the Val6O6Met mutation in the MYH7 gene
(chapter 8-1, this thesis) [43-45]. In case of a troponin-T (TNNT2) mutation the risk for
SCD is earlier in lifetime (age <20y) while patients present less evident hypertrophy,
making the clinical diagnosis a difficult issue. This early SCD is in line with our findings
which is based on two individuals from two TNNT2 families, who died before the age
of 15, and one individual who experienced an aborted SCD at the age of fifteen.
On the other hand, mutations in the myosin binding protein C (MyBPC3) have been
associated with mild hypertrophy in young patients and a late onset of symptoms and
good prognosis before the fifth decade of live [46, 47]. The incidence of SCD in families
with a MyBPC3 mutation is less significant and it is still unknown and speculative what
causes the late onset and the relative benign phenotype. Within the Dutch population
of HCM index patients, one mutation is particularly prominent. The mutation
introduces an insertion of a guanine at position 2373, codon 792 (2373insC) in exon 25
of the MyBPC3 gene [48]. The mutation was present in 18% of the HCM population
tested in our screening effort. The carriers mainly originated from the western part of
the Netherlands. Analysis of cSNPs indicated that all carriers shared an identical
haplotype which strongly supported the idea that this is a founder mutation and
preliminary results have indicated that this specific mutation may have arisen
originally in the western part of the Netherhnds about 400-500 years ago [19]. Despite
the increasing number of genetic studies and genotype-phenotype associations, useful
information in HCM is limited. Most information is available for genes that were
initially discovered and are now routinely screened. Recently, the human CRP3 gene
was be added to the list of HCM causing genes [49]- The CRP3 gene encodes a muscle
LIM protein (MLP) which is located within the Z disk of the sarcomere. Initially, this
gene was associated with dilated cardiomyopathy (DCM) in a murine MLP-gene
knockout model [50] and recently, it has been demonstrated that a specific mutation
was associated with DCM in humans as well, demonstrating that mutations within the
same gene may be involved in two distinct phenotypes (HCM or DCM) [51].
Incomplete penetrance
The failure of a disorder to become manifest has also been recognized in LQTS and
HCM. Both disorders may present with reduced penetrance and show variable
expression. Factors that may influence the phenotype are age (late-onset) and gender.
Mutations in the various genes and even mutations identified in an identical gene
demonstrate a variable expression which also varied between family members with an
identical mutation [52].
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The incidence of LQTS is estimated at 1:15,000 in live births but by taking into account
the low penetrance in some LOTS families, the mutation frequency might be even
higher as these asymptomatic individuals may remain unrecognized during life time.
Penetrance as low as 25% has been reported by Priori et al.[53]. Low penetrance
implies that individuals with a genetic defect do not necessarily present a marked
prolonged QTc interval or have clinical symptoms at all which may also complicate
effective genetic linkage analysis. In literature it has been reported that among LOTS
gene carriers 6% had a normal QT interval which may indicate that additional genetic
components or environmental factors are involved in the clinical presentation of a
mutation [54]. In case of low penetrance, LOTS indication is less sure and involvement
of a known LQTS gene can only be reasonably excluded by screening all candidate
genes. As an identical mutation may result in a phenotype, varying from mild to severe
clinical features, other modifying factors (genes) must be involved and it has become
an important issue to identify these modifier genes which could explain this clinical
heterogeneity [5]. Founder mutations in LQTS, which are normally identified within
"isolated" genetic populations, as for instance the KvLQT-Fin mutation, could provide
an excellent group for studying the impact of these modifier genes in genotyped-
phenotype association study. Another explanation for low penetrance was based on
the "nature of the mutation". One example is a C-terminal mutation in the KCNQl
gene that caused a form fruste LOTS with very mild clinical symptoms and low
penetrance [55]. In LQTS truncating mutations and also missense mutations have been
reported to cause haploinsuficiency by misprocessing of the (misfolded) protein from
the nucleus into the membrane and are believed to be more benign in their expression
[56]. Misprocessing or trafficking deficiency may be caused by several cellular
processes as (de)phosphorylation defects, post-translational modifications, disturbed
protein-assembly, targeting and anchoring defects to the specific subcellular domains.
As in LQTS families, variable expression and reduced penetrance has also been
reported in HCM families and the spectrum of the disease is large (NYHA class I-IV). An
example of variable expression and reduced penetrance is demonstrated in Figure 1,
(chapter 8-2). On the other hand, high penetrance and a late disease onset has been
reported in individuals with a MyBPC3 mutation where the disease onset can even be
expected until the fifth decade of life [57-59].
Functional testing and pathogenesis
Despite the enormous number of mutations identified in LQTS and HCM, the exact
pathogenesis is still far from clear. The significance and contribution of many DNA
variations remains to be investigated. Functional testing will be essential to support
the initial genetically defined pathogenic mutation and may gain insight into the
complex pathophysiology of these two malignant diseases.
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In LQTS functional testing is usually performed by testing the electrophysiological
properties of wild type and/or mutated ion channels in heterologous expression
systems often in combination with con-focal microscopy to indicate trafficking
deficiency. Functional testing of ion channels has already provided valuable
information on the effect of various mutations with respect to the dominant negative
effect, loss or gain of function, altered (in)activation and gating behavior, as well as
abnormal trafficking [60-63]. As the functional properties of the mutation observed in
vitro may provide information regarding the pathogenicity of the mutation in vivo,
functional tests are being performed in laboratories, specialized in electrophysiology
(our collaboration with the Department of Physiology at the University of Antwerpen;
Geelen et al. in preparation; Paulussen et al. in preparation)[64, 65].
Functional studies of mutated proteins have also demonstrated that the effect of the
auxiliary subunits may be diverse [66]. Sodium ß-subunits have been demonstrated to
be multifunctional as they both modulate channel gating and regulate the level of
channel expression at the plasma membrane. More recently, they have been shown to
function as cell adhesion molecules in terms of interaction with the extracellular
matrix, regulation of cell migration, cellular aggregation, and interaction with the
cytoskeleton [67]. At present also protein-protein association studies of the membrane
bound ion channel complex have been initiated to provide novel insights in channel
function with respect to the requirement of a macromolecular signaling complex. [68].
The identification of such a KCNQl-KCNEl macromolecular complex has already
provided a mechanism for sympathetic nervous system (SNS) modulation of the
cardiac action potential duration through I*,current.
Functional testing of HCM mutations includes 'in vitro' and 'in vivo' experiments as
well. For these purposes transgenic mice and rabbits, zebrafish, chicken embryos and
other animal (knock-out) models are currently being used to get insight into the
mechanism of hypertrophy [69, 70]. Because human tissue is largely unavailable, the
unique tool of the murine myosin heavy chain transgenic model, has also enabled
biophysical studies on the contractility of a sarcomeric mutation. Hopefully in the near
future, also advanced molecular biological techniques like gene expression profiling
and DNA micro-array analysis of human cardiac tissue will become available to reveal
pathogenic pathways in HCM and LOTS at a level which can not be reached by classical
studies alone.
Gene specific therapy
It has become clear that the unifying name of LQTS actually represents a variety of
different diseases (LQTi-6) caused by mutations in ion channels that all lead to the
same end result which is, prolonged ventricular repolarization. In LQTS medical
treatment is indicated as the mortality rate of untreated patients with LQTS is in the
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range of 1-2% per year and increases to 50% within 10-years [71, 72]. Recent data also
favor treatment of asymptomatic patients if younger than 40-years of age at the time
of diagnosis [72]. From the International LOTS Registry data indicated that in LOTl
patients, symptoms will become manifest at a younger age than in LQT2 and LQT3
carriers (age LQTl< LQT2< L0T3) [33]. This shows that in LOTS the initiation of medical
treatment likely depends on the gene involved. To date genetic analysis has allowed
medical treatment, based on the genotype of the individual at risk
The risk for cardiac arrhythmias is mainly provoked by physical stress, except for LQT3
patients, and therefore intense stress should be avoided. Stress induced stimulation of
the ß-adrenergic receptors increases the heart rate and will influence the 1^ current. In
patients who carry a KCNQl gene defect, the altered or diminished 1^ current provides
a pathogenic substrate by an abnormal ventricular repolarization. The delayed
repolarization increases the risk for Torsade de Pointes. Blockade of the ß-adrenergic
receptors with Class III anti-arrhythmic drugs decreases the heart rate, shortens the QT
prolongation and neutralizes the risk factor. This mechanism probably explains why
LQTl patients have demonstrated a good respond to ß-blockade therapy. Recently, a
different response to ß-blockade between LOT and LQT2 patients has been reported,
providing a need for further clinical investigations on the effect of medical treatment
in genotyped individuals [73, 74]. In contrary, patients with an SCN5A (LQT3) mutation
may benefit from medical treatment with a sodium channel blocker (Class IB anti-
arrhythmics). Since SCN5A gene defect carriers often present with slow heart rates,
further decrease of the heart rate by ß-blockade therapy could increase the risk for
arrhythmia. Therefore in LQT3 patients additional cardiac pacing is warranted by an
implantable cardioverter defibrillator (ICD). Recently, a gender specific response to
medical treatment has been reported which has been observed in a group of
genetically defined carriers [74, chapter 6]. In the Netherlands the general policy is to
treat every gene carrier (Marcelis C, personal communication).
Thus far genetic analysis in HCM has been used to exclude individuals for being at risk
and to advice gene carriers risk-avoiding behavior. The therapy in HCM is more
aggressive and active recruitment is mainly initiated to protect carriers against life
threatening arrhythmias by ICD implantation (chapter 7). Whether pharmacological
treatment is an option remains to be established. Hereto, longitudinal investigations
and serial non invasive measurements of the carriers (preferentially starting at a
young age) should be initiated to follow the progression of the hypertrophy and to
study the effect of long-term drug administration.
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Ethical aspects of genetic testing in LQTS and HCM
To date genetic analysis in families with LQTS and HCM has provided a diagnostic tool
for identifying individuals at risk. However, adequate risk stratification is often
complicated by low disease penetrance and the large clinical spectrum of both
diseases (LQTS and HCM) and it might be questionable whether genetic testing should
be promoted in all cases. If a genetic test is considered, genetic counseling of the
patient is necessary. In inherited diseases genetic testing not only has consequences
for the index patient but also for the family and can lead to a variety of psychological
and social complications [75, 76). In children, pre-symptomatic genetic testing can be
performed when the result of the test has clinical implications in childhood. For LQTS
families the answer is obvious and clinically affected individuals should be genotyped
because this may have implications for the therapy and management [77, 51].
Simultaneously, genetic identification is justified as these individuals may be protected
against various QT prolonging drugs (chapter 2). In LQTS, in particular young children,
are at risk for lethal arrhythmias and early diagnosis and treatment of yet
asymptomatic children can be life saving.
The question whether genetic testing is justified in case of familial HCM, is difficult to
answer as preventive measures have not been validated. The outcome of the genetic
testing however, justifies intensive follow-up. Subsequently, dangerous arrhythmias
may be prevented by the change of life style [78, 79] Avoiding vigorous and
competitive sports may result in a longer live span and a higher quality of life. For this
reason we believe that genetic testing is justified. Of course testing must be supported
by a multidisciplinary team trained in complex cardiovascular diseases and genetic
counseling [80].
Future aspects
Despite the intensive screening of all LQTS candidate genes, no genetic abnormalities
were detected in a few LOTS families suggesting that additional genes may contribute
to the wide spectrum of the LOTS phenotype. Besides disease causing mutations, the
identification of genetic modifier genes which might contribute to the phenotype as
genetic risk factors will become challenging in the near future in both, LQTS and HCM.
The increasing demand of genotype-phenotype correlation strongly supports the
implementation of an International HCM registry similar to the International LQTS
registry. Through combination of patient information world wide, enormous sets of
data could be included which might lead to a more profound knowledge of the
genotype-phenotype relationship.
The future of medicine will have a strong genetic component not only in the field of
familial disease but also in the field of common diseases. Medicine will evolve from
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treating symptoms and disease to prevention. In order to reach this level, the genetic
make-up of an individual as a whole has to be determined. This can be done l ) by large
scale genotyping to study the constitution of and variants within genes or 2) at the
genomic level by complete gene expression microarray analysis to study the activity of
genes or 3) at the proteomics level. State-of-the-art bioinformatics and statistics have
to be applied to deduce biological and medical information from rapidly accumulating,
huge data-sets. Expectations of these technologies are high and this will lead first to
improved classification of diseases by identifying specific gene expression profiles or
genotypes for specific subgroups (predictive genetic signatures). Subgroups may not
only differ in diagnosis, but also in prognosis or therapy, allowing adjustment of
patient management at the individual level. Finally, detailed insight in the
pathogenicity can be obtained by following gene expression patterns in relation to
disease manifestations in time. Successes have already been reported in this field,
predominantly in the classification of tumors [8l]. With respect to LQT and HCM
genomics can be expected to subclassify these disorders with respect to the gene
involved and also to explain eventually reduced penetrance and individual differences
in manifestation of the disease. A mutation is not a stand-alone feature, but is
integrated in a biologically active organism. This also implies a shortcoming of current
functional tests, which isolate the defect from the genetic background. Apart from
disease associated variations in gene expression and genotypes, it can also be
expected that at first sight less related processes may be involved and that also more
general differences like metabolic activity, will play a role in developing the
appropriate therapy. The true challenge of the future will be to transform all genetic
and genomic data obtained in patient cohorts to treat patients and not diseases
anymore. As many aspects are not known at this point this has to be a careful step by
step process, despite all -omics hypes of the moment.
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Figure 1. Flow chart for the Long QT syndrome
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Figure 2. Flow chart for Familial Hypertrophie Cardiomyopathy
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SUMMARY
Summary
In the last decade Genetics has become of major importance in medicine and medical
sciences. In Cardiology, the term Cardiogenetics has been introduced to indicate this
new field of health care in cardiovascular disease. The genetics revolution has been
initiated by the rapid advance in knowledge on genomes of humans and all kind of
model organisms. This has been corroborated by a rapid progress in molecular
biological and genomics technology, which has among others led to the identification
of genes involved in congenital heart diseases and primairy cardiac arrhythmias, which
is the topic of this thesis. Alterations (mutations) in these genes are a cause of sudden
death at a young age. Many investigations have been performed by us and others in
particular in congenital long QT syndrome and the hereditary disease associated with
an enlarged cardiac left chamber (hypertrophic cardiomyopathy). Especially in LQTS
the presence of a disease causing (pathogenic) mutation and the clinical presentation
within the family, has provided important breakthroughs in understanding the origin
of this inherited disease, the clinical features and the medical treatment.
The first part of this thesis covers the Long QT syndrome (LQTS). Chapter 2 reviews
clinical, genetic, functional aspects and medical treatment of LQTS and the ion channel
genes and proteins involved. The name of the disorder is derived from a characteristic
lengthening of the QT time interval. In LQTS the electric instability is caused by an
abnormal cardiac repolarization thereby creating a substrate for (fatal) cardiac
arrhythmia named Torsade de Pointes (TdP). Due to these ventricular arrhythmias,
carriers of the genetic defect may repeatedly suffer from syncope and seizures and
may in some instances lead to sudden cardiac death. LQTS is a predominantly
autosomal dominant disorder and at this point we distinguish 7 subtypes, involving
cardiac potassium channel genes (KCNQl/KvLQTl-LQTl, KCNH2/HERG-LQT2) and their
co-factors (KCNE1-LQT5, KCNE12-LQT6), a cardiac sodium channel gene (SCN5A-LQT3)
and an ankyrin gene (AnkB-LQT4). Mutations in these genes can alter protein function
in a dominant negative way and cause malfunctioning ion channels. As a result a
critical situation is created that may cause an electric instability in the heart. In
addition to the genetic form an acquired or medication induced form of LQTS exists as well.
Chapter 3 describes the results of a partial genetic screening protocol to unravel the
genetic causes of LQTs in the Dutch LQTS population. The KCNQl and HERG (KCNH2)
genes were tested by Single Stranded Conformation Polymorphism (SSCP) analysis,
followed by sequence analysis of shifted fragments. A disease causing mutation was
identified in 58% of the Dutch families and a large number of individuals at risk were
genotyped. This screening protocol was extended (Chapter 4) to all potassium channel
genes and a new more sensitive, faster and automated approach was applied by
incorporating DHPLC analysis.
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Subsequently, genetic screening was continued and extended by analyzing the entire
encoding region of the genes. With this protocol 91% of the familial cases of LOTS and
in 16% of the single cases the disease causing mutation could be clarified and follow-
up investigations in families could be offered. We conclude that our approach is highly
efficient and rapid in detecting almost all familial LOTS mutations.
Chapter 5 deals with genotype-phenotype correlations. LOTS patients have an
increased risk for ventricular arrhythmias and these events are triggered by physical
stress, swimming or diving, a loud noise or sleep. Our investigations showed that these
triggers were highly gene-specific. The highest correlation was shown for
KCNH2/HERG mutations and a load noise or acoustic trigger (5-1), but also a high
association between subtype LQTl and cold water (swimming, diving) was observed,
while other triggers were present in both subtypes (5-2). The correlation of the trigger
and the various subtypes in LQTS has been extremely valuable in selecting the genes
most likely involved for screening and has increased the speed, with which the genetic
causes can be detected, considerably. This is of major importance in a fatal, but
treatable disorder like LQTS.
In Chapter 6 the initial results of ß-blockade therapy in a group of genetically defined
carriers of subtype LQTl and LQT2 are presented. Our results indicate a significant
decrease in clinical symptoms in the group of LQTl patients (KCNOl). Within the group
of LQT2 patients the decrease in complaints, as a result of the ß-blockade therapy, was
less significant. A gender difference was also noticed with respect to the response to
medical treatment in carriers of a LQTl mutation. This phenomenon was not observed
in the carriers with a LQT2 (KCNH2) mutation.
The second part of this thesis deals with the congenital form or primary form of
hypertrophic cardiomyopathy (HCM). Chapter 7 discusses the clinical and genetic
characteristics of HCM and the genotype-phenotype correlation and treatment.
Congenital or familial HCM (FHC) is inherited as an autosomal dominant trait and is
both genetically and clinically extremely heterogeneous. At present, mutations in
twelve genes have been reported to be associated with the disease. Ten out of these
twelve genes encode for sarcomeric proteins which are involved in generating the
force and the contractility of the cardiac muscle. Alterations in these proteins may
finally result in a decreased muscle contractility and it has been proposed that a
mechanism is initiated to compensate the loss of force generating power which
promotes the local hypertrophy in the left chamber and in particular the septum. Until
now therapeutic intervention is limited and prophylactic therapy is mainly used to
minimize the progression of the hypertrophy and to prevent life threatening
arrhythmias. This can be achieved by changing the life-style and by implementing
medical therapy or an implantable defibrillator (ICD) to prevent arrhythmias.
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Additionally, in case of a conduction block the implantation of a pacemaker might be
considered. In addition to the inherited form many other, far more common causes of
cardiac hypertrophy like hypertension, coronary vascular diseases or intensive sports
(sports heart), exist.
Based on the frequency of mutations that had been reported previously genetic
screening has been initiated in the ß-myosin-heavy-chain gene (MYH7) in a number of
60 index patients all diagnosed for familial HCM and with a high risk for sudden death
(Chapter 8). The result of the genetic analysis can be valuable in identifying gene
carriers in particular in those families that are associated with a malignant form of
HCM. The protocol was based on SSCP analysis, followed by sequence analysis. The
added value of large families, in which linkage analysis can be performed is shown as
well (8-2). Linkage analysis pointed at the involvement of the a-tropomyosin (TPMl)
gene in a single large family, which was confirmed by the presence of a pathogenic
mutation in the TPMl gene. The power and the success rate of linkage analysis largely
depends on the number of individuals, affected and non-affected members, available.
In Chapter 9 an update will be presented of our own actual data and the data from
literature, together with prospective of the future. Genetic screening in families with
LOTS has been highly successful and has resulted in the identification of a causative
genetic defect in a large number of families and in further classification of the various
subtypes. Based on genotype-phenotype correlations a straightforward gene-specific
screening protocol has been developed. This offers the possibility of early identification
and pre-symptomatic diagnostics and if possible lifesaving gene-specific treatment.
Additionally, non carriers can be reassured and dismissed of further medical
treatment. In HCM, however, despite extensive research an accurate genotype-
phenotype correlation is only in rare cases possible. This complicates the selection of
candidate gene for diagnostic genetic screening. In the Dutch HCM population the
genetic screening effort now has resulted in identifying the disease causing mutation
in about 30% of the families. Again predictive testing is possible in the families of
these patients, but given the limited therapeutic options is less straightforward. In the
group of patients from families with SCD, gene carriers patients may benefit from a
more aggressive (applied) intervention. In addition to this, routine yearly screening will
be advised to follow the cardiac hypertrophy. Also prophylactic medical treatment can
be initiated to delay the cardiac hypertrophy and to guaranty a long lasting normal
heart function.
Genetics has taken a strong position in genetic cardiac disease in the last couple of
years and further technical improvement will make genetic testing the first step of the
diagnostic protocol.
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Especially, as genes can cause many phenotypes (HCM, dilated cardiomyopathy [DCM])
and phenotypes can be caused by a variety of genes (at least 12 genes in HCM), the
solution has to come either from dedicated protocols or from largely increased
mutation detection capacity. We hope to achieve the first by gene expression profiling
of affected and unaffected tissue and resolving a gene-specific profile or signature. On
the other hand given the limitations in getting access to affected tissues, up-scaling of
mutation screening programs, the second option, will be most promising and a variety
of technologies, including CHIPs, can be applied. One has to keep in mind however that
the amount of data produced does not keep pace with the interpretation of the data,
which will be the challenge for genetic service in the years to come.
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Samenvatting
De laatste decennia heeft de genetica een belangrijke plaats ingenomen binnen het
geheel van de medische zorg en wetenschap. De term Cardiogenetica reflecteert het
nieuwe samenwerkingverband op het gebied van de gezondheidszorg van
cardiovasculaire aandoeningen. Deze stormachtige ontwikkelingen op het gebied van
de genetica zijn vooral te danken aan de revolutionair toegenomen kennis van het
genoom van mens en andere species, als resultaat van het humane genoomproject, en
aan de snel voortschrijdende ontwikkelingen in moleculair biologische technieken.
Deze technieken hebben ertoe geleid dat genen konden worden geidentificeerd die
betrokken waren bij een aantal erfelijke vormen van primaire vormen van
hartritmestoornissen en hartspieraandoeningen. Dit proefschrift gaat over de genen
en gendefecten bij het aangeboren lange QT syndroom en bij aangeboren (familiaire)
spierafwijking welke resulteert in een verdikking van de linker hartkamer
(hypertrofische cardiomyopatie). Kleine veranderingen (mutaties) in deze genen
kunnen leiden tot plotse hartdood op jonge leeftijd. Bij het lange QT syndroom heeft
het onderzoek van genen en gendefecten in relatie tot het klinisch beeld in LQT
families geleid tot belangrijke nieuwe inzichten in de oorsprong van deze erfelijke
aandoening, de klinische kenmerken en de toegepaste behandelingsmethode.
Het eerste gedeelte van dit proefschrift behandelt het aangeboren lange QT syndroom
(LQTS). In Hoofdstuk 2 wordt een overzicht gegeven van de klinische, genetische en
functioned aspect en en de medische bthandeling van dit syndroom. De naam lange
QT syndroom is gebaseerd op de karakteristieke verlenging van het QT tijdsinterval,
welke duidt op een abnormale repolarisatie in het hart. Deze abnormale repolarisatie
veroorzaakt een elektrische instabiliteit, waardoor er een kritieke situatie ontstaat die
kan leiden tot een specifieke gevaarlijke hartritmestoornis genaamd Torsade de
Pointes (TdP). Bij dragers van het genetisch defect kunnen ritmestoornissen reeds op
jonge leeftijd de oorzaak zijn van herhaaldelijk wegraken en bewustzijnsverlies
(absences en syncopes) en in het uiterste geval zelfs leiden tot een plotse hartstilstand
met de dood als gevolg. LQTS erft voornamelijk autosomaal dominant over en er zijn
momenteel 7 subtypen bekend. De betrokken genen coderen voor hartspecifieke
kaliumkanalen (KCNQl/KvLQTl-LQTl, KCNH2/HERG-LQT2, KCNJ2-LQT7) en hun co-
factoren (KCNE1-LQT5, KCNE12-LQT6), een hartspecifiek natrium kanaal (SCN5A-LQT3)
en een ankyrin (AnkB-LQT4). Mutaties in deze genen veranderen de eiwitfunctie in het
algemeen via een dominant-negatief mechanisme met als resultaat siecht
functionerende ionkanalen en elektrische instabiliteit. Naast de erfelijke vorm van
LQTS bestaat ook nog een verworven of medicatie geinduceerde vorm van LQTS.
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Hoofdstuk 3 geeft een overzicht van de resultaten van het eerste onderzoek van een
deel van de betrokken genen in een aantal Nederlandse families. Van de KCNOl- en
KCNH2 (HERC)- genen werden de gebieden, welke coderen voor de
membraangebonden delen van het eiwit (S1-S6), geanalyseerd met behulp van de
"Single Stranded Conformation Polymorphism" (SSCP) analyse methode. In 58% van de
gevallen werd een mutatie aangetoond. Het genetisch onderzoek werd uitgebreid
(Hoofstuk 4) middels de volledige analyse van deze twee genen met de DHPLC-
techniek. Dit is een relatief nieuwe geautomatiseerde methode voor mutatiedetectie,
die sneller en gevoeliger is dan de SSCP methode. Hiermee kon uiteindelijk in 91% van
de onderzochte LQTS families en in 16% van de losse personen met LOT een ziekte
veroorzakende mutatie worden aangetoond. Via onderzoek in de families konden
gendragers vroegtijdig worden geidentificeerd.
Hoofdstuk 5 gaat in op de relatie tussen genotype en fenotype. Patienten met LOTS
hebben een verhoogd risico op ventriculaire ritmestoornissen. Factoren (triggers) die
deze ritmestoornissen kunnen uitlokken zijn o.a. fysieke inspanning (intensief sporten),
stress situaties, zwemmen of duiken, harde geluiden, maar ook slaap. Uit het genetisch
onderzoek is gebleken dat deze triggers genspecifiek zijn. Een zeer duidelijk verband
werd aangetoond tussen mutaties in het KCNH2/HERG gen en een plotseling hard
geluid (5-1) en in iets mindere mate tussen KCNQl-mutaties en koud water
(zwemmen, duiken). Andere triggers (inspanning, emotie) konden beide vormen van
LQTS veroorzaken (5-2). Een causaal verband tussen de trigger en de verschillende
vormen van LQTS is zeer belangrijk om het meest waarschijnlijke kandidaat-gen te
identificeren, zodat zeer snel de genetische oorzaak kan worden opgespoord. Dit is
voor een levensbedreigende, maar behandelbare aandoening als LOTS uiterst relevant.
Hoofdstuk 6 beschrijft het eerste onderzoek van een groep genetisch gedefinieerde
LQTSl en LQTS2 patienten voor en tijdens de behandeling met een ß-adrenoceptor
blokkade. De eerste resultaten duiden op een duidelijke vermindering van de klinische
klachten bij de groep patienten met een gendefect in het KCNOl/KvLOTl (LOTl) gen.
Bij de groep patienten met een genetisch defect in het KCNH2/HERG (LQT2) gen was
deze afname echter minder duidelijk. Tevens werd geconstateerd dat de QTc tijd bij de
mannelijke LQTl gendragers aanzienlijk korter werd dan bij vrouwelijke LOTl-
gendragers. Dit verschijnsel werd niet waargenomen bij de LQT2 gendragers.
Het tweede gedeelte van dit proefschrift gaat in op de erfelijke ofwel primaire vorm
van hypertrofische cardiomyopatie (HCM). Hoofdstuk 7 beschrijft de klinische en
erfelijke kenmerken van HCM, de genotype-fenotype correlatie en de huidige medische
behandeling. De erfelijke of familiaire vorm van HCM (FHC) erft autosomaal dominant
over en de ziekte vertoont zowel klinisch als genetisch een zeer heterogeen beeld.
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Inmiddels zijn twaalf genen beschreven die verantwoordelijk zijn voor net ontstaan
van de aandoening. Tien van deze genen coderen voor eiwitten die verantwoordelijk
zijn voor de contractiele eigenschappen van de hartspier. Mutaties in deze genen
kunnen resulteren in een de verminderde contractie(kracht) van de hartspier en men
vermoedt een compensatoir mechanisme waardoor plaatselijk, met name in de linker
kamer en in het septum, een verdikking of hypertrofie ontstaat. Dit kan vervolgens
weer leiden tot levensbedreigende ritmestoornissen en plotse hartdood. De
therapeutische mogelijkheden zijn bij deze aandoening tot op heden beperkt en de
profylactische interventie is met name gericht op het beperken van een progressieve
toename van de hypertrofie en het voorkomen van de ritmestoornissen. Dit kan o.a.
door middel van een aangepaste levensstijl en door toedienen van medicatie of het
plaatsen van een implanteerbare defibrillator (ICD). In geval van geleidingstoornissen
kan men het plaatsen van een pacemaker overwegen. Naast deze primaire vorm zijn
nog andere oorzaken (secundaire vormen) bekend waardoor een verdikte hartspier of
hypertroof hart kan ontstaan bijv. hoge bloeddruk, coronaire vaataandoeningen of
zeer intensief sporten (sporthart).
De hoge frequentie van de in de literatuur gerapporteerde mutaties in het ß-myosine-
zware-keten gen MYH7 was de aanleiding om genetisch onderzoek te starten in een
60-tal erfelijk sterk belaste families (Hoofdstuk 8). Dit hoofdstuk beschrijft de gevolgde
Strategie om met name ernstig pathogene (maligne) genetische variaties, waarvoor
genetisch onderzoek het meest zinvol is, met succes op te sporen. Het protocol is
gebaseerd op SSCP-analyse en daaropvolgend sequentie-analyse van de afwijkende
SSCP-profielen. De kracht van uitgebreid familie- en koppelingsonderzoek m.b.v.
genetische markers en de daaropvolgende succesvolle bepaling van gen en gendefect
is beschreven in de daaropvolgende publicatie (8-2). Met koppelingsonderzoek werd
het a-tropomyosine (TPMl) gen als kandidaatgen aangetoond en vervolgens werd de
pathogene mutatie gevonden. Helaas is in veel gevallen het aantal levende patienten
in een familie te klein om succesvol koppelingsonderzoek te verrichten.
In Hoofdstuk 9 wordt de huidige stand van zaken in ons centrum vergeleken met data
uit de literatuur en worden een blik op de toekomst geworpen. Concluderend kan
worden gesteld dat het genetisch onderzoek van het LQTS heeft geleid tot de
identificatie van de oorzakelijke gendefecten bij deze aandoening en een verdere
onderverdeling in verschillende subtypen. De duidelijke genotype-fenotype correlatie
vereenvoudigt het genetische onderzoek sterk, waardoor snel predictieve diagnostiek
op basis van DNA-diagnostiek beschikbaar komt voor de families. Indien nodig, kan
direct levensreddende genspecifieke behandeling worden gestart. In geval van HCM
heeft het uitgebreide genetisch onderzoek nog niet geleid tot een goede genotype-
fenotype correlatie. Hierdoor is het momenteel nog niet mogelijk direct het meest
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waarschijnlijke kandidaatgen te selecteren en analyseren. Momenteel heeft het
genetisch onderzoek in families met HCM in 30% een gendefect aangetoond. Predictief
onderzoek bij familieleden van de patient is opnieuw mogelijk, maar de therapeutische
mogelijkheden zijn beperkter dan bij LOTS. Het blijft wel raadzaam om jaarlijks op
controle te komen bij de cardioloog om tijdig een (plotse) progressieve toename van de
hypertrofie te kunnen waarnemen. Ook kan worden getracht om met behulp van een
profylactische behandeling de hypertrofie te vertragen om zodoende langer een
voldoende hartfunctie te garanderen.
De laatste jaren heeft het genetisch onderzoek een belangrijke positie ingenomen op
het gebied van de cardiovasculaire aandoeningen en het zal in toenemende mate,
gezien de snelle technische ontwikkelingen, een belangrijke rol in de
differentiaaldiagnostiek gaan vervullen. Met name nu steeds duidelijker wordt dat
defecten in dezelfde genen tot verschillende fenotypes kunnen leiden (HCM ofwel
gedilateerde cardiomyopathie [DCM]) of dat hetzelfde fenotype wordt veroorzaakt
door verschillende genen (tenminste 12 in HCM), is het belangrijk om ofwel een goed
protocol te kunnen opzetten formuleren ofwel de mutatie detectiecapaciteit enorm uit
te breiden. Het eerste kan hopelijk worden bereikt met behulp van gen-expressie
profielen van aangedane en niet aangedane weefsels om zodoende een genspecifiek
beeld of genprofiel te krijgen en het fenotype te kunnen sub-classificeren. Echter, met
name de toegang tot het verkrijgen van het zieke weefsel en de minieme
hoeveelheden ervan is een reeel probleem. De tweede optie is in dit opzicht veel
belovend en een scala van technieken, zoals bijvoorbeeld mutatiedetectie-CHIPs,
kunnen worden toegepast. Men moet zieh echter wel realiseren dat de hoeveelheid
data die worden gegenereerd niet altijd eenduidig geinterpreteerd kunnen worden.
Voor genetici zal het bepalen van de betekenis van genetisch variatie
(ziekteverwekkend of niet) en van de relatie tussen verschillende Varianten de grootste
uitdaging zijn in de körnende jaren.
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